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There are a number of methods available to clinicians for determining an individualised 
dosage regimen for a patient. However, often these methods are non-adaptive to the 
patient’s requirements and do not allow for changing clinical targets throughout the course 
of therapy. The drug dose algorithm constructed in this thesis, using stochastic control 
methods, harnesses information on the variability of the patient’s response to the drug 
thus ensuring the algorithm is adapting to the needs of the patient.  
Novel research is undertaken to include process noise in the 
Pharmacokinetic/Pharmacodynamic (PK/PD) response prediction to better simulate the 
patient response to the dose by allowing values sampled from the individual PK/PD 
parameter distributions to vary over time. The Kalman filter is then adapted to use these 
predictions alongside measurements, feeding information back into the algorithm in order 
to better ascertain the current PK/PD response of the patient.  From this a dosage regimen 
is estimated to induce desired future PK/PD response via an appropriately formulated cost 
function. Further novel work explores different formulations of this cost function by 
considering probabilities from a Markov model.  
In applied examples, previous methodology is adapted to allow control of patients that 
have missing covariate information to be appropriately dosed in warfarin therapy. Then 
using the introduced methodology in the thesis, the drug dose algorithm is shown to be 
adaptive to patient needs for imatinib and simvastatin therapy. The differences, between 
standard dosing and estimated dosage regimens using the methodologies developed, are 
wide ranging as some patients require no dose alterations whereas other required a 
substantial change in dosing to meet the PK/PD targets.  
The outdated paradigm of ‘one size fits all’ dosing is subject to debate and the research in 
this thesis adds to the evidence and also provides an algorithm for a better approach to the 
challenge of individualising drug therapy to treat the patient more effectively. The drug 
dose algorithm developed is applicable to many different drug therapy scenarios due to the 
enhancements made to the formulation of the cost functions. With this in mind, 
application of the drug dose algorithm in a wide range of clinical dosing decisions is 
possible.
ABSTRACT 
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1 INTRODUCTION 
The following chapter contains background information on the motivation for the 
research conducted in this thesis. Particular attention is given to introducing 
individualised drug therapy and then explaining why it is important in healthcare.  
In order to better treat the patient the stages of data collation to enable 
individualisation of drug therapy are explained. Following this, an explanation 
overviews the impact and reception of individualised drug dosing, highlighting the 
current level of research activity and with subsequent reasoning for this level. 
1.1 Introduction to Individualised Drug Therapy 
The care of a patient involves effective diagnosis and treatment; during the 
treatment of a condition or disease the clinician will often prescribe some form of 
drug therapy. This drug treatment will aim to treat the ailment directly or indirectly 
by relieving one or all of the symptoms that are presented by the patient. 
The list of drugs in healthcare used to treat various conditions and diseases is vast 
with new drugs added every year. Many drugs cause adverse events which are dose 
dependent, consequently there is a need to identify the correct dose for each 
specific patient, maximising the efficacy of the drug whilst minimising their risk of 
experiencing an adverse drug reaction (ADR).  
The identification of the optimum dose begins in an extensive multi-phase testing 
process for all new drugs. However, as a drug is often intended for wide spread use, 
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the main objective of testing is to show an acceptable level of safety and efficacy in 
the general population. Most dose identification will be optimal for the ‘average 
patient’ and this is estimated from statistical analysis of the population using 
summary statistics such as the mean drug response.  
The recent focus towards personalised medicine has highlighted this issue in drug 
dosing; the administration of the dose that is appropriate for the average patient 
will lead to a hugely variable response over the entire population. Identifying and 
measuring these sources of variability leads to drug dose algorithms which 
personalise drug therapy for the patient. The benefits of drug dose algorithms 
include more optimal treatment for the patient and the potential reduction in 
treatment costs from minimising the occurrence of adverse events.  
1.2 The Variability of Drug Response in the Population 
The objective of a drug dose algorithm, to find the optimum dose, is complicated by 
the inter-individual variability in the response of each individual patient to a specific 
drug. Inter-individual variability is inherently biological due to each patient’s PK, 
what the body does to a drug, being unique. In a population of highly variable, in 
drug response, patients, patterns of variability must be identified. 
Patterns that exist between individual patient PKs are often referred to as sources 
of inter-individual variability. A diagram showing sources of variability and the 
interaction between them is shown in Figure 1-1 presented originally in Jamei et al. 
(2009) [1]. The interplay of these various sources of variability means that each 
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patient has PK different from other patients; the modelling of this interplay is 
explained in Chapter 2 of this thesis. 
 
Figure 1-1: Relationships of Sources of Variability Affecting the PKs of the Patient (Jamei et al., 2009). 
The various relationships shown in Figure 1-1 and their effect on patient response 
will be more consequential for some drugs and nullified in others, for example, 
renal function will impact on clearance of all renally excreted drugs [2] whereas 
brain volume is only considered when drug molecules are small enough to enter the 
brain [3].  
Due to inter-individual variability, prescribing a single dose of a drug for all patients 
does not induce efficacy in the majority of patients and can be potentially 
dangerous. Therefore, each drug that is to be prescribed to a patient represents a 
new challenge to the clinician in the determination of the optimal dosage regimen 
for the patient. Considering this challenge, various statistical methods have been 
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applied to the individualisation of a dosage regimen to aid clinicians in drug therapy 
decisions. Examples include linear regression methods in warfarin therapy [4], 
maximum a posteriori (MAP) Bayesian methods also in warfarin therapy [5] and 
stochastic control methods in digoxin [6]  
Overall, the information for individualising a dosage regimen comes from many 
different sources. Identifying and measuring the variability that these sources cause 
in PK/PD response is important so that statistical methods can predict future PK/PD 
response of various patients in a population that require individualised dosage 
regimen to reach therapeutic targets. Often sources of variability are identified 
from specialised studies, such as clinical trials looking at the pharmacogenetics, the 
study of how genetic differences affect drug response. Gaining this information on 
variability from specialised studies means collaboration across disciplines is needed 
to incorporate the information effectively. 
1.3 The Stages Involved in Individualising Drug Therapy 
Intra-individual variability is the difference in patient response over time. This is due 
to changes in bodily processes such as drug absorption and metabolism [7]. Causes 
of these intra-individual changes include diet and fluctuating co-morbidity [8, 9]. 
Due to intra-individual variability a patient may require different amounts of drug 
over the course of therapy. Estimating when these changes in dosage requirements 
occur is another challenge to the clinician. Most current statistical methods do not 
consider this aspect of individualised drug therapy, for example, linear regression 
methods estimate an individualised dose by accounting for the average effect of 
covariates on patient response [10].  
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Often both sources of variability do not act in a linear way or act together to 
produce an enhanced effect on patient response to a drug. Understanding the 
magnitude of effect from the sources of variability is a requirement to facilitate 
individualise drug therapy. However, this understanding involves many different 
fields of medicine, which also relies upon effective collaboration. For example, to 
understand the effects of a patient’s genetics on drug response the expertise of a 
pharmacogenetic researcher is required, however, to then relay this expertise into 
a PK/PD model a pharmacometric researcher would be needed.  
This multi-disciplinary need of the personalised medicine approach means not only 
that differing types of research are needed but also that there are overlaps of 
research and requirements of information from one discipline to another discipline 
in order to continue research into individualising a dosage to prescribe a patient. 
Due to research occurring at different stages, the personalised medicine approach 
incurs a natural timeline, shown in Figure 1-2. The understanding of this time line in 
reference to when proposed research is best conducted is crucial. 
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Figure 1-2: Flow Diagram of the Individualisation of Dosing. 
The main focus of this thesis, the development of a drug dose algorithm, requires 
research into the magnitude of the variability caused by patient characteristics. 
Therefore the ability to estimate an individualised dose for a specific patient, 
currently, is only possible relatively late after a new drug is developed.  
Figure 1-3 is taken from a publication highlighting the importance of genomically 
derived biomarkers by Meyer et al. (2002) [11]. Within the circle of Figure 1-3 there 
are phases of research that reveal sources of variability to individualise drug 
therapy. Moreover, Figure 1-3 shows research is conducted into the clinical targets 
for drug therapy, this research is a particular requirement to allow statistical 
methods to be utilised to individualise dosage regimens. For example, targeted 
studies confirm clinical PK/PD response targets that are used directly in algorithms 
as a mechanism to ‘judge’ dosage prospective dosage regimens; this will be 
explained further in Chapter 4.  
Animal Modelling Biomarkers Target Study 
Co-Morbidity 
Study 
Co-Medication 
Study 
Pharmacogenetics 
Pharmacometrics 
Individualised 
Dosing 
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Figure 1-3:  Personalised medicine — integrating drug discovery and development through molecular 
medicine. Genomically derived biomarkers are being identified throughout the drug discovery and clinical 
development process. They will not only support personalized medicine, but will also enhance drug discovery 
and clinical development by generating new targets, validating targets and identifying patients that will 
benefit from novel therapeutics. ADMET, absorption, distribution, metabolism, elimination, toxicity [11]. 
The research in personalised medicine is shown in this section to be a connected 
network of various disciplines and areas of science. This research network seeks to 
improve the care of the individual patient by continual investigation of both intra- 
and inter-individual variability in patient response to drug therapy. This variability is 
then considered in statistical methodology to individualise dosage regimens that 
seek to bring a patient to therapeutic response. 
1.4 The Types of Individualised Drug Therapy  
Perceived variability in drug response can be used to indicate where individualised 
drug dosing will be particularly beneficial. The impact of individualised drug therapy 
is particularly clear in drug therapies that incur a large amount of variability in drug 
response, for example, individualised dosing of vancomycin has been researched 
previously [12]. However, the different levels of variability seen in the response to a 
drug often determine the type of dose individualisation methodology required. 
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Holford and Buclin (2012) [13] considered different levels of perceived variability of 
drug response and dosing methods available to create a criterion for dose 
individualisation. The different dosing types were population dosing (single dose for 
all patients), group dosing (different doses based on covariates) and target 
concentration intervention (doses estimated through monitoring measured drug 
responses) depending on the predictable and unpredictable variability seen in the 
drug response of the population. This thesis focuses on using stochastic control to 
achieve the latter type of individualised dosing.  
Target concentration intervention is used alongside prediction-based learning of a 
patient’s drug response utilised with certain methodologies, e.g. stochastic control. 
The dose-exposure-response relationship is derived which allows estimation of a 
patient’s dosage regimen [14]. By making a prediction about the patient’s response 
based on the known pharmacological information the process of individualised 
therapy is begun before any response data is collected from the patient. This also 
means that if response data is collected it can be reconciled with predictions 
(bottom-up) with actual measurements (top-down) to reduce variability in the 
system [15, 16]. This is in contrast to the current process of determining dosage 
regimen that relies solely on detecting pattern recognition in plasma concentrations 
(or other PK/PD responses) measured through blood sampling. The PK/PD models 
required to perform the bottom-up approach will be elaborated upon in Chapter 2 
of this thesis, whilst the reconciliation of the top-down measurements from a 
patient will be researched in Chapter 4.  
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Overall, when perceived variability complicates the estimation of an individualised 
dosage regimen stochastic control methodology has been used to guide a patient to 
therapeutic response. Firstly the system is individualised by predicting the response 
of the patient to different dosage amounts. Secondly, the vast information and 
research assimilated to aid the decision of individual dose is continually updated. 
And finally, when measurements are taken they are reconciled with the predictions 
made by the dose-exposure-response model to ensure variability around the 
patient response is reduced. 
1.5 The Reception of New Research into the Individualisation of 
Drug Therapy 
The uptake of sophisticated methods to achieve the goal of individualising drug 
therapy, such as stochastic control, has been limited despite their long time 
availability. To name but one, the Laboratory of Applied Pharmacokinetics (LAPK) 
has produced research based on stochastic control methods for over 20 years [17]. 
As highlighted in this chapter, research in this area has been limited by the need for 
collaboration between disciplines. The fusion of clinical expertise and statistical 
methodology needed for sources of variability to be correctly integrated into a drug 
dose algorithm is hard to attain. For large scale uptake of drug dose algorithms to 
occur collaborations need to be assembled internationally.  
Single disciplinary approaches in the area of individualised drug therapy have led to 
research which is one dimensional in application. In one extreme, entirely clinically 
relevant research is conducted but lacks the statistical methodology to optimise 
therapy; a case study of this is given in Chapter 3. However, on the other hand, 
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methodological research is undertaken that would appropriately harness the 
variability in pharmacology yet applicability is not fully considered; explained more 
in Chapter 4. 
With these issues in consideration the reasons for the lack of drug dose algorithms 
being used in standard clinical practice is understandable. Yet, the advancements 
that could be achieved with further research must not be overlooked; already 
benefits have been shown such as in Jelliffe et al. (2012) [6] where an explanation is 
provided as to how digoxin therapy has been optimised for patients since the 
1980s. To improve individualised drug therapy by better estimating the patient 
response and incorporating more clinical opinion, further research into applying 
stochastic control theory to individualising dosage regimens is presented in this 
thesis. In Chapters 5, 6, and 7 of this thesis examples will be given that demonstrate 
the applied methodology of the stochastic control approach explained in Chapter 4.  
Chapter 5 will concentrate on estimating dosage regimens to induce a PK target. 
Initial applications will explain the stochastic control approach and introduce novel 
methodological research presented in this thesis. The final example of chapter, 
section 5.3, utilises the full stochastic control methodology proposed in section 4.3. 
The research of section 5.3 has been presented previously at the Drug Information 
Association 2012 conference and the Population Approach Group Europe 2012 
conference and subsequently published as abstracts [18, 19].  
Chapter 6 introduces new methodology for individualised dosage regimen 
estimation by discrete outcome variables. Initial sections 6.2 and 6.3 focus on post-
dosage regimen estimation diagnostics that show the clinician the probabilities of 
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therapeutic effect and an adverse event occurring. Section 6.4 explains the new 
methodology of incorporating a Markov model within the cost function to consider 
probabilities in dosage regimen estimation. The methodology is then applied to the 
imatinib example again to enable comparison of the dosage regimens estimated in 
section 6.5. 
Chapter 7 details an example of stochastic control applied to a PD target. The 
example consists of a simulated control trial for simvastatin therapy. This is the first 
use of simulation in stochastic control guided drug therapy. A main intention of the 
research in Chapter 7 is to enable uptake of the methodology by providing evidence 
to suggest individualised dosing is effective.  
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2 PHARMACOKINETICS AND PHARMACODYNAMICS 
Chapter 1 introduced the paradigm of individualising dosage regimens prescribed to 
the patient. The PK/PD of a patient can be represented in a mathematical model, 
the study of pharmacometrics. From this model the response of the patient can be 
predicted and estimated for different dosage regimens.  
This chapter begins with a brief explanation of the science that the PK/PD model is 
to represent, as well as an introduction to the objective of PK/PD models in 
translational medicine. With this background, the pharmacometric model is laid out 
including an explanation of the parameters within the model. Finally, approaches 
used in current software packages that calculate PK/PD parameters are explored.  
2.1 Background Science and Basis of Translational Objective 
2.1.1 What is Pharmacokinetics? 
PK is an umbrella term for many areas of research into the mechanisms of 
absorption and distribution of an administered drug, the chemical changes of the 
substance in the body and the effects and routes of elimination of the drug from 
the body. Overall, PK is the study of how the body affects an administered drug. 
The research areas in PK are condensed into the acronym ‘LADME’ that stands for: 
Liberation Absorption Distribution Metabolism and Elimination. 
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In each area, there can be significant intra and inter-individual variability, due to 
this variability, the study of PKs is crucial in the determination of the appropriate 
dosing of a drug to a particular patient. To appropriately mimic patient PK, 
mathematical models are required that include parameters representative of the 
PK processes in the body. PK studies are necessary to determine by how much or 
why parameters vary between individuals.  
PK is often studied along with PD, which is the study of how the drug affects the 
body. Both areas provide valuable information when investigating a drug’s possible 
effect both on a population of patients and/or an individual patient and as a 
consequence can inform individual dosage regimens, with the aim of increasing 
efficacy and reducing the risk of adverse events.  
2.1.2 What is Pharmacodynamics? 
The study of what the drug does to the body is called PD. Examples of PD outputs 
include the intensity and duration of a drug’s therapeutic effect or an adverse drug 
reaction. The biology in PK refers to how much of a drug is at a site of effect in the 
body. PD studies investigate the effect that this amount of drug is generating by 
being at the site of effect, therefore PK is tandem to PD. PK/PD models will model 
the complete process from dose to drug effect (see section 2.2.5).  
In some situations whilst the drug may be abundant at a site of effect the 
subsequent effect of the drug on the body may not be therapeutic. This means that 
some drugs are not dosed according to PK targets but rather according to a PD 
target. For instance in the case of the anticoagulant drug warfarin [20], a PK 
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dependent variable (plasma concentration or clearance) of the drug in the body is 
not indicative of therapeutic effect [21], and thus warfarins PD response, measured 
in terms of the International Normalised Ratio (INR), is referred to instead to 
indicate a therapeutic effect.  
2.1.3 The Use of Mathematical Models in Pharmacokinetics and 
Pharmacodynamics 
The application of mathematical modelling to PK/PD, called pharmacometrics, 
allows models to be constructed to derive an estimate for PK/PD responses over a 
continuous time frame, such as the concentration of a drug in the plasma of the 
blood after an IV infusion. Pharmacometrics uses statistical techniques to estimate 
parameter values. The relationship between these parameters, the model, 
describes the time profile of a PK/PD response. The PK/PD model facilitates the 
ability to compare, evaluate and predict future PK/PD response. 
Pharmacometrics is best applied assuming a stochastic framework. This implies that 
the parameters are random in the sense that their values cannot be expressed as a 
single value such as in deterministic models. Parameters in stochastic models are 
presented as a distribution which is a statistical technique for describing the range 
of values that are permissible for the parameter. The values in this range will have 
probabilities attached to them meaning that the higher the probability the more 
likely that the parameter will be that value at any time point. If it was possible to 
measure the value of a parameter from a stochastic model repeatedly and plot a 
histogram of the measurements, the histogram would resemble the probability 
distribution of the parameter. 
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To construct a combined PK/PD model the relationship between the concentration 
of drug in the body/plasma (the PK measurement) and the magnitude of the drug 
effect (the PD measurement) must be established. This link between the PK and PD 
varies in mathematical complexity, as will be explained in section 2.2.  
2.1.4 Data in Pharmacokinetics 
PK data is variable in quantity; datasets can be sparsely or densely sampled. 
Densely sampled data tends to be difficult to obtain, this is due to the processes 
needed to measure the PK response. Sampling is normally done by taking blood 
through IV bolus or cannula and due to the invasive nature patients are often 
reluctant to consent to frequent sampling, hence sparse sampling is often 
undertaken. However, with fewer samples from a single patient often intra-
individual patient variability is hard to quantify and this impacts on the certainty of 
subsequent parameter estimates of patient PK/PD.  
Sparse sampling is often used when data is required from specialist populations 
leading to paediatric, elderly and at risk patients being included as the amount of 
blood required over a dose interval is significantly reduced. For these reasons it has 
become more common to develop models using sparse data and PK/PD analyses 
are often conducted on as little as one sample per patient. Analytical techniques 
will be explained in section 2.3 with a discussion of the strands of the modelling 
methodologies and their respective strengths and weaknesses. However the focus 
of this following section is on how to model a patient PK/PD. 
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2.2 Formulating the Pharmacometric Model 
2.2.1 Modelling Methodologies 
When applying statistics to biological systems there is need to make assumptions to 
allow the construction of mathematical models that appropriately represent 
collected data. The assumptions are necessary because statistical models are more 
simplistic than biological systems that exist in our bodies [1]. However, although 
these models are more simplistic, the discrepancy between statistical models and 
actual biological systems need not be an issue when assumptions are properly 
handled.  
For the construction of the models there are a number of mathematical techniques 
used to model PK/PD processes including, in order of diminishing complexity, 
physiology based, compartmental and non-compartmental models.  
Predominantly physiology based modelling has only been used in PK application, 
physiologically-based PK (PBPK). For this modelling technique, anatomical and 
chemical pathways in the body are both considered individually in the model. For 
example, the anatomical pathway of blood flow between the spleen and portal vein 
[1].  
This is in contrast to compartmental modelling where several PK processes are 
simplified, such as the gut being represented as a single compartment. This 
approach is the most commonly utilised due to the wealth of methodology 
accumulated from its long term use in PK/PD modelling. 
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Thirdly, non-compartmental models consider the concentration profile of a patient 
without time. Using this approach the concentration is not constrained to follow 
assumptions that are made in compartmental modelling.  
The pharmacometrician must be aware of the trade-off between simplified and 
complex modelling. Simplified modelling will bring benefits such as easier 
comprehension, less computational requirements and reduced mathematical 
complexity whereas more complex modelling may lead to greater accuracy in 
predicting a PK process [1, 22]. 
To allow the methodology to be explained thoroughly, in this thesis, compartmental 
modelling will be utilised. Compartmental modelling is preferable as it has been the 
standard modelling technique in pharmacometrics for over forty years [23]. 
Further, compartmental modelling involves significantly less mathematical 
formulae than PBPK modelling; this allows for more complex control methods, 
explained later in the thesis. With concentration-time sensitive responses being 
considered this thesis, such as an adverse event caused by a drug concentration 
above a certain value in time, non-compartmental modelling would not be 
appropriate as time is not considered in these models. 
2.2.2 Compartmental Modelling 
In a crude sense, compartmental modelling reduces the PK/PD system of the body 
to the drug moving between ‘boxes’. Consider a box that is wholly sealed apart 
from flows of a liquid into and/or out of the box. A system of differently sized boxes 
and variable flow speeds into and/or out of the boxes can be used to cause the 
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liquid to flow differently. This system of boxes provides a crude parallel with the 
body’s PK/PD system as a drug moves across tissue membranes within the body.  
Each box represents a different aspect of the body’s pharmacology; an area 
commonly represented in PK applications is the central plasma compartment where 
the concentration of the drug in the plasma of blood (the ‘plasma concentration’) at 
the site of drug action is considered.  
The flow rates between boxes describe the drug concentration being distributed 
around the body or excreted out of the body. The flow rate can be as simple as a 
unit amount of drug per hour up to more complex systems like those described by 
Michaelis-Menten kinetics [24]. More boxes and complex absorption rates lead to 
more PK/PD parameters to estimate, shown in section 2.2.4. 
Compartmental modelling seeks to describe the PK/PDs of the body in a more 
simplistic way to the actual bodily processes. Due to this, PK/PD data from different 
studies of the same drug may be modelled differently; in two publications regarding 
the PK of warfarin by Hamberg et al. (2007 & 2010) [21, 25] two different models 
were used. This difference in models can occur due to a number of factors including 
different sampling frequencies in the data, assay errors of measurements and the 
different inter-individual variabilities seen in the two derivation cohorts.  
The PD of a drug in compartmental modelling is described by compartments in 
tandem from the central plasma compartment of the PK model. This can range 
from a simple extra compartment attached to the PK model through to complex 
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multi-chain compartments designed to model various phases of drug effect. PD 
models will be discussed further in section 2.2.5. 
2.2.3 Commonly-used PK Parameters 
Although compartmental modelling is a simplification of the biological processes 
seen in the body, the parameters used in modelling can still be interpreted 
physiologically. This is important as patient characteristics can be drawn from 
specific parameter values, for example, lower than normal parameter values for a 
patient’s elimination of a drug could indicate deteriorating condition. Parameter 
values can be calculated for either a population (population mean) or an individual 
patient (patient-specific mean) along with their respective variances. 
The PK parameters for absorption can range from a single constant to more 
complex absorption rates involving several parameters. For oral dosing, the 
standard modelling technique is to use an absorption compartment which acts to 
gradually release the drug into the blood, this mimics the gastrointestinal tract [26]. 
Whereas with intravenous infusion the release is considered instantaneous as the 
drug immediately enters the blood stream [27]. In the simple case for oral dosing 
the PK parameter, the rate constant of absorption, denoted    is used. The rate 
constant of absorption describes the rate the drug enters the apparent site of 
interest, e.g. plasma concentration of a drug in the plasma of the blood. 
To model the distribution of the drug around the body the parameter, volume of 
distribution denoted    is used. Similar to absorption, the number of parameters 
used to model the distribution of the drug in the body will be from one upwards 
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depending on the complexity of the distribution model. The parameter is 
theoretical in the sense that the volume of distribution is the amount of volume 
that the drug would have to equilibrate over in order to derive similar 
concentrations of drug in the plasma. Whilst the name suggests a quantity of space, 
the parameter considers elements such as solubility and size of the drug molecules. 
Drugs that have a larger molecule size will have a smaller volume of distribution to 
the drugs with smaller molecule size due to distribution across different tissue 
membranes [28]. The drug in the blood is assumed to instantaneously mix over the 
entire volume of a compartment, for example, it would be assumed that blood 
samples from two different areas of a compartment would contain the same 
concentration of the drug. 
Elimination is the rate the drug is excreted from the body over time. In the simplest 
case, three parameters contribute to this phase of PK, the volume of 
distribution,    , the clearance denoted    , and the constant of elimination 
denoted    . The clearance is the amount of blood that has drug extracted from it 
over time. These elimination parameters are proportional through the volume of 
distribution with a linear relationship described as such, 
  
   
  
  
 2.1 
 
These parameters are used in models to construct a relationship that derives the 
concentration,   , of a drug in a compartment or compartments. The different ways 
they can be used to model various drugs will now be investigated. 
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2.2.4 Commonly-used Compartmental Models 
Different drugs will have different systems of PK parameters as the body processes 
the drugs in different ways. PK/PD models can parallel bodily processes sufficiently 
to generate acceptable predictions that coincide with measurements taken from a 
patient, such as, plasma concentrations of a drug measured from blood samples. 
The predictive power of a model is determined by how close estimations are to 
measurements. 
Pathways of administration are drug formulation specific. Different pathways of 
administration include constant intravascular (IV) infusion over a certain duration of 
time, IV bolus and oral dosing. Each pathway of administration needs to be treated 
differently when modelling. With IV routes of administration it is assumed that the 
drug is instantaneously absorbed into systemic circulation [29]; whereas with oral 
dosing the absorption process is not instantaneous and so there is a need to 
calculate the appropriate absorption PK parameters.   
Figure 2-1 describes the effect that different routes of administration have on the 
plasma concentration of a drug in the central plasma compartment of the body. All 
three graphs in the diagram are generated from a model where the administered 
drug enters a single compartment which then has only one outflow (representing 
the excretion of the drug).  
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Figure 2-1: Concentration-Time Plots for Different Routes of Drug Administration in a One Compartment PK 
Model. 
The biggest difference in the curves comes from the oral dosing route of 
administration. The curve generated arcs up and then down compared to the 
instantaneous decline of plasma concentration after administrations of IV infusion 
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and IV bolus doses. This is due to the drug being gradually released into the central 
plasma compartment through gradual absorption. To model this gradual absorption 
an extra compartment is needed; in this extra compartment the oral dose 
instantaneously appears and is released at the desired rate into the central plasma 
compartment. With IV infusion and IV bolus routes it is assumed that the drug 
instantaneously enters the central compartment thus the concentration curves are 
declining once the drug enters the compartment.   
The three curves in Figure 2-1 are derived from a one compartment PK model. A 
one compartment model assumes that the entire area of distribution in the body is 
one rapidly mixed compartment where the drug flows around constantly and is not 
subject to different rates of flow. This model is applied to various drugs [30, 31].  
 
Figure 2-2: Graphical Representation of the One Compartment Model. 
The one compartment PK models for IV infusion (equation 2.2), IV bolus (equation 
2.3) and oral dose (equation 2.4) are parameterised as  
 
   
     
    
 (       ) 2.2 
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where       is the infusion rate given during the time interval (     ),      is an 
IV bolus dose given at time  ,    is an oral dose given at time  .  
Some drugs, such as vancomycin [32], are better modelled with a two compartment 
PK model. The concentration time curve will display a two stage elimination when 
the drug has to travel through different mediums of tissue in the body leading to 
some of the drug being distributed quickly and the remainder distributing more 
slowly [33]. To model the different phases of elimination, an extra compartment is 
added to the model, the ‘peripheral compartment’ which has two pathways one in 
and one out of the central compartment.  
Figure 2-3 describes the plasma concentration time curves derived from three 
different routes of administration and the two compartment PK model. The axis 
ranges are the same as in Figure 2-1 to allow comparison of the concentration 
values over time. The two stage elimination can be seen in these concentration 
time plots. 
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Figure 2-3: Concentration-Time Plots for Different Routes of Drug Administration in a Two Compartment PK 
Model. 
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Figure 2-4: Graphical Representation of the Two Compartment Model. 
The two compartment PK models for IV infusion (equation 2.5), IV bolus (equation 
2.6) and oral dose (equation 2.7) are described mathematically as: 
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where     
 
 
((          )  √(          )          ) formulated 
in Metzler et al. (1971) [34] includes parameters     and     that represent the 
flow rates into and out of the central plasma compartment,   . 
Models can be extended to more than the one and two compartmental models 
discussed above by adding compartments to describe different PK processes until 
the model represents the complete physiology of the patient; this is the 
methodology of PBPK modelling [1]. With PBPK intricate and precise processes will 
be mathematically described leading to individual pathways and organs being 
described with their own flow rates and compartments.  
2.2.5 Pharmacodynamic Modelling 
Modelling pharmacodynamics (PD) means deriving the relationship between drug 
concentration and drug response. As shown in the previous sections, modelling PK 
allows patient absorption, distribution, metabolism and excretion to be 
investigated. The subsequent relationship between these concentrations and the 
response to the drug can also be modelled leading to a PD model. A model that has 
both PK and PD aspects has the acronym PK/PD model.  
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The process of linking the PK of a drug to the PD in modelling begins by interpreting 
the concentration of the drug in the central compartment as a magnitude of effect 
that then occurs as a consequence. For instance, a model for warfarin would link 
the concentration in the plasma to the consequential anticoagulation effect of the 
drug. Often, there is a delay in a patient experiencing a therapeutic drug effect after 
a target drug exposure is attained [35]; this delay is modelled by adding one or 
more compartments to the PK model. The Hill equation is one of several models 
used to interpret the concentration of the drug in the central compartment as a 
value of drug effect [36].   
 
           
       
       
 2.8 
where       is the effect of a drug at time  .       is the baseline effect on the 
body in absence of the drug, for example an INR value of 1 before warfarin is 
prescribed [21]. If there is no baseline effect level in the body in the absence of a 
drug then       is equal to zero, this occurs in drugs that cause effects that 
naturally the body wouldn’t exhibit, for example, muscle relaxation and altered 
central nervous system function [37, 38]. The maximal effect that the drug can 
cause to the body is described by the parameter     . The parameter      is the 
concentration that is required to produce 50% of the maximal effect of the drug.  
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Figure 2-5: Graphical Representation of the Two Compartment PK Model with an Effect Compartment.  
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The effect of the drug at time  ,     , is the amount in the effect compartment 
connected to the central compartment. Figure 2-5 graphically describes a two 
compartment PK model with an effect compartment. The additional mathematical 
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equation to describe the effect compartment is given in equation 2.9. To describe 
the entire model in Figure 2-5 mathematically equations 2.6,   2.7 and 2.9 are used. 
The PD model described in this section can be used to describe various drug effects. 
For example, later in this thesis, the PD effects of imatinib and simvastatin will be 
considered with the above model. Imatinib is a drug used to treat leukaemia by 
encouraging cytogenetic and molecular effects in the body [39], whilst simvastatin 
is dosed to reduce a patient’s cholesterol levels in a desired target [40].  
2.3 Software Packages for Pharmacometric Analysis 
As shown in section 2.2, PK/PD model consist of parameters that describe internal 
processes, e.g. the absorption of a drug from the gut. Due to the multiple 
parameters involved in PK/PD model particular software is required to analyse data. 
PK/PD data is analysed to estimate values of parameters however different 
methods and assumptions are used by software packages. One particular difference 
in methodology regarding the estimation of individual parameters is important due 
to the derived distributions. The different methodologies parametric and non-
parametric are discussed briefly in the next two sections. 
2.3.1 Parametric Approach Software 
The main software package associated with parametric modelling is ‘NONMEM’ 
which is an acronym for non-linear mixed effects modelling. NONMEM was 
developed at the University of California at San Francisco by Lewis Sheiner and 
Stuart Beal [41]. 
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The NONMEM software is a program that performs regression analysis and in 
particular is able to perform non-linear regression. As parameters within PK/PD 
models are random variables, distributions of these random variables require 
particular estimation methods. The parameter estimation methods included in 
NONMEM, such as conditional likelihood and Laplace transforms, mean parametric 
distributions can be calculated for parameters. 
NONMEM includes fixed effects in models as population values of parameters then 
random effects represent the between subject variability. Both of these values are 
assumed to be represented by a parametric distribution. The combination of these 
two effects into a mixed-effect model allows individual parameter distributions for 
each patient. For example an individual’s clearance is expressed as 
 
        
 ̂ 2.10 
where      is the typical (population) value,  ̂ is a random effect quantity for an 
individual. This relationship leads to a   being a log-normally distributed individual 
parameter distribution which is appropriate as pharmacometric parameters tend to 
follow this behaviour [42] and a property of the distribution is restriction to  non-
negative values. This is important as PK parameters are assumed non-negative 
biological values. 
2.3.2 Non-Parametric Approach Software  
An example of non-parametric modelling software is Pmetrics [43]. Importantly, it 
should be noted recent iterations of NONMEM and Pmetrics [41, 43] allow both to 
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perform parametric and non-parametric analysis however both packages retain 
their respective main approaches of parametric and non-parametric analysis. 
With a non-parametric approach, the models for a patient’s PK/PD remain however 
the parameters in the models are not assumed to follow a distribution such as log-
normal. The basic intention is to allow the data to determine the shape of the 
distribution. As the distribution is purely determined from empirical data and not 
altered by a parametric assumption the statistical property of consistency is 
assured. As more data is collected the distribution of the parameters will approach 
the true distribution of the parameters.   
The strength of this non-parametric approach is that outliers and sub-populations 
are more likely to be included in the parameter distributions. For example, in the 
parametric approach slow- and ultra-metabolisers of a drug might only be included 
in the tails of distributions meaning they are ‘highly unlikely’ patients however a 
non-parametric approach will be more sensitive to these sub-populations and 
appropriate probabilities will be attached to the sub-populations. Figure 2-6 
presents a graph from the Neely et al. (2012) showing a comparison between a 
non-parametric approach and a parametric approach. In the graph two parameters 
volume of distribution,   , and constant of elimination,     (denoted in this thesis 
by   ) have been estimated. 
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Figure 2-6: The Comparison of Non-Parametric and Parametric Analyses (Neely et al. (2012)). 
“A, Results of the NPAG fit. True parameter values from the simulated population are shown as black 
squares, with NPAG support points shown as circles whose size is an approximate multiple of the size of 1 
square, proportionally increased according to the probability of each NPAG point.  
B, Results of the IT2B fit. True parameter values are shown as white squares. Note the outlier in the upper 
right corner. The bivariate normal parameter distribution estimated by IT2B is depicted as ellipses of fading 
colour corresponding to the percentile of the distribution. The white cross at the centre is the mean.” 
In the top right of A and B in Figure 2-6 there is an outlying set of parameters, it is 
clear that whilst the non-parametric analysis (A) attributes probability to this point, 
the parametric approach (B) does not do so. Secondly, the parametric approach 
used in B, has the ability to define a bimodal distribution. A bimodal distribution 
would potentially be more appropriate for this data but analysis does not conclude 
a bi-modal distribution, rather the two ‘strands’ of parameter sets are combined 
into a unimodal distribution in B.  
The grey circles in Figure 2-6 A represent support points and their respective 
probabilities based on the size of the circle. In a population sense, each grey circle is 
a set of parameters with their prevalence observed in the current data expressed as 
a probability. Currently in Pmetrics individual posterior distributions are formed by 
reweighting the support points based on subsequent individual data. If data is 
similar to that already in the population model then this distribution will be entirely 
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appropriate however when data from a new patient indicates a parameter set that 
is in between support points the posterior is less precise. The impact of this 
approach to deriving individual parameter estimate will be discussed in section 4.3. 
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3 ASSESSMENT OF A DRUG DOSE ALGORITHM NOT INFORMED 
BY A PHARMACOMETRIC MODEL 
Drug dose algorithms are effective when they capture a high amount of inter-
individual variability in the population. However, often a large amount of data is 
needed to identify sources of variability but the required data can be hard to 
obtain. 
In view of this challenge, a large amount of research has been conducted that does 
not require invasive data such as plasma concentrations. In this chapter, 
methodology outside the main focus of this thesis, stochastic control methods, is 
presented. A commonly utilised method, the linear regression algorithm, is 
presented as a worked case study in warfarin. In comparison to other methods the 
application of a linear regression algorithm requires reduced computational 
demand and data which is easier to obtain, such as the demographic factor, age.  
In light of these positive aspects and the popularity of linear regression algorithms, 
the purpose of this chapter is to clarify the limitations of such an approach when 
pharmacometric models are not utilised and discern requirements for a drug dose 
algorithm to be fully effective. 
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3.1 A Review of A Priori Regression Models for Warfarin 
Maintenance Dose Prediction 
3.1.1 Introduction 
Warfarin is the most commonly used anticoagulant in the UK, with an estimated 1% 
of the population currently undergoing warfarin therapy [44]. The aim of warfarin 
therapy is to bring INR, a measure of the patient’s clotting capability, within a 
therapeutic range, and to maintain it within that range. Although warfarin is an 
effective anticoagulant, determining the dose required to achieve a stable 
therapeutic INR (the ‘stable maintenance dose’) is difficult due to the large inter-
individual variability in maintenance dose requirements, and warfarin’s narrow 
therapeutic index.  
The therapeutic INR range is typically 2 to 3 for warfarin patients, and outside this 
range adverse events are more likely to occur [45]. If the concentration of warfarin 
in the body is too low then the drug will not provide desired therapeutic effects, 
leading to a risk of thrombosis. Conversely, if the amount of warfarin in the body is 
too high there is an increased risk of the most critical adverse event associated with 
warfarin therapy, severe haemorrhage [44]. In a recent large study of reasons for 
hospital admissions in the Merseyside, England, warfarin was shown to be the third 
highest cause of an ADR, being responsible for just over 10% of all hospital 
admissions for adverse drug reactions [46].  
Due to the difficulties in determining the required stable maintenance dose for a 
given patient, several different regression models for dose prediction have been 
proposed worldwide. These models vary in terms of the predictive factors they 
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include, with some including only patient demographics such as age, weight, height 
and co-morbidities, others including details of initial INR measurements and loading 
doses and others including details of co-medication with drugs known to alter the 
effect of warfarin. Models comprising only demographic, loading dose or co-
medication details use information that is readily available to the clinician and a few 
recent studies have derived such algorithms [47, 48].  
More recently, to explain more variability in individual maintenance dose 
requirements, dosing algorithms have also included genetic factors [4, 49-52], in 
particular variants in the VKORC1 and CYP2C9 genes. These genes have been 
identified in pharmacogenetic studies to be consequential in dosing requirements 
due to their effects on PK/PD [53]. However, the benefit of including genetic 
information in dose prediction remains to be shown in practice [54, 55] despite the 
science being conclusive that a patient’s genetics alter their warfarin dose 
requirements [44, 53].  
When developing dose prediction regression models, the outcome of interest is 
stable maintenance dose; therefore it is necessary to identify, for each patient 
included in the dataset used to derive the model (the ‘derivation dataset’), the dose 
at which stable, in-range INR has been achieved. However, since INR is sensitive to 
many factors, including dietary changes [56] and alcohol intake [51], measurements 
often fluctuate out of range even after an initial period of stability has been 
achieved.  
Figure 3-1 shows three different patients all receiving standard care and, in all but 
one patient, INR measurements do not continuously stay within therapeutic range 
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(INR 2-3). Thus, defining what constitutes a patient’s stable maintenance dose is 
difficult and importantly this dose may change over time. 
 
 
Figure 3-1: INR-Time profiles of three patients receiving standard warfarin therapy. 
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The top graph for patient 1 demonstrates an example of a patient with highly 
fluctuating INR level. At some points the dosage amount of 6mg appears to induce 
an in-range INR value however at other times it is not sufficient for efficacious 
effect. For patients such as this constant monitoring and appropriate dosage 
regimen adjustment is recommended to ensure maximal warfarin therapy. 
Unfortunately, linear regression methods are non-adaptive to patient response and 
such dosage adjustment is only possible if particular covariates are included. For 
example, if an INR measurement on a certain day after therapy initiation was 
included as a covariate. 
The middle graph shows patient 4 on a constant dose who remains within the 
therapeutic range for the duration of the study. With a drug such as warfarin this is 
a rare occurrence; however the patient’s INR curve does move very close to the 
minimum and maximum target INR values on two occasions. These small 
divergences could be due to demographic changes such as weight fluctuations, 
dietary factors or co-medications that cause only slight effects on the efficacy of 
warfarin. Linear regression methodology does not permit effective modelling of 
small divergences as parameters are assumed constant.  
In the bottom diagram patient 26 through a combination of frequent dose 
modification and apparent warfarin resistance did not achieve steady state dosing. 
The INR curve appears to be less subject to high fluctuations despite the frequent 
dose changes. Assuming full compliance, the patient appears to have an underlying 
resistance to warfarin.  
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Patient 26 is a clear example of variability that maintenance dosing algorithms do 
not incorporate as the patient has not been induced to a constant in-range INR 
level. Linear regression methods use a process of patient selection through steady 
state criteria to build a dataset for dose algorithm derivation. This process could be 
seen as a ‘cherry picking’ process where patients whose dosage regimen does not 
cause a constant in-range INR, potentially entire outlying populations of patients, 
are excluded from the dataset. These outlier patients are exactly those who require 
accurate dosage regimen estimation the most.  
Despite the number of published dose prediction regression models, they have 
rarely been integrated into standard clinical practice [54]. This, in part, is due to the 
fact that most of these algorithms have not been externally validated in an 
independent dataset and if they have then replication has been poor [10, 57, 58].  
With a view to assessing how well previously published models predicted dose in a 
dataset outside the derivation dataset, their predictive ability was tested in an 
independent patient cohort. This also allowed the performance of the models to be 
compared against each other. Further, it allowed the evaluation of how suitable 
linear regression, the most commonly utilized method for deriving warfarin dosing 
algorithms, is to estimate maintenance dosing; particularly in light of the fact that 
the stable dose for a patient can change with time. 
3.1.2 Methods 
Patients included in the validation cohort were a subset of those previously 
included in a prospective study of warfarin pharmacogenetics (the ‘Liverpool 
study’)[20]. Patients were recruited from the Royal Liverpool and Broadgreen 
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University Hospitals Trust and University Hospital Aintree between November 2004 
and March 2006. Patients were required to be initiating warfarin therapy and able 
to provide informed consent to participate in the study. Since the study was of an 
observational nature, patients received customary clinical care and dosing was in 
line with standard protocol within the recruiting hospitals. At the patient’s index 
visit demographics and baseline INR were recorded, and a blood sample was taken 
for genotyping.  Three further fixed study visits were scheduled for 1, 8 and 26 
weeks after initiation onto warfarin. All INR values measured and dose changes 
made during the follow-up period were recorded. Three patients fitted with 
mechanical prosthetic heart values, who therefore had a recommended INR range 
of 3-4, were excluded from the current study, leaving a total of 997 patients. Full 
information on the procedure for the genotyping of patients is presented in the 
original paper on the Liverpool study [20]. A summary of patient demographics, 
clinical information and pharmacogenetics is given in Table 3-1. 
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Table 3-1: Demographic, Clinical and Pharmacogenetic Information of Patients in the Validation Cohort. 
Variable Patient Data 
Number of Patients 508 
Age Mean 68 (SD 13)  
Gender Male: 280 (55%) Female: 228 (45%)  
Weight (kg) 82 (SD 19) 
Height (cm) 169 (SD 11) 
Therapeutic dose (mg) 4.19 (SD 2.05) 
On  Amiodarone Co-medication Yes- 46 (9%) No- 462 (91%) 
CYP 2C9 \ *1 *2 *3 
*1 313 98 43 
*2  4 9 
*3   3 
VKORC1 GG GA AA 
206 224 77 
SD: Standard Deviation 
In the Liverpool study, a stable maintenance dose was defined as the daily dose 
required to achieve three consecutive INR measurements within the individual’s 
target range (2-3 unless patient required a different therapeutic range). A stable 
maintenance dose was identified on the assumption that patients fully complied 
with their dosing regimens and that the only reason for dose modification was 
recorded clinical practice. After applying this definition of stable maintenance dose, 
of the initial 997 patients, 508 patients were found to have achieved stability during 
follow-up and they formed the subset of patients included in the ‘validation 
cohort’. 
The intention was to obtain a set of dose prediction regression models that were 
relatively recent, sufficiently diverse from each other, applicable to our validation 
cohort and had high performance in their original derivation dataset. Models were 
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not considered from publications over ten years old which meant that the majority 
incorporated pharmacogenetic information [53]. Variables included in the models 
included a unique combination of any of the following types demographic, clinical, 
pharmacogenetic, and dose response and co-morbidity information. Applicability to 
the validation cohort was mandatory; this meant models selected would need to 
consist of covariates measured in the Liverpool study. The models’ initial 
performance in the derivation dataset was also highly important, on the basis that 
algorithms tend to predict less of the variability in validation datasets [10, 58]. The 
search for dose regression models was conducted on the 20th of December 2011. 
3.1.2.1 Statistical analysis 
To determine the ability of the regression models to explain variability in dose 
requirements in the validation cohort the warfarin dose predicted by the regression 
model was plotted against the actual warfarin dose and then a linear regression line 
fitted. The accuracy of the algorithms was judged using the R-squared statistic 
(unadjusted and adjusted), mean absolute error (MAE), mean percentage absolute 
error, and the slope and intercept of the regression line.  
The R-squared statistic is a measure of the amount of variability explained in a 
dataset. However, the R-squared statistic is not affected by a constant error in dose 
prediction; for example, if an algorithm in this study was altered by adding 100mg 
to each dose prediction, the R-squared statistic would remain the same even 
though the dose predictions would now be severely over estimated.  
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The mean absolute error (MAE) statistic measures how close the predictions are to 
the actual values across all patients in a dataset, and therefore is important when 
considering which model has the best predictive capability. However, the clinically 
desired value of this statistic varies. For example, in an opinion publication Kimmel 
[59] recommended a MAE of 1mg/day because ‘a change in warfarin dose from a 
baseline of 5mg is sufficient to change the INR by 0.5’.   
The slope and intercept of the R-squared line are also measures of a model’s 
accuracy, a slope of one and an intercept of zero indicate that there is no 
proportional or constant error respectively. If the slope coefficient is different from 
one there will be either over or under prediction in some, if not all estimated doses. 
The intercept term gives an insight into how well the model is predicting at low 
doses. These statistics should all be used together to appropriately judge a model 
as each statistic can appropriately assess a different aspect of the model’s 
predictive ability. 
3.1.3 Results 
The selection process (the four questions given in section 3.1.2) found six dosing 
models which meet the criteria specified in the Methods section of this manuscript, 
these are detailed in Table 3-2.  
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Table 3-2: List of dose prediction models [4, 47-50, 60]. 
1. Was the paper published after 2002? 
2. Does the model contain more than two different covariates than another dose prediction 
regression model already selected? (Although, where relevant novelty existed similar dose 
prediction regression models were compared and this novelty explained.)  
3. Does the model include only covariates measured in the Liverpool study? 
4. As R-squared is the most frequently reported statistic to judge model performance in the 
reviewed papers, is the value of this statistic above 0.5?  
*R-squared statistic from derivation dataset not reported.  
#Reason for inclusion explained in manuscript. 
The model presented by Le Gal et al [48] includes only clinical covariates, including 
INR measurements on day 5 and day 8 and the total dose of warfarin taken during 
the first week. The second model, proposed by Solomon et al [47] includes 
Paper Dosing Equation 1 2 3 4 
Le Gal et al. ln(Dose) = 2.5 + 0.1*(Total first week dose)       
 – INR at day 8 + 1.5*(INR at day 5 <2.0) 
2009 Y Y 0.88 
Solomon et al. Dose = 3.26 – 0.31*(amiodarone) – 0.032*(age)  
+ 0.28*(Loading Dose/end of load INR)  
2004 Y Y 0.80 
Anderson et al. Weekly Dose = 1.64 + exp[3.984 – 0.197*(*1*2)  
– 0.360*(*1*3) – 0.947*(*2*3) – 0.265*(*2*2)  
– 1.892*(*3*3) – 0.304*(VKORC1 CT)   
– 0.569*(VKORC1 TT) – 0.009*(age) +0.094*(gender) 
 + 0.003*(weight)]  
(25% dose reduction for those on amiodarone) 
2007 Y Y U* 
Wadelius et al. √(Weekly Dose) = 9.46832 – 0.90112*(VKORC1 AG) 
 – 2.01863*(VKORC1 AA)  – 0.50836*(CYP2C9 *1*2)  
– 0.97546*(CYP2C9 *1*3) – 1.10204*(CYP2C9 *2*2)  
– 1.74761*(CYP2C9 *2*3) – 3.40061*(CYP2C9 *3*3)  
– 0.036868*(age)  – 0.27698*(female)  
– 0.06992*(# of drugs which increase INR) 
2008 Y Y 0.59 
Sconce et al. √(Dose) = 0.628 – 0.0135*(age) – 0.240*(CYP*2)  
– 0.370*(CYP*3) – 0.241*(VKOR) + 0.0162*(height) 
2005 Y Y 0.54 
Zhu et al. ln(Dose) = 1.35 – 0.008*(age) + 0.116*(gender)  
+ 0.004*(weight) –  0.376*(VKORC1-AA)  
– 0.318*(2C9_3) + 0.271*(VKORC1-GG) – 0.307*(2C9_2) 
2007 N
#
 Y 0.61 
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information on total loading dose, INR at the end of the loading phase, age and the 
use of the co-medication amiodarone. The drug amiodarone inhibits the clearance 
of warfarin meaning that patients taking it should be prescribed a reduced dose of 
warfarin. These two models do not include any information on genotypes and, as a 
consequence, may have an advantage in that they are based on data readily 
available to the clinician, so can be used without having to attain a patient’s 
genotype information.  
Four of the included models include genotypes for variants in CYP2C9 and VKORC1. 
The models proposed by Anderson et al. (2007) [4] and Wadelius et al. (2009) [60] 
assume that CYP2C9 alleles are non-proportional, thus including a separate 
covariate for each possible genotype, whereas the models proposed by Sconce and 
Zhu assume an additive effect of the variant allele.  
The models proposed by Anderson et al. (2007) [4] and Wadelius et al. (2009) [60] 
calculate a total weekly dose of warfarin; consequently clinicians would have to 
divide the recommended weekly dose into seven daily doses as they consider 
appropriate.  
Anderson et al.’s (2007) model [4] includes demographic, genotype, and co-
medication covariates. The model was applied in the randomized control trial and 
information on the model’s R-squared in the derivation cohort is not supplied. 
However, the performance of a model used in a randomized control trial is of 
interest in this study. The model from Wadelius et al. (2009) [60], contains the 
largest number of covariates incorporating demographic, genotype and co-
medication information.  
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The model proposed by Sconce et al. (2004) [47] included fewer covariates than 
most of the other pharmacogenetic models, with demographic information only on 
age and height being included along with information on the genotypes.  Similar in 
composition, but including weight instead of height, the model derived by Zhu et al. 
(2007) [49] has already been externally validated once in the recent study by Linder 
et al. (2009) [58], and was found to explain slightly less variability in the validation 
dataset than in the derivation dataset.  The reason for the inclusion of two similar 
dosing equations was to assess whether the model developed by Sconce et al. 
(2005) [50] derived at the University of Newcastle, United Kingdom has an 
advantage over models derived in other countries in explaining variability in the 
Liverpool-based validation cohort. Similarities could be evident in, for example, 
demographics and the ethnical constitutions of the two cohorts. The strength of 
these two models in particular was that they contain a small number of covariates 
yet explain a large amount of variability in their respective derivation datasets.   
3.1.3.1 Dose Prediction Model Performance 
Predicted versus actual stable maintenance dose for each validated model are 
shown in Figure 3-2 and Figure 3-3. Further summary statistics are presented in 
Table 3-3 and provide a deeper insight into the ability of the models to correctly 
estimate the required maintenance dose. 
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Figure 3-2: Graphs of clinically guided predicted dose and actual warfarin dose. 
 
Figure 3-3: Graphs of pharmacogenetics guided predicted dose and actual warfarin dose. 
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Table 3-3: Table showing summary statistics about the performance of the six dose prediction models. 
Model Absolute Error R-squared (%) Intercept Slope 
(Error) 
Mean ± SD 
(Percentage)
Mean ± SD 
Coefficient of 
Determination 
Adjusted 
Solomon 1.21 ± 1.23 36.3 ± 60.0 34.9 34.0 2.06 0.48 
Le Gal 1.20 ± 1.31 39.3 ± 73.4 39.2  38.8 1.47 0.60 
Anderson 1.16 ± 0.99 39.5 ± 68.6 41.4 40.6 2.71 0.45 
Zhu 1.29 ± 1.34 32.6 ± 46.0 38.8 38.1 2.02 0.30 
Sconce 1.28 ± 1.28 38.1 ± 64.5 29.5 28.8 2.41 0.38 
Wadelius 1.46 ± 1.28 51.0 ± 88.5 35.6 35.0 3.15 0.46 
From Figure 3-2 it can be seen that the Le Gal et al. (2010) model has predicted 
negative doses for some of the study participants. The reason why these patients 
were estimated as requiring a negative warfarin maintenance dose was a high INR 
or low dosages during the first week of treatment. The model does not have the 
ability to deal with these events and consequently the predicted doses for these 
patients are not applicable.  To further investigate the model’s ability all negative 
warfarin dose estimations were set to zero, with this change the percentage of 
variability explained improved to 46.2%. 
3.1.4 Discussion 
The concept of individualized warfarin dosing is desirable for the patient, clinicians 
and wider health organisations, due to warfarin’s narrow therapeutic index and 
large inter-individual variability in dose requirements. The patient can be reassured 
that the drug dose is tailored towards their needs and the clinician can make 
medical decisions based on a dose algorithm which seeks to bring the patient within 
58 
 
 
 
a therapeutic INR range. Further, if clinical endpoints are improved this often 
means the cost of therapy reduces [20, 61].  
There is little doubt that pharmacogenetics can greatly inform warfarin treatment 
and this has been recognised with the updated recommendations on warfarin 
packaging by the United States Food and Drug Administration [62]. Further, a 
recent paper by Schwab et al. (2011) [63] declared the goals to achieve optimal 
complex, patient-dependent dosing regimens was to inform clinicians of 
pharmacogenetic principles and to build up health care teams. 
Several warfarin dosing algorithms have been published, many including 
pharmacogenetic information, and the majority are in the form of linear regression 
models. In this chapter, six different dose prediction linear regression models were 
compared using an independent cohort of patients to test their predictive ability 
outside their original derivation cohorts. This was done by re-fitting each model in 
turn to the validation dataset and assessing the variability explained (R2), as well as 
comparing the predicted stable dose against actual stable dose. Acknowledgement 
is required that, unlike randomized control trials, this method of validation does not 
allow for dose prediction models to be assessed by clinical endpoints, for example 
time spent within therapeutic range as patients are not prescribed the dose 
predicted.  
At the time of writing there have been six randomised trials of different warfarin 
dosing algorithms to standard therapy [54, 64-66]; with the exception of Caraco et 
al. (2007), which concluded a significant improvement in both primary clinical 
endpoints, these trials did not report significant differences in primary clinical 
59 
 
 
 
endpoints.  However, several large, well powered trials are currently underway to 
investigate clinical endpoints further [67-69].  
Unsurprisingly, the performance of all six models was worse in the validation cohort 
as compared to the derivation cohort [10, 58]. Although the diminished 
performance could be explained by several factors, this poor replication has also 
been observed previously [10, 51], leads us to hypothesise that regression 
modelling may not be the most optimal approach for developing a warfarin dosing 
algorithm.  
A key reason for this is the fact that developing a regression model necessitates 
each patient’s stable maintenance dose to be determined in accordance with a 
particular definition of stable dose. Choosing this definition in itself is difficult as 
evidenced by the many different definitions given in the literature (see Section S2, 
Supplementary Appendix 1 [70]), and stable dose of a patient under one definition 
may well be different to the patient’s stable dose under another. Further, 
depending on the definition used, some patients are excluded from analysis on the 
basis that their dosing history never meets the criteria specified in the definition.  
For example, in the validation cohort stable dose was defined as three consecutive 
INR measurements within the individual’s target range, at the same daily dose. Due 
to frequent fluctuations in and out of range, and corresponding dose changes, the 
dosing history of 492 patients did not meet this criterion and therefore they had to 
be excluded from analysis. Not only is this a significant loss of information, but 
more importantly it might lead to important sources of variability being missed 
since the least stable patients are necessarily excluded from analysis. Therefore, 
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dose prediction regression models can overlook information needed to 
appropriately recommend doses for the least stable patients – exactly the patients 
who need individualized dosing. 
All six dose prediction regression models, including two non-pharmacogenetic 
models, have performed at similar levels in this chapter. Based on these findings, it 
is stipulated that linear regression models may not be able to fully draw on the 
variability that pharmacogenetics can explain.  
The need to exclude non-stable patients, the lower than clinically desired 
performance and apparent low ability to incorporate pharmacogenetic information 
[54, 59, 65, 66] of the linear regression dose prediction models validated here 
suggest that more advanced methods may be required for dose estimation.  
Methods such as those implemented in Hamberg et al. (2010) [21] and Perlstein et 
al. (2011) [71] incorporate non-stable patients into the analysis as well as looking at 
PK/PD parameters.  
Research has been undertaken to explain the variability in PK/PD parameters for 
warfarin [21, 25, 50, 58, 72, 73]. PK/PD modelling along with the study of the 
variability in PK/PD parameters endeavour to explain the non-linear relationship 
between warfarin dose and response [21, 25]. Deriving information on patients 
PK/PD parameters allows for more adaptive models which in turn may improve the 
individualisation of warfarin therapy for patients. Adaptive models would ideally 
provide initial dose recommendations, based on demographics, genotype and other 
readily attainable information and response could then be fed back into the model 
regularly, with the model then providing updated dose predictions. 
61 
 
 
 
It must be noted, however, that models used to represent PK/PD are complex and 
therefore their implementation into clinical practice involve a large degree of 
collaboration. Dosing algorithms must be convenient and applicable to a practising 
clinician. In consideration of this, potential presentation solutions have been 
constructed, for example, the dose advisor made available through the internet 
(www.warfarindosing.org), an Excel spreadsheet warfarin dose calculator [52, 70], 
however this calculator’s algorithm are based on linear regression models. 
Alternatively, a table of recommended doses given in Hamberg et al. (2010) [21] 
generated by simulation from a PK/PD model. The potential solutions given are 
effective as initial dose recommendations, however if the patient does not respond 
to the recommended dose they offer no adaptive solutions.  
In summary, validation in an independent dataset is paramount for any warfarin 
dose prediction regression model and, as demonstrated in this chapter, the 
predictive ability of a model diminishes in an independent dataset compared to a 
derivation dataset. Even for the best performing model investigated here, over half 
of the variability in stable maintenance dose requirements remains unexplained. 
Further, a significant proportion of patients are excluded from the datasets used to 
derive dose prediction models since the criteria set out in the definition of stable 
dose precludes them. This can have a detrimental effect on model performance 
since it means that information needed to appropriately recommend doses for the 
least stable patients – exactly the patients who need individualized dosing – may be 
overlooked. In light of these issues, more advanced methods of developing dosing 
algorithms should be explored. In particular, these methods should not assume a 
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single value of stable dose for a patient, but rather allow dose requirements to 
adapt with time, to reflect the sensitivity of INR to variation such as dietary 
changes, alcohol intake and co-medications.  
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4 STOCHASTIC CONTROL METHODOLOGY 
In Chapter 2, a PK/PD model was explained that allows prediction and estimation of 
future patient drug response. However, in Chapter 3 an alternative approach to the 
individualisation of a dosage regimen was explored which does not require a PK/PD 
model. PK/PD models involve a higher level of computation and statistical 
methodology; however, their merits include better prediction and estimation of 
patient drug response. 
The linear regression methods of Chapter 3 also demonstrate a lack of adaptability 
to the patient. This is caused by two factors; firstly, the parameters used to inform 
the linear regression algorithms are deterministic, meaning that the full possibilities 
of patient response are not considered. Secondly, further measurements from the 
patient cannot be used to individualise a dosage regimen if the patient’s current 
drug therapy is not efficacious. 
In this chapter, the methodology of stochastic control is explained which allows an 
adaptability to a drug dose algorithm in order to better treat the patient. Initial 
sections introduce the stochastic control methodology and provide a history of the 
approach. Then the novel innovations to the methodology are introduced alongside 
a description of mathematical notation and formulae. 
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4.1 What is Stochastic Control? 
Stochastic control is implemented on systems that characteristically contain 
random deviations, for example, aircraft navigation systems [74] and financial 
markets [75]. The goal is to control the system such that system’s deviation from an 
intended course is minimised. In contrast to systems of deterministic parameters, 
where the true value of the parameter is estimated given certain information, the 
basic element of stochastic control is that a system’s parameters are assumed to be 
random variables thus containing uncertainty.  
Random parameters are often analysed using a number of summary statistics such 
as measures of average (means, medians, etc.) and measures of variability and 
deviation (standard deviation and variance). When predictions of future system 
behaviour are made using summary statistics, rather than the entire distribution of 
the parameter, the full range of possible outcomes from the system are not 
considered. This is the issue when random parameters exist in the system; whilst 
measures of average describe a ‘general tendency’ of a parameter there is a need 
to control in respect of entire distributions and evolving parameter values.  
As discussed in Chapters 1 and 2 a random parameter may be generated naturally 
or by human interaction. The controller must attempt to measure these random 
parameters and input statistics from these measurements into a model.  The model 
can then be used to make estimates as to how the system will perform over a 
period of time in the future. From this the system inputs are controlled to attain 
maximised rewards from the system, for example an in-range value of INR after 
warfarin therapy.  
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In section 3.1 the estimation of an efficacious warfarin dosage regimen was 
considered using linear regression methodology which does not allow the merits 
given above of stochastic control. The ability to deal with stochastic parameters 
leads to stochastic control presenting a superior method for the estimation of 
dosage regimens. Over the course of this chapter the way in which stochastic 
control is applied to dosage regimen estimation will be explained. The highlights of 
the stochastic control method are given including the consideration of noise within 
patient PK/PD parameters, the use of prior information, the use of a cost function 
and feedback of future measurements to individualise the dosage regimen.  
 
4.2 A Brief History of Control Methodologies in Drug Therapy 
The search for control literature that contained applications in medicine generated 
a selection of publications from a number of years beginning around the latter 
nineteen-seventies with the initial publication of Sawchuk et al. (1977) [76]. This 
section highlights different approaches to control that have been developed by a 
number of different research groups around the world; the technical details of the 
stochastic control approaches will be discussed later in this thesis.  
The initial paper by Sawchuk et al. (1977) used what is commonly referred to as the 
Sawchuk-Zaske method, which derives individual PK parameters that are then used 
to predict a future steady-state concentration trough or peak. These equations 
were then optimised by which dosage amount induced the desired steady state 
concentration.  
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The assumption of steady state concentration was relaxed in the methodology 
presented by Sheiner et al. (1979) [77] and Peck et al. (1980) [78]. These papers 
prompted the beginning of maximum a posteriori (MAP) Bayesian methods in drug 
therapy; where previous information on parameters is combined with current data 
to derive individual estimates of PK parameters that would then be used to 
calculate an individualised dosage regimen. MAP Bayesian methods estimate point 
estimates of PK parameters therefore uncertainty around the patient’s PK/PD 
response is not considered in this approach. To ensure the entire possibilities of 
PK/PD response are considered parameters in pharmacometric models must be 
described with a distribution and not as fixed values. In section 4.5.2 the effect of 
stochastic parameters on the range of estimated PK output is shown. 
Based on the MAP Bayesian approach many software packages have been 
developed including TCI Works [79], OPT [80, 81], MWPharm [82] and Abbottbase 
[83]. 
In certain areas of medicine where near constant feedback of patient response is 
possible, for example, anaesthesia, the proportional-integral-derivative (PID) 
controller has been applied. PID controllers utilise a linear approximation of non-
linear processes and are unable to predict future measurements, individualisation 
occurs by adjusting the drug input based on the observed error between system 
prediction and past measurements from the patient [84] [85] [86] and Slate et al. 
(1982) [87]. With most drug therapies the level of measurement feedback that is 
required to utilise PID controllers is not possible due to the invasive nature of 
sample collection, i.e. from blood samples. 
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Stochastic control methodology that considers the uncertainty of patient PK 
parameters has been utilised to individualise drug therapy. In Schumitzky et al. 
(1986) [88] a stochastic control approach is considered alongside non-parametric 
methods of estimating patient PK parameters. The methodology of Schumitzky et 
al. (1986) [88] was developed into the multiple model (MM) approach. The MM 
approach is first presented in the 1994 publication by Bayard et al. (1994) [89] along 
with an application in lidocaine therapy (this application will be presented as an 
example later in this thesis). The MM approach links together the non-parametric 
approach, explained in section 2.3.2, to population PK parameters [17] with 
measurement feedback impacting on parameter model probabilities [90]. 
Based on a PK population non-compartmental model derived using parametric 
methods, Lago (1992) [91] presents an open loop stochastic control method. To 
individualise drug therapy to the patient the approach reduces the normally 
distributed population model to a number of equally spaced discrete points, which 
are then assigned probabilities meaning the approach is similar to the MM 
approach. Two applications are presented, the first without discrete point 
probabilities (appropriate for dosing a population) and the second with model 
probabilities (more individualised to the patient).  
Katz et al. (1986) [92] was the first publication from another group; in their research 
they perform a control with PK parameters in a compartmental approach and a 
parametric population PK model. Further publications from this group include 
publications detailing stochastic control application in PD processes [93, 94] using 
maximum likelihood techniques. With maximum likelihood techniques the dose is 
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chosen that maximises the likelihood that the probability distribution of the PK/PD 
response is in a desired therapeutic interval.  
In the stochastic control methodologies presented in this section, distributions are 
presented as a series of discrete points. Each discrete point is treated as a possible 
parameter value for a patient and the probability is distributed around these points. 
Possible parameter values not given a point are considered to have zero probability 
of occurring; this can lead to a parameter with a range of values that are difficult to 
interpret. For example, a discrete parameter distribution could have points for the 
parameter to take the value of 0.1 and 0.2 whilst values of any small amount either 
side such as 0.11, 0.09, 0.19 or 0.21 are determined to have zero probability of 
occurring. This property of discrete distributions does not appear to fit the 
individual patient well as intra-individual variability is best considered as a 
continuous distribution [1, 95, 96]. In section 4.5.2 the impact of continuously 
distributed parameters on the PK/PD output will be considered further. 
The work of the Laboratory of Applied Pharmacokinetics (LAPK), some of which was 
explained in section 2.3.2, has led to a software package MM-USC*PACK [97] being 
developed as well as Pmetrics [43] that runs in the R statistical package [98]. MM-
USC*PACK and Pmetrics provide interfaces, primarily for clinicians, to personalise a 
dosage regimen to a patient’s individual needs. 
Control methods where alternatives to PK/PD models inform patient response 
predictions have been published. For example, in Arnsparger (1983) [99] 
parameters were recalculated by a recursive least-squared estimator; the 
parameter were linear regression coefficients that related the dose to the desired 
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outcome, blood pressure. To understand further about the patient’s individual 
response to a drug the focus must be to investigate and formulate a model that 
provides a prediction based on PK/PD parameters. As Chapter 2 explained, PK/PD 
compartmental models are not entirely paralleled with the true PK/PD of a patient. 
However, the merits of formulating the PK/PD models allow some physiological 
meaning to parameters (see section 2.2.3). 
This brief history is intended to reinforce that control methods are variable in their 
approaches to individualising a dosage regimen. However, the control problem can 
be generalised as will be explained in section 4.4 of this chapter. The next section is 
an introduction to a new approach presented in this thesis for individualising a 
dosage regimen using stochastic control. 
4.3 A  New Approach in the Application of Stochastic Control 
Theory in PK/PD 
Based on the literature review of the previous section, broadly speaking, control 
approaches perceive individual PK parameters in two ways. Firstly, as MAP Bayesian 
estimates with no variance attached, this assumes the patient’s pharmacokinetics 
are known to be that value and are without uncertainty. In taking this approach, the 
information given about the variance from PK analysis is either not analysed or 
discarded reducing the precision of predictions from the model, which is 
paramount for optimal control the of a PK/PD response. 
Secondly, population distributions of parameters are weighted to produce a 
posterior distribution for the patient (see section 2.3.2). The MM approach taken by 
the LAPK group perceives an individual’s parameters in such a way alongside non-
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parametric methods of deriving the population distribution. The weighting 
increases the probability of points of the population distribution that are derived as 
more likely to describe the patient’s true PK parameters. Consequently, the 
weighting reduces the probability at points where the parameter values are less 
likely to describe the patient’s true PK parameters.  
Assuming statistical consistency, with more samples the posterior distribution will 
tend to the true distribution of the individual’s PK parameters. To achieve this, if a 
patient is between points, meaning that their derived PK parameter set does not 
have a point in the population distribution then a grid of new points is added to the 
posterior based around a point estimate of the patient’s PK parameter set, however 
these points do not remain in the distribution [90]. Overall, the effect of less likely 
PK parameter sets, to represent the individual, only tend to zero probability with 
patient samples rather than simply and appropriately being discarded.  
A new perspective on the individual PK/PD parameter set is proposed in this thesis 
and applied in latter examples of the next chapter. The approach needs to consider 
the entire distribution of the individual’s PK/PD parameters and further focus upon 
the individual’s PK/PD behaviour (intra-individual variability). Synthesising these 
two approaches leads to each individual having their own PK/PD parameter 
distribution. For example, a patient’s volume of distribution would have a 
distribution indicating a range of values that have been derived as plausible for the 
parameter value at any given time.  
The range of values applicable to the parameter can be derived parametrically or 
non-parametrically, explained in section 2.3. In the absence of individual data such 
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as plasma samples, the individual PK/PD parameter distribution should be based on 
parameter-covariate relationships quantified in population PK analysis. The impact 
of this new approach will be shown in examples presented in Chapters 5-7 of this 
thesis. 
4.4 Considerations for Application to Pharmacokinetics 
4.4.1 Preliminaries for Stochastic Control Application 
The PK/PD of a drug act over a continuous time frame, as shown in previous 
chapter diagrams. For example, in section 2.2.4, the plasma concentration in the 
central compartment is considered to have a value at every given time. In general 
stochastic control methodology, the subject of control, such as the plasma 
concentration or other PK/PD response, is referred to as the state,  , of the system. 
The set of all possible states,  , can be continuous or discrete but the system 
always occupies a state    . 
The action of control,  , is an intervention performed to alter the state to a desired 
value. The dosage regimen (often in mg/h for infusion or mg for dose) is the action 
of control that is taken to induce certain PK/PD responses. The clinician will decide 
from a range of efficacious dosage regimens,  , within a set of all possible dosage 
regimens,  , e.g. doses cannot be negative. At state  , the set of possible actions 
given that the patient is in this state is      e.g. doses above a certain amount 
may be known to induce adverse events based on toxicology data. 
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Decisions to alter dosage regimens can be made when a clinical event causes the 
need for action, such as an adverse drug reaction, or at clinician designated times. 
Therefore, the action of control occurs at the discrete time steps, 
   (       ) 4.1 
where    . When   is a finite number, the control is a finite horizon problem, 
and in the infinite case an infinite horizon problem. In a finite horizon case, at time 
  no action is implemented as the system has reached a pre-designated conclusion.  
4.4.2 The Mechanism of Stochastic Control in Pharmacokinetics 
Assume a time point    , and a dosage regimen,   , required for a patient that 
induces them to a desired PK/PD response at the next discrete time point    , 
    . To calculate the value of      a function is required - the state function. In a 
PK/PD application, state functions and parameter values will be derived using the 
methods explained in sections 2.2 and 2.3. The state function is:  
        (          ) 4.2 
where    is a known function at time   and   is a set of pharmacokinetic 
parameters. The state function consists of information the previous PK/PD 
response   , the dosage regimen,   , noise of the system and parameters being 
included in the system. Process noise,  , can be an error in drug administration, 
dose timing or model inaccuracies and will be discussed further later in section 
4.5.2.  
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Dosage regimen information,   , is expressed as: 
      (       ) 4.3 
 
where    is a known function at time   and    is the value of a measured PK/PD 
output at time  . This dosage regimen information is paralleled to the decision 
process of a clinician in drug therapy; a dosage regimen prescribed will be based on 
the predicted current PK/PD response of the patient,   , and the available 
measurements of PK/PD responses,   . 
The measurements of a PK/PD response,   , e.g. plasma concentration, can be 
taken via procedures such as blood samples. Whilst they are a direct measurement 
of the PK/PD response, as opposed to predictions from the state function, 
measurements are still subject to variability from separate sources. The precision of 
the measurement can be impaired by aspects such as assay error and time record 
errors [17, 100].    is expressed: 
      (     ) 4.4 
where    is a known function at time   and    is the measurement variance that 
indicates the precision of a measurement.  
The information provided on current PK/PD response, current dosage regimen and 
measurements (equations 4.2, 4.3 and 4.4 respectively) is collated to make a 
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decision about the next dosage regimen to prescribe a patient. This decision is done 
with the aid of a cost function which considers all current information alongside 
future prediction of patient PK/PD response and derives an optimal dosage regimen 
for a given therapeutic target. Without the cost function the estimation of the 
dosage regimen to cause the given therapeutic effect in the patient is subject to 
bias as subjective decisions would replace the objective cost [101-103]. In PK/PD 
application, a control function is formulated to penalise deviations outside the 
therapeutic range caused by different dosage regimens; the least penalised dosage 
regimen is then recommended for prescription. 
The cost function of the system,  ( ), occupying a state,     , after the dosage 
regimen    , between   and     is; 
  ( )   ( (       )) 4.5 
where    is a known function linking a certain PK/PD response and dosage regimen 
to a cost. The cost is considered a random quantity as it is conditional on future 
PK/PD response,     , derived from random PK/PD parameters,   (explained 
further in section 4.5.2). The entire set of possible actions of control,  , is 
considered in order to estimate the maximal dosage regimen for the patient. 
Extending the cost function of equation 4.5 to multiple future time steps,  
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 ( )  ∑  ( (       ))
 
     
 4.6 
The cost function considered over multiple time steps allows greater control of the 
PK/PD response. In PK/PD applications this means that a dosage regimen can be 
estimated based on predictions about the patient’s PK/PD response further into the 
future. An issue in past studies into individualising dosing is that the future PK/PD 
response of the patient only is considered over a short time [102-104]. Often, 
dosage regimens are required that provide an initial loading dose and then a 
reduced maintenance dose, such as in warfarin therapy. Estimating the PK/PD 
responses of the patient throughout this process of dosage adjustment is important 
to maximise the therapeutic effect of a drug.  
In light of this, the cost function is to be formulated drug specifically to enable 
determination of an appropriate dosage regimen for the patient. An example of a 
cost function is one that penalises for distance away from a desired therapeutic 
point: 
 
 ( )   ( ∑    ( ̂    )
 
 
     
) 4.7 
where    is a nonnegative multiplicative constant which reflects the importance of 
control at time   and  ̂  is the estimated PK/PD response.    is the target state 
which the system is to be altered to by using a specific dosage regimen,     . In this 
case, a dosage regimen would be estimated by minimising the cost function (the 
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expected value of the mean squared error between the predicted PK/PD response 
and the target PK/PD response). This cost function is best used for drugs that cause 
a therapeutic effect at specific plasma concentrations.  
The overview in this section of the mathematics required to individualise dosage 
regimens reveals the objective mechanism, the cost function, central to stochastic 
control. However, whilst the cost function is objective it is not at the expense of 
important clinical expertise. For example the target PK/PD response,  , is identified 
using clinical expertise. 
As explained before, the cost function is a random quantity as the variables used to 
calculate its value are random parameters. The distribution of the cost function is 
the subject of the next section (section 4.5), with particular reference to prior 
distributions of the parameters required in calculation, the consideration of noise in 
PK/PD applications and the ability to consider the cost function over time. 
To ensure greater control, measurements of PK/PD responses can be fed-back to 
the system at time points to allow an interactive aspect to the stochastic control. In 
section 4.6, the extra mathematics and explanation required to perform this 
feedback will be given. 
4.5 Derivation of the Cost Function Distribution  
4.5.1 Prior Distributions 
The distribution of control function value,  ( ), is derived from random 
parameters. Each random parameter requires known prior distributions to attribute 
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probabilities to their range of values. The following prior distributions are assumed 
known: 
  )  (  | )  )  (    |        ) 
 )  (  |  )  )  ( )
       4.8 
Equation 4.8a is the probability distribution for the initial state and can often be 
derived exactly; however, it can also be interpreted from prior PK/PD response 
information.  (  | ) is required to start the ‘domino’ process of PK/PD response 
determination as subsequent distributions of the PK/PD response,     , will be 
estimated using equation 4.2. 
Secondly, equation 4.8b is the probability density function for process noise given 
the current PK/PD response, dosage regimen and parameters. This distribution will 
be explored further in section 4.5.2. 
The measurement variance density, equation 4.8c, is constructed by parameterising 
the error of the assay used to measure PK/PD responses. The assay error of PK 
measurements is a subject of debate [17], different models consider that the error 
is a constant percentage of the actual value and that there is a lower limit where 
measurements are unquantifiable below this concentration [105]. Whereas other 
models represent the assay errors as finite values for all concentrations and 
develop an assay error polynomial to represent this knowledge [17].   
Finally the distribution of the pharmacometric model parameters (see section 2.2) 
is specified in equation 4.8d. The specific process needed to calculate this 
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distribution was explained in section 2.3. For a population wide dosage regimen the 
population PK/PD parameter distributions could be used to estimate the dosage 
regimen that, on average, induces over the population some specified therapeutic 
effect. This technique offers little individualisation of dosage for patients because 
the dose will be tailored to treat the ‘average’ patient and variability in the 
population will cause this approach to be sub-optimal. Therefore this distribution of 
PK/PD parameters needs to be individualised towards the patient.  
The distributions shown in equation 4.8 are all used to derive the probability 
distribution of     , 
  (    |              )  4.9 
The many inputs into this distribution indicate just how intricate the system is able 
to be. This intricacy is important and necessary in PK/PD application as different 
sources of variability affect an output. Previously, the effect of noise, , has not 
been considered in the state function in PK/PD application. The next section will 
consider the impact of different parameterisations of noise on the prediction of the 
future PK/PD response. 
4.5.2 The Distribution of Predicted Plasma Concentration 
In this thesis, each patient is considered to have their own individual distribution of 
parameters. However, individual PK/PD parameter distributions are not routinely 
calculated in practice. Software packages, such as NONMEM or Pmetrics, have the 
ability to calculate individual PK/PD parameters however either variance is not 
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calculated (point estimates) [106] or not representative of intra-individual 
variability due to calculation from reweighted population PK/PD distributions [43]. 
The effects of different implementations of process noise on the predicted PK/PD 
response are considered in this section. The simulations of this section are informed 
by the PK parameters,  ( (     )), expressed as,   
 
 
 (  (   ))    (  (   )     ) 
 (  ( ))    (  (   )      ) 
 (  (   ))    (   (    )    ) 
    4.10 
where    
  
  
. A simulation consists of the plasma concentration time profile of a 
patient, with a starting plasma concentration distribution,  ( ̂ | )  (       ), 
after administration of a single oral dose,    , of 400mg.  ̂   ̂ , indicating that 
the starting concentration is assumed to be normally distributed around 
1000ng/ml, this could be from a blood sample taken at the time or a derived 
estimation. 
Firstly, a one compartment PK oral dosing model (see section 2.2.4) is assumed 
without noise included in the system, hence  (  |        )   , described 
mathematically as, 
     
  
                   
   
  
 
     
  
       4.11 
The simulation described above was repeated 10,000 times and the final plasma 
concentration values from those repetitions,  ( ̂  | ̂             ), are 
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presented in Figure 4-1 by a histogram. MATLAB (The MathWorks Inc., Natick, MA, 
version 2011a) was used to perform this simulation by running equation 4.11 
through an ordinary differential equation solver. 
 
Figure 4-1: Histogram of Predicted Plasma Concentration from a Model Not Including Noise. 
Whilst the data appears to have a near to central peak, the Jarque-Bera test for 
normality provides evidence to suggest that the distribution is not normal by 
rejecting the null hypothesis that the values come from a normal distribution (p-
value=0.003). Whilst the plasma concentration doesn’t have to obey a specific 
distribution there are considerations when the estimated plasma concentration is 
distributed other than normally.  
Noise is now introduced into the ordinary differential equations thus formulating 
stochastic differential equations. Using the current methodology for introducing 
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noise to the estimation of individualised dosage regimens [88] noise was added. 
Accordingly, the model for plasma concentration was changed to,   
     
  
                       (
     
  
     )        4.12 
where the noise is parameterized as  (  |        )    ,    is Brownian motion 
[107] such that process noise,   
   
  
 and    (    ). The histogram of 10,000 
simulations  ( ̂  | ̂             ) generated from the 4.12 model is shown in 
Figure 4-2. The data fails to pass the same test of normality (P-value=0.0001). 
 
Figure 4-2: Histogram of Predicted Plasma Concentration from a Model with Brownian Noise. 
To truly represent intra-individual variability, PK/PD parameters must be allowed to 
vary over time [108]. Changing parameter systems have been considered before 
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with the Interacting Multiple Model (IMM) [109] however the approach considered 
the entire patient’s parameter distribution to change only at points of 
measurement or when a new dose of a drug is given. The main application of the 
IMM approach was for patients deteriorating in condition or with known time 
dependent effects that impact on parameter values. The IMM approach has been 
applied to the individualisation of gentamicin and vancomycin to patient 
undergoing cardiothoracic surgery [12]. In Macdonald et al. (2008) [12] the IMM 
method performed optimally by setting a 3% chance of PK parameter change.  
The intention of the process noise to be used in this thesis is different from the 
IMM approach [108]; the formulation considers at every time step, not just at dose 
changes and PK/PD response measurements, that the patient PK/PD parameters 
could have changed to different values rather than have changed to a new 
parameter value. In this approach the individual’s PK/PD parameter distribution is 
not altered at each time step but rather explored further to discover the full range 
of the patient’s possible PK/PD response. Factors such as diet [110] and fluctuating 
co-morbidity [111] are best modelled in this way as they cause small unpredictable 
changes to PK/PD parameters [112].  
To implement the new method of process noise the model was changed back to 
equation 4.11, however, the parameters values were allowed to change randomly 
within their distributions, kept at the same values as in the simulations of the other 
histograms of this section, once every minute leading to 1,440 time steps. 
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  (  |  )    (   
 ) 
4.13 
The histogram of  ( ̂  | ̂             ), generated by 10,000 equation 4.13, is 
presented in Figure 4-3 appears to be normally distributed (P-value=0.29). 
 
Figure 4-3: Histogram of Predicted Plasma Concentration from a Model with Stochastic Noise. 
The Jarque-Bera test of normality used in this example, as well as other tests of 
normality, is highly powered with large samples sizes such as 10,000. This means 
that for most sets of 10,000 data points the test would reject the hypothesis that 
the data is normally distributed. Therefore, the rejection of the null hypothesis may 
not necessarily lead to the conclusion that the data is not normally distributed.   
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4.5.3 Using the Cost Function to Determine the Optimal Dosage Regimen  
Now a future PK/PD response value can be computed with process noise included, 
the cost function can be utilised to estimate the best dosage regimen for the 
patient given the intra-variability perceived in their PK/PD parameters.  
In equation 4.6, the cost function value,  ( ), consists of determining the PK/PD 
response value at future points  , subject to actions of control,  . The example of a 
cost function in equation 4.7 seeks to find the maximal state value,   
 , which is 
closest to   . This is done by considering the entire set of actions of control,    and 
determining the optimal dosage regimen,     
 , at all the time points in   to cause 
this maximal PK/PD response value,   
  consistently. For equation 4.7 this process is 
mathematically presented as: 
 
    
        
  
( (∑    (  
   
 
) 
 
     
)) 4.14 
The determination of this optimal dosage regimen can be done in different ways, 
generalised into the backwards and forwards approach. Working backwards would 
mean a target is specified and then dosage regimens are chosen to minimise the 
cost function given this target [113].  
For instance, differential equations of a pharmacokinetic system can be solved by 
specifying the final concentration value needed and rearranging to find the dosage 
regimen which gives that solution. This approach incurs the problem of 
dimensionality and is not simple to solve when across several decision epochs due 
to the solutions being hard to optimise. In a high-dimensional space (each PK/PD 
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parameter in the predictive model has a range of values as well as a number of 
possible dosage regimens) this means a large number of possible paths are 
considered and often several paths meet the objective of this approach. 
Forward methods in stochastic control start with, in the PK application, dose-
concentration trajectories. The general idea is to guide these trajectories to the 
desired PK/PD response at one or more time points. An example of the forward 
method is when different dosage regimens,  , are simulated through the process 
explained in section 4.5.2. Doses that cause a therapeutic PK/PD response in 
simulation, such as the target response    in equation 4.8, are the optimal dosage 
regimens.  
A similar level of computation is required for forward and backwards methods in 
determining the dosage regimen to prescribe to the patient. However, forward 
methods begin at the current time and often from a point where the PK/PD 
response has been measured either at that time or recently rather than a 
theoretical point such as in backwards methods.  
In past applications cost function values have been calculated only at discrete time 
points [89] [113] and this is the standard methodology currently being used [114]. 
To ensure the control is not separated from potential activity between decision 
epochs, in this thesis, the approach of complete simulation over the entire time 
horizon of the problem is considered.  
For example, in section 4.5.2 histograms were presented for the predicted plasma 
concentration at the end of twenty-four hours, however, in this thesis, the 
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predicted plasma concentration will be considered throughout the twenty-four 
hours. This allows research to extend into incorporating control of the entire 
system process.   
4.6 Enabling Feedback to the System 
4.6.1 Open-Loop and Closed-Loop Control 
A dosage regimen can be estimated purely by predicting future patient PK/PD 
response based on current information [89, 103, 104, 115]. As explained in the 
previous section 4.5.3, this involves the use of a PK/PD model and process noise to 
estimate the predicted distribution of the PK/PD response at given times in the 
future. This predicted distribution of future PK/PD response is then used in a cost 
function.  
This process is called open-loop control as a dosage regimen is derived solely by the 
prediction of the model [100]. When the PK/PD model is appropriately predictive of 
the individual patient then open-loop control is appropriate. However, in PK/PD 
applications the parameters are virtually always subject to very high levels of 
uncertainty to be assured of this appropriateness. 
The issue with open-loop control in individualized therapy is that parameter values 
are drawn from distributions with a wide range of values. Equation 4.3 indicates 
that a measurement of the PK/PD response,   , is considered alongside a prediction 
of the PK/PD response,     , when estimating a dosage regimen,   , for a patient. 
Without these measurements the range of the patient’s estimated PK/PD response 
is not considered with up to date feedback.  
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Therefore, methodology where measurements are taken into account is needed to 
ensure optimal drug therapy; meaning that a dosage regimen is informed by 
measurements from the patient as well as predictions from PK/PD models so as to 
then reach a desired future PK/PD response or therapeutic response. 
Any control that can react to measurements taken is considered a closed-loop 
control. Closed-loop control allows reduction of the uncertainty in the system by 
comparing model predictions with measurements from the patient [100]. This is 
done by the system predicting future PK/PD responses and then, when a 
measurement of a PK/PD response is made, attempting to reconcile the evidence of 
both the prediction and the measurement.  
A simple diagram of a closed-loop system is shown in Figure 4-4,  
 
Measurements,  , are fed back into the system for the controller’s use at the next 
decision point in  . The clinician can re-evaluate clinical targets for PK/PD responses 
and the cost function will derive the best dosage regimen to meet these targets. 
 
Figure 4-4: A Graphical Representation of a Closed-Loop System 
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Essentially the system reinitialises with new initial conditions, such as the prior 
distributions in equation 4.8, are now dependant on data obtained. If the   loop is 
removed from the diagram then an open-loop control is represented instead. 
The merit of closed loop systems is that the methodology leads to reduced 
uncertainty of the patient’s PK/PD response, which is used to better individualise a 
dosage regimen for a patient. However, PK/PD responses are often sparsely 
sampled leading to limited measurements being available for feedback. As an 
alternative, if surrogate measures of patient response exist and their relationship to 
the PK/PD response can be expressed in a function then these too can be fed back 
into the system.  
In this thesis the update of both PK (e.g. plasma concentrations) and PD (e.g. 
cholesterol levels) outcomes is considered. However, Chapter 8 includes a 
discussion of the future work required to include appropriate consideration of 
intra-individual variability in the methodology of parameter re-estimation.  
4.6.2 Example of a System that Updates with Measurements 
The process of feeding back measurements to the system can be done by a number 
of mathematical algorithms; these are collectively known as filters. Examples of 
filters are the Gaussian Sum, the MM, Particle and Kalman [116-119]. Filters are 
effective in the PK/PD application as they account for the variability around a 
measurement, the assay error. Failure to account for the assay error means 
measurements are treated as entirely accurate and therefore estimations are not as 
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reliable due to unconsidered variability. Despite this, there are examples in 
literature where filters are not utilised [103, 104, 120-122]. 
In order to update the system with measurements the Kalman filter is utilised in 
this thesis. The Kalman filter is used to generate an reconciled estimate of PK/PD 
response based on a measurement and respective PK/PD model prediction [123]. 
The Kalman filter has been used successfully in both space and military technology 
before being applied to pharmacokinetics and dose estimation [124]. 
The system diagram shown in Figure 4-5 demonstrates the general idea of a Kalman 
filter system. Firstly, the PK/PD responses in the body,  ̂, are calculated to provide 
an a priori prediction of PK/PD response. This prediction is weighted with a noisy 
measurement of the PK/PD response, often taken through a blood sample. This 
weighting produces an a posteriori PK/PD response,  ̃, estimate with reduced 
uncertainty. 
 
Figure 4-5: Diagram Showing a Generalisation of the Kalman filter 
The Kalman filter seeks to manage the various sources of noise and variability in the 
PK/PD system. Sources of variability are modelled through process noise, , 
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included in the state function (see section 4.5.2). These sources need to be 
controlled as optimally as possible; therefore, the filter reconciles this process noise 
in the system to provide an a posteriori estimate of PK/PD response that accounts 
for several types of noise and variability. 
The Kalman filter will derive this a posteriori estimate with all information described 
above informing the value. Therefore, the system has no need to retain any other 
information than the a posteriori estimate for the subsequent measurement in time 
(where it will become the a priori estimate). The Kalman filter therefore is a 
recursive filter requiring only the last estimate for future derivations. 
Overall, the Kalman filter enables an interactive aspect to the estimation of the 
dosage regimens by calculating more certain estimates of PK/PD response based on 
measurements. This means that the dosage regimens will be able to respond to 
measurements when they are taken and provide updated estimates of the required 
dosage regimen. This will be important in applications, such as warfarin dosing, 
where large numbers of patients never reach stable dosing and must be monitored 
regularly. 
The following sub-sections offer a description of the mathematics involved in the 
Kalman filter.  
4.6.2.1 Prediction 
The standard Kalman filter is described in the following sub-sections, which is 
applicable in this thesis because of the normally distributed PK/PD response shown 
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in section 4.5.2 [16]. There are several stages to the Kalman filter beginning with 
prediction. The prediction of the PK/PD response,  ̂ , is found by 
  ̂   ( ̂      ) 4.15 
which is calculated from the mean value of methods shown in section 4.5.2 in 
absence of process noise. The variance of  ̂  is derived from the following equation: 
  ̂     ̂     
     4.16 
where    is the state transition model, which is used to derive how the system 
covariance is changing over time, and    is the variance of the process noise,   , in 
the system. Importantly, the covariance is a product of the previous covariance 
‘evolved’ by    with the addition of    which is used to introduce noise caused by 
small parameter changes or model misspecification. Utilisation of the previous 
system covariance in this way preserves the recursive nature of the Kalman filter. 
Based on the work in section 4.5.2, an alteration will be made to the calculation of 
 ̂  and  ̂ , this will be shown in section 4.6.2.5 as the rest of the methodology for 
the Kalman filter is best explained before the novel alteration. 
The two equations 4.15 and 4.16 form the prediction part of the Kalman filter. The 
filter will compare the predicted value,  ̂ , and variance attached,  ̂   to the 
measurement,   , taken in order to calculate an a posteriori PK/PD response,  ̃  
estimate and covariance,  ̃ . 
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4.6.2.2 Update 
For an update to occur first a measurement    is taken at any time  , then the 
measurement residual is given by 
          ̂  4.17 
where    is a known value which relates the predicted state to the measurement. 
     when the measurement is of the predicted PK/PD response.      when, 
for example, predicting plasma concentration and creatinine clearance is used as a 
surrogate measure and the relationship of the surrogate measure to the plasma 
concentration is required. 
 The covariance of this residual is derived by 
       ̂   
     4.18 
Where the measurement relationship model,  , similar to    in equation 4.16, 
‘evolves’  ̂  to be comparable with   , which is the variance of the measurement, 
e.g. assay error. Notice this function is the scaled current system covariance plus 
measurement variance. In the case where     and     ̂    .  
4.6.2.3 Adjustment of State Value 
To complete the process some formulae are introduced that take the residual,   , 
and residual covariance,   , values and reconcile them with the predicted PK/PD 
response value,  ̂ , and covariance,  ̂ . Firstly, the Kalman gain is calculated by 
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     ̂   
   
    4.19 
This value is how the Kalman filter determines the ‘weight’ of the residual in the 
next formula to derive the new a posteriori PK/PD response estimate. The case 
where      and     ̂      leads to     ̂ ( ̂    )
  
 showing the Kalman 
Filter is a ratio between system covariance in the absence of and including 
measurement variance.  The new estimate of PK/PD response,  ̃ , reconciling 
prediction with measurement, is given by 
  ̃   ̂        4.20 
The residual error can be positive or negative which leads to an appropriate, as per 
the ratio seen in equation 4.19, addition or subtraction from the a priori prediction 
to the a posteriori estimate. The a posteriori covariance,  ̃ , is calculated by 
  ̃  (      ) ̂  4.21 
These formulae take us on one ‘loop’ and now equations 4.20 and 4.21 will be 
taken into consideration at the next loop when another measurement is taken. By 
using these equations the drug dose algorithm becomes a closed-loop controller. 
4.6.2.4 Cases of Values Tending to Zero in the Kalman Filter 
The ability of the Kalman filter to derive an a posteriori PK/PD response estimate 
based on the relative variability in the system is shown when  ̂  and    tend 
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towards zero. So in the first case where  ̂  tends to zero, this would be when the 
prediction from the PK/PD model becomes completely accurate. If 
  ̂    
       
      
  ̃   ̂  
  ̃   ̂    
4.22 
As can be seen, despite any value of measurement the Kalman filter will recognise if 
the process noise is tending to zero and gradually increase the magnitude of the a 
priori prediction in the a posteriori estimate. 
Now in the case of    tending towards zero, which would occur when the 
measurements are entirely accurate indicators of the true PK/PD response,  
       ̂   
  
      
   
  ̃   ̂    
      ̂    
  (      ̂ )    
     
  ̃  (    
    ) ̂    
4.23 
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This shows that when the measurement variance tends to zero the a posteriori 
estimate will tend to the measurement value divided by the measurement 
relationship model used to translate indirect measurements to that of the primary 
PK/PD response, an example of this is given just after equation 4.17. 
4.6.2.5 Considerations for the Estimation of State and State 
Covariance in the Kalman Filter 
The description of the formulae in the Kalman filter, gave equations 4.15 and 4.16 
as the estimates of PK/PD response,   ̂ , and PK/PD response covariance,   ̂  , 
respectively. In equation 4.16 of the Kalman Filter methodology, the prediction of 
the PK/PD response covariance is done by taking the covariance at the previous 
measurement and prediction reconciliation,   ̂   , and using the Kalman filter to 
evolve the covariance value to a current prediction of PK/PD response covariance, 
   ̂   
 . The      term added in equation 4.16 to allow classification of perceived 
noise into the PK/PD response covariance. Overall, the method of the Kalman Filter 
is to use analytical functions to derive the distribution of the predicted PK/PD 
response. 
Earlier in section 4.5.2 an example was given that generated a distribution of the 
predicted plasma concentration through repeated simulation. The simulated 
distribution derived gives a prediction of the PK/PD response value,  ̂ , and the 
PK/PD response covariance,   ̂ . Therefore the information that the Kalman filter 
requires about the PK/PD response estimate and covariance are provided without 
the need to determine   . The simulated sample variance will replace the    ̂   
  
term from equation 4.16. This use of a simulated distribution contrasts to the 
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analytical method of the Kalman Filter. With the noise of the parameters now 
included in the PK/PD response covariance,   ̂ , the additive term    seen in 
equation 4.16 will represent model misspecification in this thesis. This classification 
of the different sources of noise within the system means the system can be 
analysed more effectively rather than pooling all sources of noise into one 
value,  . 
The distribution of the predicted plasma concentration given by equation 4.13 was 
generated from 10,000 samples and was deemed to be normally distributed. A 
reduced amount of samples from  (    |              ) will be considered in the 
following chapters. The mean and variance of the reduced number of samples will 
be the predicted PK/PD response value ( ̂ |   ) and the predicted PK/PD response 
covariance (  |   ) respectively. If the plasma concentration samples were not 
normally distributed then the Extended Kalman Filter would have to be utilised 
instead of the standard Kalman Filter [16]. The Extended Kalman Filter handles non- 
normally distributed state distributions by forming a normal approximation of the 
distribution [119]. 
4.6.3 Application of the Kalman filter for the dosing of lopinavir 
4.6.3.1 Introduction 
The main interest of this section is to demonstrate an application of the Kalman 
filter. Individualised dosage regimens are not considered which allowed the focus 
to be on explaining how measurements can be fed back into the drug dose 
algorithm to enable a closed-loop control.  
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The Kalman filter, explained in the previous sections, allows feedback of PK/PD 
response to be reconciled with predictions generated from a PK/PD model. In doing 
this a closed-loop system is formed. An example of a closed-loop system is shown in 
this section for patients receiving the antiretroviral drug lopinavir.  
Lopinavir is used to treat HIV-infected patients and is given as an oral dose at, most 
often, a daily interval. To reduce pill burden the drug is often given in combination 
with ritonavir, since the mechanism of action of the two drugs produces a desired 
antiretroviral effect. 
4.6.3.2 Method 
The dataset of patients used in this example of a closed-loop system had been used 
in a population PK/PD analysis by Dickinson et al. (2011) [125]. For the following 
example, a dataset of healthy volunteers from two London based hospitals was 
used. The doses of lopinavir and ritonavir given to the sixteen patients in the 
original study were 400/100mg and then 800/200mg; eighteen plasma 
concentration samples at both dose amounts were taken over a 72 hour period 
post-doses. The dataset studied in thesis comprised of patient ID, sampling times, 
dosage amounts (mg), and the area under the plasma concentration curve of 
ritonavir (mg.h/l). Further detailed information on the data can be found in Boffito 
et al. (2008) [126] and Dickinson et al. (2011) [125].  
 
The data was inputted into MATLAB (The MathWorks Inc., Natick, MA, version 
2011a). MATLAB is a software package for mathematical computation, visualization, 
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and programming. Therefore the language of the programme allowed the 
description of Kalman filter and the pharmacometric model in differential equation 
and analytical form. The filter utilised the predictions ( ̂ ) given by the model in the 
original paper and the plasma concentration samples as measurements (  ).  
The model used for lopinavir was a one compartment PK model for the 
concentration of the drug in the plasma,   , with an extra equation used to mimic 
the absorption of the oral dose into the central plasma compartment is, 
     
  
                   
   
  
 
     
  
       4.24 
To enable individualisation in the lopinavir clearance parameter a power 
relationship was derived with the area under the curve (AUC) of Ritonavir [125], 
which is expressed as 
        (        ⁄ )   4.25 
where     is the apparent oral clearance of Lopinavir of the  th patient,    is the 
population estimate of the apparent oral clearance,      is the AUC of Ritonavir of 
the  th individual of which      is the median value and finally    is the scaling 
power of the effect of      on    . This is a method of modelling the effect of co-
medications on PK parameters of drugs. The population mean PK parameter values 
were taken from Dickinson et al. (2011) [125], expressed as,   
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   (   )       
  ( )      
  4.26 
where    
  
  
.  The effect of not individualising these parameters was investigated 
by comparing predictions of PK response to measurements taken from the patient. 
The outputs of this study were the estimates of plasma concentration over time 
and the error attached to these estimates. To represent the time-dependent error 
of predictions made by the model of lopinavir an equation was introduced to model 
this variance in the system, 
  ̂           4.27 
This variance was plotted alongside the mean value of plasma concentration over 
time. 
4.6.3.3 Results 
Data from sixteen patients was used in the Kalman filter. The dataset include 10 
male and 6 female patients; the median age was 42 years (range 25-55 years); and 
the median weight was about 85 kg (range 53-115 kg). 
The concentration-time graphs for the 72 hours of sampling are shown for 4 
patients in Figure 4-6 to Figure 4-9. As the population PK parameters were used to 
derive predictions of the plasma concentration this will mean that the predictions 
will be for the ‘average’ patient in the population. In Figure 4-6 and Figure 4-7 the 
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predictions tended to be similar to the measurements taken, whereas Figure 4-8 
and Figure 4-9 show predictions further away from the measurements taken.  
 
Figure 4-6: Plasma Concentration-Time Profile of Patient 1 Receiving a 400mg Dose of lopinavir. 
 
Figure 4-7: Plasma Concentration-Time Profile of Patient 7 Receiving a 400mg Dose of lopinavir. 
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Figure 4-8: Plasma Concentration-Time Profile of Patient 3 Receiving a 400mg Dose of lopinavir. 
 
Figure 4-9: Plasma Concentration-Time Profile of Patient 5 Receiving an 800mg Dose of lopinavir. 
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The variance attached to the estimated plasma concentration is represented in the 
figures by a block around the mean estimate, the black line. When a measurement 
is fed back the variance is reduced to equal or less than the measurement assay 
error. Then the variance around the patient plasma concentration increases from 
the value at time of measurement; this is due to the system relying on the 
prediction from the pharmacometric model, which is less certain than a 
measurement from a blood sample. 
4.6.3.4 Conclusion 
When a measurement is taken the Kalman filter reconciles the measurement with 
the predicted value. Unless the measurements and the predictions are the same 
values, curves that are not smooth will always be expected. Figure 4-6 and Figure 
4-7 are examples where because the predictions and the measurements taken are 
similar to the estimate of PK/PD response, the blue line, tends to be smoother. 
Figure 4-8 and Figure 4-9 shows what happens when predictions and 
measurements are further apart. The PK/PD response estimate line has more 
breaks as the prediction, derived from population pharmacokinetic parameters, is 
not directly comparing with the more accurate measurements, taken from the 
patient at discrete time points.  
In this case where the prediction is less accurate, from the proof given in equation 
4.23 as the assay error of the PK/PD response measurement reduces, the new 
PK/PD response estimate tends to the measured value. Shown in both Figure 4-8 
and Figure 4-9 the PK/PD response moves most of the way towards the 
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measurement taken however it finally settles just short due to the prediction form 
the PK/PD model still providing some information to the estimate. 
In this example, population PK parameters were used to provide prediction of an 
individual’s plasma concentration level of lopinavir. The inaccuracies of the 
individual plasma concentration predictions were less consequential on overall 
PK/PD response estimation as frequent plasma samples taken kept the system 
informed of the current plasma concentration of the drug. When fewer blood 
samples are taken over the dose interval the system is provided with less feedback 
and therefore relies more on the predictive capabilities of the PK model. 
Consideration to maximise the accuracy in both the predictions made and 
measurements taken is needed to ensure optimal performance of the Kalman filter.  
4.7 Discussion 
The methodology of stochastic control was introduced in section 4.1 with a brief 
history of publications applying the method in the medical setting given in 4.2. In 
order to apply stochastic control methods effectively, whether it is to individualise a 
dosage regimen or otherwise, the application must be considered mathematically. 
Due to this, section 4.4 detailed the mathematical formulae required to perform a 
stochastic control.  
Over the course of this chapter, a stochastic control system has been constructed, 
proposed in section 4.3, consisting of attributes that enable individualisation of 
dosing for the patient. A diagram of the overall drug dose algorithm is shown in 
Figure 4-10.  
104 
 
 
 
 
Figure 4-10: System Diagram of Drug Dose Algorithm. 
 
The control presented considers entire distributions and thus is stochastic; this 
attribute means the dosage regimen derived in respect of all possible individual 
PK/PD responses and not merely the average patient response. Most current 
dosage individualisation methodology is centred on using MAP Bayesian estimates; 
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with large uncertainty around the patient response it is important to consider what 
variability there could be around a point estimate.  
An alternative methodology in the individualisation of dosage regimens is to 
reweight the population distribution according to point estimates. This approach 
derives an estimate of variability in a patient’s PK/PD parameters to allow dosage 
regimens to be estimated considering the perceived range of a patient’s PK/PD 
response; a stochastic control approach. However, in this approach an assumption 
is made, the amount of inter-individual variability in the population PK/PD 
parameters is representative of the amount in an individual’s PK/PD parameters. 
This assumption of equivalency of inter-individual variability to intra-individual 
variability has not been justified. Considering that the variabilities are of different 
values [112], research is recommended into identifying not only the quantity of 
intra-individual variability in PK/PD but further just how this intra-individual 
variability impacts on PK/PD response over time.   
Three ways to consider how intra-individual variability in PK/PD response impacts 
over time were explained in section 4.5. To explore a new implementation to 
process noise in this thesis, the prediction of the PK/PD response in the drug dose 
algorithm will be done according to research by Delattre et al. (2011) [108] that is 
more biologically relevant than previous implementations. The consideration of the 
entire patient parameter distribution in this way leads to more informed 
distribution of the PK/PD response. Further the assumption of equivalency of the 
intra and inter individual variability is not relaxed. 
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To allow reconciliation of PK/PD model prediction to measurements sampled from 
the patient, current methodology in using the Kalman filter was reviewed. The 
implementation of process noise used in this thesis required the mathematics of 
the Kalman filter to be reconsidered. Currently variance around the mean patient 
PK/PD response is calculated by the Kalman filter, whereas, in this thesis the 
variance is to be estimated from separate simulations. This allows the standard 
Kalman filter to be used in non-linear PK/PD models rather than the extended 
Kalman filter that requires approximations of the PK/PD models in order to 
estimate variance [16, 119]. 
Overall the system proposed is a stochastic closed-loop control that considers noise 
within the dynamics. To demonstrate the different parts of this system the next 
chapter will present examples highlighting certain aspects of the drug dose 
algorithm (sections 5.1 and 5.2) before using the full proposed system in the final 
example (section 5.3). 
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5 STOCHASTIC CONTROL WITH PHARMACOKINETIC TARGETS 
The following chapter applies the stochastic control method explained in Chapter 4 
to a set of individual dosage regimen estimation problems. To allow deeper 
understanding of the stochastic control approach the examples will be applied with 
different aspects of the methodology. This chapter provides examples of drug 
therapies that can be individualised by PK targets. 
The first example for lidocaine therapy is primarily intended to introduce the 
handling of stochastic parameters within control theory. The second example with 
warfarin explains an alteration in current methodology in order to deal with 
patients who have missing covariates, as well as also introducing noise into the PK 
response estimation. Finally, the full stochastic control methodology explained in 
Chapter 4 is applied to imatinib therapy showing the robust and adaptive abilities of 
the approach.   
5.1 Example of Obtaining an Optimal IV Infusion Regimen without 
Feedback 
5.1.1 Introduction 
The following example from Bayard et al. (1994) [89] is an introduction to the 
control of dosage regimens. The example considers a single patient requiring a 
dosage regimen of changeable continuous IV infusion. The drug to be controlled is 
the local anaesthetic and antiarrhythmic lidocaine.  
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The individualised dosing of lidocaine had been considered several times before 
Bayard et al. (1994) by Vozeh et al. (1984, 1985 & 1987) [127-130]. In Vozeh et al.’s 
applications individual PK/PD parameters were calculated by adjusting population 
PK/PD parameters by patient factors, i.e. weight, heart failure. Beach et al. (1988) 
[131] also reported a dose individualisation study, based on the same methodology 
as Vozeh et al.’s applications.  
The key difference between Bayard et al. (1994) and similar studies into 
individualised lidocaine dosing at that time was the parameterisation of the 
population PK/PD distributions. In Bayard et al. (1994) a distribution of discrete 
points was used to describe population PK/PD parameters, the probability of the 
points are reweighted accordingly for individual patient PK/PD. In previous 
applications, the population PK/PD log normal distributions appear to be 
individualised by shifting the distribution according to the mean estimates of 
individual PK/PD parameters. 
In this section, the discrete distribution of an individual’s PK/PD parameters is 
investigated. Considering how appropriate the method of reweighting a population 
distribution is for individualised drug therapy. 
5.1.2 Method 
The individual’s PK parameter distribution in Bayard et al. (1994), shown in Table 
5-1, is derived from a non-parametric population PK distribution (using software 
similar to the current Pmetrics programme [43]). The derivation of the individual’s 
PK parameter distribution is done by assigning each discrete support point in the 
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population PK distribution a probability corresponding to the probability that the 
patient has that specific parameter value. 
Table 5-1: Table of PK Parameters and their Respective Probabilities 
 
As lidocaine displays ‘two-stage’ elimination on its concentration time curve it is 
assumed that a two compartment PK model best fits the data. Extending equation 
2.5 to multiple infusions, the concentration time equation for the central 
compartment is: 
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5.1 
where     
 
 
((          )  √(          )          ) formulated in 
Metzler et al. (1971) [34]. The IV infusion of lidocaine will be changeable at seven 
time points given in minutes;   
  with         represents the start of each level 
of infusion with    
 
 corresponding to the end of the level of infusion. The time 
points are closer together at the start of treatment to allow the drug to accumulate 
to a desirable level in the central compartment. To extend equation 5.1 to changing 
infusion rates the two sets of time points   
  and   
  are: 
    (     ) prob     (     ) prob     (     ) prob    ( ) prob 
0.0180 0.3085 0.0330 0.4013 0.0190 0.401 13.7 0.401 
0.0225 0.383 0.0660 0.440 0.0380 0.440 27.4 0.440 
0.0270 0.3085 0.132 0.159 0.0760 0.159 54.9 0.159 
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For example, applying these time points at the second infusion change point, the 
plasma concentration at this time is calculated as, 
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5.3 
Each parameter (  ,    ,     and   )  can take one of three values, shown in Table 
5-1 all of which are assumed statistically independent. All possible models of the 
combination of the four parameters with three possible values are considered 
therefore there are (34) eighty-one models in total. This is to be seen as eighty-one 
different PK parameter sets with varying probabilities of appropriately describing 
the patient’s individual PKs.  
The probabilities of the eighty-one parameter sets are calculated by multiplying the 
single parameter probabilities, given in Table 5-1 together. This leads to some 
parameter sets being more likely than others, the lowest probability of a parameter 
set being 0.3085*0.1587*0.1587*0.1587=0.0012 and the highest probability is 
0.383*0.44*0.44*0.44=0.033 (almost 3 times as likely to be the patient’s PK 
parameter values than the lowest probability) .  
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With the pharmacometric model the plasma concentration of an individual patient 
can be calculated at infusion change points. To guide the plasma concentration to 
the desired therapeutic target, the cost function to be minimised is: 
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 5.4 
where     (                                   ) and   is the number of the 
parameter set. Notably equation 5.4 contains the probabilities of the individual 
parameter sets, which give a weighted average of all possible model outputs. The 
target lidocaine concentration of 3µg/ml in the central plasma compartment was 
chosen by Bayard et al. (1994) [89] and the therapeutic range is suggested as 1.5-
6µg/ml.  
To find the optimal regimen to treat all the eighty-one possible models the ‘Solver’ 
algorithm was used in Microsoft Excel 2007. The algorithm works by inputting 
different dose regimens until the minimum of the cost function is found [132]. 
Whilst the algorithm works by trial and error, successive trials are educated ‘leaps’ 
to another dosage regimen rather than incremental steps. 
5.1.3 Results 
Applying the algorithm, the maximal regimen,     , was found to be: 
 
    (                                  ) 5.5 
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These values, given to 3SF, are identical to those reported in Bayard et al. (1994). A 
concentration time plot of all eighty-one parameter sets is shown in Figure 5-1, the 
values are simulated based on giving the dosage regimen. None of the parameter 
sets produce a concentration higher than 6µg/ml, at any infusion change point, as 
required. However just over 40% of the observations are below the minimum 
required concentration of 1.5µg/ml demonstrating that the control is tending to 
favour low concentrations. The target concentration of 3µg/ml is closer to the 
lower bound of the therapeutic range so this will encourage concentrations to be 
lower than if the bound was set in the middle of the therapeutic window.  
If the target concentration was changed to 3.75µg/ml, the maximal regimen was 
found to be: 
 
    (                                  ) 5.6 
The new target concentration causes an expected increase in the recommended 
infusion rates to meet the target. However, still around 35% of the observations are 
outside the therapeutic range of 1.5-6µg/ml with 17 observations now above 
6µg/ml. Additionally, there is still a tendency for the majority of observations to be 
grouped at the lower concentrations. 
113 
 
 
 
 
Figure 5-1: Concentration time plots from the 81 parameter sets given dosage regimens in equations 5.5 and 
5.6 to target 3 and 3.75µg/ml respectively. 
The probabilities are multiplied against the squared distance away from the 
therapeutic target in the cost function, as shown in equation 5.4. This means higher 
probabilities will be higher multipliers; minimisation will be best achieved when the 
highest probabilities are multiplied by the lowest squared distances. This leads to 
the dosage regimen derived being correctly favourable to minimising the distance 
away from therapeutic target in the highest probability parameter sets. Reducing 
the left plot of Figure 5-1 to the ten highest probability parameter sets is of interest 
to demonstrate that the control has performed in this intended way. 
As can be seen from Figure 5-2 apart from two time points the dosage regimen has 
caused the concentrations from two respective parameter sets to reach and stay 
within the desired therapeutic range of lidocaine. This demonstrates, firstly, that 
the cost function has worked to encourage the dosage regimen by controlling the 
parameter sets that have higher probabilities of occurring. However, the range of 
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responses is not constant due to the discrete non-parametric individual parameter 
distribution. A constant range could potentially better describe patient response as 
biological pathways tend to produce a continuous range of output [133].  
 
Figure 5-2: Concentration time plots from the ten highest probability parameter sets given the equation 5.5 
dosage regimen. 
 
Comparing Figure 5-2 to Figure 5-3, the concentration time plot of the ten lowest 
probability parameter sets, Figure 5-3 contains mostly observations below the 
therapeutic range. The dosage regimen of equation 5.5 is less appropriate for the 
lowest probability parameter sets; this is due to the cost function incurring less cost 
for these concentration points being outside the target range. 
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Figure 5-3: Concentration time plots from the ten lowest probability parameter sets given the equation 5.5 
dosage regimen. 
 
5.1.4 Conclusion 
The way a stochastic control algorithm considers the entire distribution is 
demonstrated in this example. The eighty-one parameter sets, of the PK parameter 
density, represented all the different possible parameter combinations of the 
patient’s PKs. Uncertainty involved in a PK system is represented as any one of the 
eighty-one models could feasibly describe the patient. 
In Bayard et al. (1994) a subsequent control is applied where the eighty-one models 
are reduced a MAP estimate [89]. This singular MAP is the average of all the 
parameter sets and therefore the dosage regimen that is derived using this method 
is for the ‘average’ patient PK/PD response. The dosage regimen for the MAP 
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estimate is then given in simulation to the eighty-one parameter sets the variability 
of the plasma concentration increases, with observations ranging from 0.9-9µg/ml. 
This increased range of potential concentrations highlights the risk in assuming that 
the patient’s PKs are best described by the ‘average’ of potential values. However, 
even in the stochastic control approach, studied in this section, the estimated 
optimal infusion rates caused 40% of the predicted plasma concentrations to fall 
outside the therapeutic range of lidocaine.  
One potential reason for this high amount of out of range predictions could be due 
to the nature of the control utilised. In Bayard et al. (1994) an open-loop control 
was used; however, the MM approach can perform closed-loop control when 
measurements of PK response become available. When measurements from the 
patient are fed back, the MM approach probabilities are re-calculated  through 
finding how close the prediction from the PK parameter sets is to the measurement 
and reweighting according to proximity [90]. The parameter sets that generate 
predictions closer to the measurement are derived as a higher probability than 
those that are further away with their predictions. This process is repeated for 
every PK measurement taken.  
With increasing measurements the derived PK distribution will tend towards 
describing the patient’s true PK. However, this reliance on feedback suggests a 
potential concern in regards to the adaptability of the MM approach. This study, in 
particular, raises questions as to whether the MM approach is appropriate for 
patients with limited or no measurements.  
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For example, the majority of out of range concentrations were from parameter sets 
that have a volume of distribution value 54.9L. This is where the PK parameter 
distribution is to be analysed as to whether it is appropriate to the individual 
patient. If the value of 54.9L is not appropriate to describe an individual patient’s 
volume of distribution, the parameter sets that include 54.9L, even with low 
probabilities, contribute to altering the dose away from that which is beneficial for 
the patient.  
In contrast, if the patient’s volume of distribution is appropriately described by 
54.9L and the control is run including only parameter sets (27 of the 81 parameter 
sets) with a volume of distribution of 54.9L the individualised dosage regimens are 
nearly four times the amount of drug compared to those given in equation 5.5. If 
the patient’s true PK parameters are of this sub-group of parameter sets then they 
would benefit from a more individualised dosage regimen to bring them within 
therapeutic range.  
This issue suggests that quick identification of whether a patient is in this subgroup 
is important. With various factors affecting volume of distribution such as body 
weight [127], genetics [134], even hydration level [135], it is possible to weight 
patient probabilities more towards subgroups of the volume of distribution and 
then, if concentration time data becomes available for the patient, update the 
weighting. This enhanced method of weighting parameter sets can potentially 
mean adaptability is enhanced. 
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In light of the conclusions from this study, in the next example, the MM approach is 
used in an altered way to allow a stochastic control based on covariates affecting PK 
parameters.  
5.2 Example of Obtaining an Optimal Oral Dosage Regimen with 
Noise Introduced and an Altered Multiple Model Approach 
5.2.1 Introduction 
The drug of interest in this example is the anticoagulant warfarin; current dosing 
algorithms for warfarin, derived by linear regression methods, were explored in the 
Chapter 3. The difficulties of deciding upon an appropriate maintenance dose for a 
patient are complicated by high inter-patient variability caused by, for example, 
pharmacogenetic factors and warfarin being sensitive to dietary intake [44]. When 
initiated on warfarin therapy the patient is given loading doses before dosing is 
refined to a daily maintenance dose.  
In the previous example of individualising Lidocaine using a MM approach, the 
adaptability of the methodology was entirely reliant on attaining concentration 
time measurements. To reduce this reliance on measurements, information on 
covariates that affect PK parameters can be used in conjunction with the MM 
approach. To adjust the MM methodology to this new approach, probabilities of 
parameter sets correspond to the prevalence of covariates that cause variability in 
PK parameters. 
Assuming concentration targets can be created for warfarin therapy then the drug 
dose algorithm can estimate a dosage regimen to reach these targets. However, 
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warfarin is not dosed according to plasma concentrations; the INR measurement 
informs most dosing decisions with many different nomograms available for use in 
the maintenance dosing phase [10]. In the study of this section, concentration 
targets are derived from Hamberg et al. (2010) [21]. 
5.2.2 Method 
This example assumes that the loading dose is fixed for each patient, often the 
‘10mg, 10mg, 5mg’ regimen is used in the United Kingdom, with the focus being on 
a dosage regimen that provides maintenance dosing after this period of loading. To 
model the PK of warfarin, a one compartment model with full bio-available oral  
dosing is appropriate [21]. The following equations were used to describe how the 
plasma concentration of warfarin changes with time: 
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5.8 
To find values for the parameters in equation 5.7 and 5.8 literature on warfarin PK 
parameters was searched and in the study by Hamberg et al. (2010) values have 
been derived for warfarin S-clearance in differently genotyped CYP2C9 patients of 
various ages. 
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where                in        are CYP2C9 and age dependent values for S-
warfarin clearance respectively, age is given in years, and             are 
genotypes known to affect clearance [73]. Two PK parameters were fixed at the 
population values reported in Hamberg et al. (2010) [21],   (     )        , 
  ( )      , and    
  
  
. 
Several values for the clearance of warfarin can be achieved by inputting a range of 
ages along with different genotypes into the equations 5.9 and 5.10. Using the age 
range of eighteen to ninety-nine and all possible CYP2C9 genotypes led to 
81*3=243 possible parameter sets. This density resembles the previous lidocaine 
density, Table 5-1, in composition; a density of discrete PK parameter points. 
However, whereas in the lidocaine example the probabilities had been derived in 
Bayard et al. (1994) from a measurement of PK response (the MM approach); in this 
warfarin example patients without PK parameters who require individualised 
dosing are considered in a new altered MM approach by weighting by prevalence of 
covariates in the population. Prevalence of different covariates were documented 
in a recent large warfarin study by the International Warfarin Pharmacogenetics 
Consortium (IWPC) [70] and these informed the probabilities for all 243 parameter 
sets.  
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All 243 possible parameter sets would only apply to patients of whom there was no 
covariate information but some demographic information, such as age, is easy to 
obtain. In this altered MM approach, when there are covariates that require further 
diagnostic tests, such as genotyping, whilst the value of the covariate is being 
determined, dose estimates can still be obtained for the patient based on the 
prevalence of the covariate.  
If another demographic variable that affected the clearance of warfarin was 
unknown, such as another genotype, the prevalence could be found for the various 
variants of that genotype and the 243 parameter sets possible for a new patient 
would grow accordingly. 
 To demonstrate the altered MM approach, parameter sets for a 20-year old and a 
71-year old patient with unknown genotype were considered. Overall, the dose 
regimen tends towards the most likely parameter sets; however, less likely, but still 
probable, sets would not be discarded until the covariate is determined. When the 
value of the covariate is determined the number of parameter sets that are 
attributable to the patient would be reduced accordingly until eventually only a 
single parameter distribution is attributed to the patient.  
The objective is to find the optimal dosage regimen in this system using the cost 
function given by, 
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where    is an oral dose given at time  ,   is the number of parameter sets 
applicable to the patient,    is the plasma concentration target at time  ,  ( |  ) is 
the prevalence of the parameter set   in the population and    is a weighting that 
penalised higher doses. The optimisation problem was set to minimise equation 
5.11.  
The algorithm was applied to two different scenarios; firstly, when dosing to the 
parameter sets of a 71 year-old with unknown CYP2C9 genotype and secondly, 
when dosing to the parameter sets of a 20 year-old also with unknown CYP2C9 
genotype. There will be three concentration targets of 0.4, 0.3 and 0.2 mg/l; these 
represent the three concentrations that lead to an INR value of 2.5 for the three 
different VKORC1 genotypes G/G, G/A and A/A respectively [21]. The results will 
present an individualised approach to dosing based on previous information. 
To find the optimal regimen to treat the six possible models for each patient, the 
models were inputted into Microsoft Excel 2007 and the dosage regimens 
calculated via the Solver algorithm [132] minimising the cost function. 
5.2.3 Results  
The dose recommendations for a 71-year old patient are given in Table 5-2. After 
the three loading doses the control derives a ‘refinement’ dose before the next 
three doses, which are of similar amounts; from Figure 5-4, Figure 5-5 and Figure 
5-6 it can seen that this is due to the loading doses having caused the 
concentrations from the parameter sets to rise above or dip below the 
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concentration target . The concentrations for genotypes that are less prevalent in 
the population appear to be diverging away from the target concentration. 
Table 5-2: Dose Recommendations for a 71-year old Patient with Unknown CYP2C9 Genotype. 
Target     
(  ) 
Loading 
1 
Loading 
2 
Loading 
3 
Dose Day 
4 
Dose Day 
5 
Dose Day 
6 
Dose Day 
7 
(mg/l) (mg) 
0.4 10 10 5 9.42 7.32 7.43 7.62 
0.3 10 10 5 4.79 5.45 5.55 5.71 
0.2 10 10 5 0.16 3.59 3.67 3.79 
Figure 5-4: Dose Derivation in for the VKORC1 G/G Target Concentration: 71-year old patient with unknown 
CYP2C9. 
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Figure 5-5: Dose Derivation in for the VKORC1 G/A Target Concentration: 71-year old patient with unknown 
CYP2C9. 
 
Figure 5-6: Dose Derivation in for the VKORC1 A/A Target Concentration: 71-year old patient with unknown 
CYP2C9. 
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From equation 5.10 clearance of S-warfarin is shown to decrease with age 
therefore, due to the PKs, for the same concentration targets the doses 
recommended will be higher for a 20-year old compared to a 71-year old, this is 
shown in Table 5-3. A similar pattern, compared to Table 5-2, of dose loading, single 
refinement and then converging maintenance doses is seen in Table 5-3. Again, 
lower probability parameter sets appear to be diverging away from the target 
concentration in Figure 5-7, Figure 5-8 and Figure 5-9, however, in this case the 
divergence occurs with more acceleration. 
Table 5-3: Dose Recommendations for a 20-year old Patient with Unknown CYP2C9 Genotype. 
Target 
(  ) 
Loading 
1 
Loading 
2 
Loading 
3 
Dose Day 
4 
Dose Day 
5 
Dose Day 
6 
Dose Day 
7 
(mg/l) (mg) 
0.4 10 10 5 13.95 9.96 10.13 10.47 
0.3 10 10 5 8.67 7.42 7.57 7.84 
0.2 10 10 5 3.39 4.88 5.01 5.21 
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Figure 5-7: Dose Derivation in for the VKORC1 G/G Target Concentration: 20-year old patient with unknown 
CYP2C9.. 
 
Figure 5-8: Dose Derivation in for the VKORC1 G/A Target Concentration: 20-year old patient with unknown 
CYP2C9. 
 
Figure 5-9: Dose Derivation in for the VKORC1 A/A Target Concentration: 20-year old patient with unknown 
CYP2C9. 
127 
 
 
 
In Table 5-2 a common complication of optimisation is presented. For the lowest 
target concentration of 0.2mg/l the dose recommended on day 4 is below the 
lowest dose that a clinician is currently able to prescribe. With this particular output 
from the drug dose algorithm the clinician would decide whether to not give the 
patient a dose of warfarin that day or to give them the lowest possible dose. Other 
dose recommendations shown in Table 5-2 and Table 5-3 are able to be rounded to 
doses that can be prescribed. 
5.2.4 Conclusion  
This study suggests the benefit of including covariates that affect PK parameters in 
an altered MM approach. Currently, the MM approach does not consider covariate 
information [136] however the alteration performed in this study suggests a 
methodology to incorporate such data. 
This inclusion of covariate information is one form of closed loop feedback as it 
causes the system to update parameter information. In clinical practice basic 
demographics like age are recorded routinely and are readily available to the 
clinician. Whereas some covariates will require extra testing to determine, for 
example, genotyping tests often take time to be completed and as a result will not 
be directly available to be included in initial dosing decisions. The drug dose 
algorithm of this section considered weighted probabilities to estimate dosage 
regimens, in absence of genotype covariate information. 
Considerations in using the altered MM approach would the requirement of 
sufficient data for particular covariates to be investigated. Even when the 
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parameter distributions are generated from larger datasets, such as in this example, 
assumptions still have to be made. In the example above, a linear relationship was 
assumed for age however more data could suggest the relationship between age 
and a clearance to be more complex. 
In addition to linear regression methods, MAP Bayesian control has also been used 
to individualise warfarin dosing [5, 79]. The control approach used in this study can 
be used alongside this current methodology; the relevant parameter-covariate sets 
for a patient can be used as prior information when plasma concentrations are 
sampled. If the covariate that affects the PK parameter is determined, the posterior 
results of MAP Bayesian control can be used to inform the respective parameter set 
for that covariate. For example if there are measurements taken from a patient 
before they are identified to have CYP2C9 *1*3 genotype then the information 
from the measurements along with other CYP2C9 *1*3 patient measurements will 
be used to inform the CYP2C9 *1*3 parameter set in a subpopulation PK analysis. 
This informed CYP2C9 *1*3 model will then be available in dosage recommendation 
for future patients.  
Further work to make this example of stochastic control more robust would have 
been to feedback measured concentration values. This process ‘checks’ the 
prediction of the pharmacometric model against the measurement and reconciles 
the two to reduce the uncertainty around the true concentration of warfarin in the 
body. This reconciliation will be done in the next example using the Kalman Filter, 
explained in section 4.6. This feedback is considered in the subsequent example of 
this chapter. Further, the plasma concentration over continuous time, rather than 
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at dosage changes, will be estimated to ensure the patient is dosed after 
considering the entirety of predicted future outcomes. 
Secondly, the noise introduced to the plasma concentration predictions was done 
by adding a random value onto the prediction, see equation 5.7. As discussed in 
4.6.2.5 this process of inputting noise does not lead to a distribution of predicted 
patient response that is reconcilable using the Kalman filter. In the next example, 
noise through varying the parameters of the PK model within their distributions by 
the process explained in 4.5.2 is implemented. 
This example has shown that covariate-parameter relationships can be used to 
inform dosing for a new patient. The parameter values for the example were taken 
from literature and therefore represent an approach in which data is compounded 
from other sources rather than concentration-time data. Thus reducing the need 
for measured patient samples, which require analysis using pharmacometric 
software incurring extra time and resources.  
5.3 Example of Obtaining an Optimal Oral  Regimen with 
Parameter Noise Introduced and Measurements Used to Update 
the System 
5.3.1 Introduction 
Imatinib, used in the treatment of leukaemia [137], has an established standard of 
care however patient PK/PD response is ranging largely due to the inter-individual 
variability in the population [138]. Imatinib is usually administered as a 400mg dose 
regardless of patient dosing needs with 800mg doses prescribed if there is an 
apparent resistance to the drug. Recent publications suggest that the drug be dosed 
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to maintain an individual trough plasma concentration of around 1000ng/ml [39, 
137], this is to ensure that the plasma concentration of the drug stays high enough 
to inhibit proliferation of Philadelphia positive (Ph+) metaphases [138]. 
Instead of the MM approach, used in the previous lidocaine and warfarin examples, 
patient PK parameters point estimates were calculated from the data and a 
distribution of intra-individual variability was constructed around these point 
estimates. The measured plasma concentrations were then fed back into the 
system to reduce uncertainty around the plasma concentration of imatinib. 
5.3.2 Method 
Serial blood samples were collected from a sample of twelve patients attending 
routine clinic visits at The Royal Liverpool University Hospital between April 2006 
and August 2011. The patients were taking imatinib as treatment for chronic 
myeloid leukaemia. The dataset extract for this study includes patient ID number, 
time interval since last dose taken (hours), last dose taken (mg) and plasma 
concentration measurements (ng/ml). The twelve patients in the dataset had their 
plasma concentrations of imatinib measured six to eight times in a twenty-four 
hour period post-dose.  
Peripheral blood was collected in EDTA coated Monovettes® (Starstedt, Germany) 
and stored at 4°C until processing.  The blood was spun at 500 rcf (relative 
centrifugal force) and the plasma collected was stored at -80°C until analysed. 
Imatinib plasma levels were determined by simple UV-HPLC analysis as described by 
Davies et al. (2009) [139]. 
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The plasma concentration over time is appropriately modelled by a one 
compartment PK model with full bio-available oral dosing [39, 137]. The following 
equations describe how the concentration changes with time: 
 
    
  
        5.12 
 
   
  
 (
     
  
     ) 5.13 
where           (   
 ) are stochastic variables that change randomly every 
time step (see section 4.5.2).   
The estimated individual parameters are shown in Table 5-4 calculated using 
NONMEM (Version 7.2) in a previous study by Lane et al. (2011) (unpublished 
work). NONMEM produces point Bayes estimates of individual parameters 
therefore the values of Table 5-4 formed the mean ( ) of the PK parameter 
distribution. Since distributions indicating intra-individual variability were required 
for this imatinib example, literature was searched to find estimates of intra-
individual variability previously seen in patients taking imatinib. Haouala et al. 
(2009) [140] indicate that imatinib has a low intra-individual variability however the 
referenced paper by Picard et al. (2006) [39] does not provide a value for intra-
individual variability. Widmer et al. (2006) [141] reported intra-individual variability 
of 31% in the plasma concentrations of imatinib patients however the paper is 
unclear as to whether the assay error was included in this amount.  
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The following methods were performed in MATLAB and a code is provided in 
Appendix: I of this thesis. To allow an amount of intra-individual variability in the PK 
response to be studied two parameters,    and    were selected to vary within 
their distributions with respect to time. Due to the relationships between all the 
parameters, varying these two variables caused the entire patient PK to vary with 
time. In absence of intra-individual variability indication in literature, the lognormal 
distributions of    and    were described by    (  (    )      ) where      is 
the value of the respective parameters in Table 5-4. Due to noise being introduced 
to the system five simulations were used for each dosage regimen to predict a 
distribution of plasma concentration.   
Table 5-4: Individual PK parameter Bayes estimates. 
Patient ID.    
(1/h) 
   
(1/h) 
   (l) 
28 0.436 0.0613 232 
54 0.703 0.0459 313 
56 0.727 0.0523 312 
78 0.617 0.0594 275 
91 0.494 0.0285 297 
101 0.307 0.0632 295 
118 0.684 0.0583 287 
119 0.454 0.0617 280 
122 0.317 0.0437 353 
124 0.722 0.0578 193 
244 0.674 0.0396 271 
328 0.190 0.0361 335 
At every measurement time point the Kalman filter [142] is utilised to reconcile the 
prediction from the differential equations given in equation 5.12 and the 
measurement. After the measurements were feedback, dosage regimens for seven 
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twenty-four hour periods were required. A dosing period of seven days allowed 
patients who may have trough concentrations below or above the desired trough 
concentration to be prescribed doses to bring them closer to the target 
concentration before the system derives the appropriate maintenance dosing of 
imatinib.  
The dosing period of a week was assumed long enough for therapeutic trough 
plasma concentration of imatinib to be achieved and then maintained with the final 
estimated dose. The drug dose algorithm was only allowed to derive doses in 
multiples of 100mg as these are the smallest available tablet sizes of imatinib [143] 
and therefore the dosage regimens that were estimated can be prescribed to the 
patient.   
Given the metrics of the dose requirements and the target trough concentration of 
1000ng/ml, the cost function is expressed as: 
 
  
        
(   )
∑∑(       )
 
 
   
 
   
 5.14 
        is the number of simulation chains used.  
To show the effect of the adjusted dosage regimen derived by the drug dose 
algorithm each individual patient’s trough concentration over seven days given two 
dosage regimens were simulated; the dose they were receiving at the time of 
sampling and the recommended doses estimated by the system. The difference 
between the trough concentration values achieved and the target trough plasma 
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concentration of 1000ng/ml [39, 137] is an indicator of the performance of the 
control.  
5.3.3 Results  
The dosage regimes derived from the set of twelve patients included in this study 
are shown in Table 5-5. Results show that the drug dosing algorithm derived new 
dosage regimens for all but three patients. Of those identified as requiring a 
different dosage regimen none of the derived dosage regimens recommend a 
return to the original dose of imatinib after seven days of revised therapy. This 
suggests that the standard 400mg dose of imatinib does not bring the majority of 
patients to the TTL of 1000ng/ml. Further in the cases of patients 119 and 122 who 
were on a dose of 800mg daily when blood samples were taken, only the dosage 
regimen of patient 119 suggests this was an adequate adjustment to meet the 
trough plasma concentration target.  
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Table 5-5: Comparison of the Performance of Current and Revised Dosage Regimens for Each Patient. 
P
a
ti
en
t 
ID
 
Current Revised  Mean 
Dosage 
Difference 
(mg) 
Daily 
Dose 
(mg) 
Average 
Deviance 
from TTL 
(ng/ml) 
Seven Day Dosage Regimen (mg) Average 
Deviance 
from TTL 
(ng/ml) 
28 400 -400 800, 700, 700, 700, 700, 700, 700. 30 314 
54 400 -328 700, 600, 600, 600, 600, 600, 600. 13 214 
56 400 -442 800, 700, 700, 700, 700, 700, 700. -43 314 
78 400 -489 800, 800, 800, 800, 800, 800, 800. 0 400 
91 400 453 200, 200, 300, 300, 300, 300, 200. 47 129 
101 400 -512 800, 800, 800, 800, 800, 800, 800. -54 400 
118 400 -504 800, 800, 800, 800, 800, 800, 800. -29 400 
119 800 -13 No revision needed   
122 800 432 400, 500, 600, 600, 500, 600, 600. 9 143 
124 400 -244 600, 500, 500, 500, 500, 500, 500. -50 114 
244 400 -13 No revision needed   
328 400 21 No revision needed   
Also shown in Table 5-5 are the average deviances from the TTL, which is an 
indicator of the accuracy of the dosage regimens derived by the system. As the drug 
dosage algorithm is restricted to estimating feasible doses of 100mg multiples the 
TTL may not be exactly met even with the revised dosage regimens. If the patients 
who are advised onto revised dosage regimens were to stay on their standard daily 
doses then the patient will be up to 48.9% away from the TTL which would lead to 
doubts as to whether the drug is indeed providing sufficient enzyme inhibition [39]. 
The concentration-time curves for firstly, the dash dot line, if the patient continued 
receiving the same dose as at the time of sampling and then secondly, the double 
dash line, if they were prescribed the derived dosage regimen are shown in Figure 
5-10 to Figure 5-18. 
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Figure 5-10: Plasma Concentration time profile of Patient 28 receiving imatinib. 
 
Figure 5-11: Plasma Concentration time profile of Patient 54 receiving imatinib. 
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Figure 5-12: Plasma Concentration time profile of Patient 56 receiving imatinib. 
 
Figure 5-13: Plasma Concentration time profile of Patient 78 receiving imatinib. 
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Figure 5-14: Plasma Concentration time profile of Patient 91 receiving imatinib. 
 
Figure 5-15: Plasma Concentration time profile of Patient 101 receiving imatinib. 
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Figure 5-16: Plasma Concentration time profile of Patient 118 receiving imatinib. 
 
Figure 5-17: Plasma Concentration time profile of Patient 122 receiving imatinib. 
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Figure 5-18: Plasma Concentration time profile of Patient 124 receiving imatinib. 
 
5.3.4 Conclusion 
Research into individualising imatinib therapy is available in literature. One 
particular area of research is in identifying a plasma concentration target that leads 
to therapeutic response in patients. Based on studies by Picard et al. (2007) [39] 
and Larson et al. (2008) [137] a target of 1000ng/ml was utilised in this study. 
However, further research into the individualisation of plasma concentration 
targets would be recommended, Gotta et al. (2012) [144] reported that variable 
therapeutic plasma concentration targets had been derived in different population 
studies. Variable therapeutic plasma concentration targets in different populations 
would suggest that targets could be individualised based on covariates such as race 
or pharmacogenetics. Studies where individualised dosage regimens are estimated 
do not appear in literature. This study suggests that individualised imatinib dosing is 
preferable to standard dosing in bringing a patient to TTL. 
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Of the revised dosage regimens the largest average deviation is 5.4% below TTL, 
which shows the drug dose algorithm is attempting to bring the patient to TTL. 
Especially encouraging is that patient 78, who was shown in simulation to 
experience the largest deviation of 48.9% from TTL if they continued to receive 
standard dosing, would greatly benefit from the therapeutic effect of the revised 
dosage regimen, which causes no departure from TTL, shown in Table 5-5 and 
Figure 5-13. 
Further, all of the revised dosage regimens show large reductions on the deviations 
for TTL, as shown in Table 5-5. The drug dosage algorithm is restricted to estimating 
feasible doses of 100mg multiples the TTL may not be exactly met even with the 
revised dosage regimens. If the patients who are advised onto revised dosage 
regimens were to stay on their standard daily doses then they will be up to 48.9% 
away from the TTL, further seven of the ten patients will be an estimated between 
24.4-48.9% below the TTL, which would lead to doubts as to whether the drug is 
indeed providing sufficient enzyme inhibition  
For some patients a constant dosing level does not appear suitable to maintain 
them at the desired TTL. This is apparent with patients 91 and 122, see Figure 5-14 
and Figure 5-17 respectively, as their doses never converge to one constant daily 
amount unlike the other patients in the study. These patients would benefit from 
the drug dose algorithm outlined in this study as the algorithm will derive the best 
possible doses to reach therapeutic targets whereas in practice only constant daily 
doses of 400/600/800mg are prescribed. 
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The approach utilised in this section used parameter densities that represented the 
intra-individual variability of each patient. This ties into a wider philosophy 
presented in this thesis that each patient has their own unique parameter density 
that describes their intra-individual variability by central tendencies and 
uncertainty. This is in contrast to the previous lidocaine study, in this thesis, where 
an optimal infusion rate was determined by the MM approach [89], which uses 
probabilities attached to a reweighted population parameter density to 
individualise the control to the patient.  
The comparison between MM approach and the new methodology applied in this 
imatinib dosing study is that the intra-individual variability is not assumed to take 
the value ranges of the inter-individual variability seen in the population. Further, 
with the intra-individual distributions in this study dosage regimens were estimated 
that considered the potential for patient PK parameters to change over time. This is 
in contrast to current individualised dosage regimen control approaches that either 
assume PK parameters remain fixed throughout studies [145] or can only change 
value when measurements are taken [109]. 
The Kalman filter was used to estimate the plasma concentration of patients when 
measurements were taken. This particular feedback can be thought of as a ‘soft 
reset’ for the system as only the output parameter, the plasma concentration in this 
example, is being adjusted. If any future measurements are taken, after a new 
dosage regimen has been prescribed, the drug dose algorithm can loop these 
measurements in as well and then derive any further revisions of the drug dose 
regimen that are required. Further research into identifying the intra-individual 
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variability seen in PK parameters is required to improve the feedback approach in 
this study. A potential area would be the development of methodology that 
calculates the likelihood of PK parameters given the data however does not assume 
that parameters are time-homogenous. 
In conclusion, the drug dose algorithm described in this study provides an effective 
method to estimate individualised dosage regimens for patients receiving imatinib 
therapy. The drug dosage algorithm used the Kalman filter to process feedback 
from plasma concentration samples and predictions from the PK model. The 
predictions from the PK model were derived from PK parameters allowed to vary 
within their distributions that represented intra-individual variability. Dosage 
regimens were calculated by a control function that seek to bring a patient to the 
reported therapeutic target of imatinib. The system is able to be updated at any 
point when a measurement from a patient becomes available and a new dosage 
regimen for any length of treatment can be derived to meet changing therapeutic 
targets.   
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6 STOCHASTIC CONTROL INCORPORATING DISCRETE 
OUTCOME PROBABILITIES 
The cost function was explained previously in Chapter 4 as a mathematical equation 
that determines the optimal dosage regimen from a set of all possible dosage 
regimens. The particular example of a cost function considered in the examples of 
Chapter 5 determined the optimal dosage regimen by minimising the distance of 
the predicted PK/PD response from the target value.  
The stochastic control of discrete outcome probabilities is presented in this chapter, 
which requires new formulations of the cost function. The first four sections explain 
the different ways to utilise discrete outcome probabilities in the individualisation 
of drug therapy ranging from a post-estimation diagnostic to merging Markov 
modelling into the cost function of the stochastic control method.  
Another example of applying the drug dose algorithm in imatinib therapy is 
presented where the control function is formulated to control multiple targets, 
which include probabilistic targets of PD outcome. The results of the approach are 
compared to the results of section 5.3, the imatinib therapy example. 
6.1 Examples of Discrete Outcomes in Pharmacometrics 
Application 
6.1.1 Adverse Drug Reactions 
The individualisation of a dosage regimen to a specific patient is undertaken to 
determine the optimised therapy given clinical targets. One such target is a desired 
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plasma concentration and in previous chapters of this thesis the methodology of 
using stochastic control to derive a dosage regimen that achieves target PK 
concentrations is discussed and demonstrated.  
Another clinical target, which also affects dosing decisions, is the risk of adverse 
drug reactions. Dose-dependent adverse drug reactions account for the majority of 
adverse events; in many cases, higher doses lead to a heightened risk of an adverse 
drug reaction [146]. However, higher doses can also be required to induce a 
required therapeutic plasma concentration. This trade off complicates dosing 
decisions; with some drug therapies achieving the plasma concentration target may 
be paramount and an increased risk of adverse drug reactions is an unfortunate 
consequence in the need for a definite treatment effect. This is often the trade-off 
between efficacy and the risk of an ADR required in cancer therapy as curing or 
preventing the spread of cancer is the main priority due to the high death rate from 
the disease.  
However, other drugs can cause severe ADRs, in this case, reducing the risk of 
occurrence is seen as more important. For example, in warfarin therapy, whilst 
there are long term health risks with thrombosis, if a higher dose is causing severe 
side effects then the clinician may consider lowering the dose of warfarin.  
ADRs can be predicted by generating models based on data collected from patient 
response and use of these models is possible in individualised drug dosing [147]. 
One way to predict the chance of an adverse event is incidence rate monitoring, 
which is demonstrated later this in chapter. 
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6.1.2 Therapeutic Outcomes 
The relationship between drug dose and therapeutic effect on the body is often 
non-linear. Often the non-linear relationship is modelled by the Hill equation [148]. 
As the Hill equation is a logistic function, at the lowest and highest possible 
concentrations the effect of the drug on the body will be the two polar extremes of 
patient response; between these points the range of concentrations will cause 
gradually increasing magnitudes of drug effect. However, when the relationship 
between the drug and patient response is not fully established dosing decisions are 
more complicated. In this situation a probabilistic approach is recommend. In this 
chapter, probabilities of patient response will be derived and their use in the drug 
dose algorithm discussed.   
Discrete patient responses (DPRs) are set of particular patient responses rather 
than a continuous scale of patient response. An example of a DPR is the level of 
therapeutic outcome; e.g. low, moderate or high pain relief. Often a link can be 
hypothesised between a PK target and a PD effect but the mechanism between the 
two is not modelled due to issues such as complexity of the mechanism or the 
inability to measure components of the mechanism. 
The incorporation of probabilistic ADRs or DPRs (‘discrete events’) into the 
estimation of a dosage regimen using stochastic control theory has not been 
explored previously. In this chapter, methodologies for analysing data to derive 
probabilities of future ADRs or DPRs are explained, beginning with utilising 
population data and then progressing to a more mathematical approach of Markov 
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modelling. Similar to pharmacometric data, reporting can be varied in quantity and 
quality, the effect of this variability will be discussed in the next section. 
6.2 Discrete Event Reporting 
Discrete event reporting is required in many areas of research including 
pharmacovigilance, hospital operations and recently the emerging field of health 
economics. Health economics research utilises discrete event data to ascertain the 
costs of treatments. Therefore, the main requirement of the discrete event data in 
health economics is the information on the occurrence and around consequence 
and treatment.  
For discrete event data to be incorporated into the stochastic control algorithms, 
information is required on why the discrete event occurred. If the discrete event is 
dependent on the PK response of a patient the ideal source of data would be a PK 
response measurement at the time of the event. In practice this is not routinely 
collected and, in the absence of individualised data, other techniques are used, 
such as the event concentrations from a few sampled patients being extrapolated 
across the entire population.  When PK sampling is not possible in patients, event 
rates can be presented in respect of dosage amounts. Whilst some dosages of a 
drug could be linked to event rates over a population, on an individual level this 
approach ignores the variability in the PK/PD between patients.  
For example, consider a population of two patients, one with a low rate of drug 
clearance and the other with a high clearance, a dose of any amount would cause 
different plasma concentrations at time points post-dose. If the low drug clearance 
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patient was to experience an event then the event rate for that given dose would 
be 50%. Now if this information was utilised to individualise a dose for a new 
patient, regardless of whether a patient’s rate of drug clearance was known, all 
dosing at that given dose would have to be considered as incurring a 50% chance of 
an event. If the plasma concentration of the patient experiencing the event had 
been measured then there would be the opportunity to introduce individualisation 
as the event rate is no longer associated with the dose (the input to the PK/PD 
system) but rather the plasma concentration.  
To enhance the ability of the drug dose algorithm presented in this thesis, which 
estimates individualised dosage regimens to induce therapeutic targets, this 
chapter will explore probabilities of discrete outcomes. This builds on the research 
presented in previous chapters, a stochastic control system constructed in Chapter 
4 to estimate dosage regimens that induce a certain plasma concentration, 
examples of which are given in Chapter 5. The enhancement will be the 
methodology of how to derive and incorporate the information from probabilities 
into the drug dose algorithm. The following examples will discuss the use of 
discrete event data within stochastic control algorithms. The first example will 
discuss a post-control application with subsequent examples incorporating the data 
into the control function.  
6.3 Post-Control Determination of Discrete Event Probability 
6.3.1 Use of Discrete Event Data Stratified by Dose 
In this approach the dosage regimen estimated using stochastic control is subject to 
post-control assessment with criteria determined by adverse event data. As the 
149 
 
 
 
adverse event data is used post control it does not affect the dosage regimen 
estimation but does provide a probability that the dosage regimen will cause an 
adverse event in the average patient. 
As an example of this approach data presented in literature from a study 
investigating the safety of topiramate, a drug used in the treatment of epilepsy 
[149], is applied. In the publication, a table explaining the adverse events at 
different dosages is presented. If a stochastic controller for topiramate was 
constructed then dosage regimens derived from the controller could be assessed 
for their adverse event rates. To demonstrate this assessment, ten ascending 
dosage regimens were considered, these dosage regimens range from the lowest 
possible dose to the highest possible dose. 
Table 6-1: Table of Probabilities of Adverse Events Occurring at Different Dosages 
Dosage Regimen Probability of Developing the Adverse 
Event ‘Confusion’ During the Dosage 
Regimen 
200, 200, 200, 200, 200, 200, 200 0.09 * (1) = 0.09 
as probability is constant throughout 
200, 200, 200, 400, 400, 400, 400 0.09 * (3/7) + 0.15 * (4/7) = 0.12 
400, 400, 400, 400, 400, 400, 400 0.15 
400, 400, 400, 600, 600, 600, 600 0.17 
600, 600, 600, 600, 600, 600, 600 0.18 
600, 600, 600, 800, 800, 800, 800 0.16 
800, 800, 800, 800, 800, 800, 800 0.15 
800, 800, 800, 1000, 1000, 1000, 1000 0.24 
1000, 1000, 1000, 1000, 1000, 1000, 1000 0.28 
Table 6-1 shows the different probabilities for respective dosage regimens, the 
clinician would be able to see the probability that different dosage regimens have 
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of causing adverse events over the population. If the probability of adverse event 
was considered too high in the clinician’s opinion, they could adjust the dosage 
regimen accordingly. This process allows important clinical judgement to be 
introduced at another stage of the drug dosing algorithm. 
This method serves as a diagnostic on already derived dosage regimens; the next 
examples will explore how to incorporate the information into the control.  
6.3.2 Use of Discrete Event Data Stratified by PK response 
If a certain plasma concentration was known to induce discrete events then to 
perform a post-control evaluation of an estimated dosage regimen, firstly, 
information on the plasma concentration at which the events have occurred would 
be pooled. This is similar to identifying an appropriate concentration level for 
therapeutic effect, for instance the 1000ng/ml target used in the imatinib example 
from section 5.3.  
Consider a drug X that is dosed according to a therapeutic trough plasma 
concentration of 800ng/ml whilst a trough plasma concentration in excess of 
1500ng/ml is linked with an ADR. To calculate the probability that the patient will 
experience the ADR the predicted trough plasma concentration distribution will be 
estimated and the probability to the right of 1500ng/ml will be the probability of 
experiencing an ADR on the given dosage regimen.  
For example, consider the probability distribution shown in Figure 6-1. The 
distribution in the grey shaded area is the probability of an ADR occurring at any 
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time,  , on the derived dosage regimen. Each individual dose in the dosage regimen 
would have a probability distribution attached. 
 
Figure 6-1: Post-Control Discrete Event Probability Determination at Time   . 
6.3.3 Considerations of Post-Control Discrete Event Probability 
Derivation 
The above examples are sub-optimal for use in individualising drug dosage 
regimens as the data are not used in the derivation of the regimen but rather as a 
diagnostic. With this methodology important clinical data is separated from the 
derivation of the dosing regimen. This separation means the dosage regimen 
cannot be declared optimal as the discrete data was not incorporated into the 
control and therefore whilst dosage regimens could induce plasma concentrations 
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to reach the required therapeutic targets they may also induce plasma 
concentrations that increase the risk of a discrete event, such as, ADRs.  
However, there are advantages to post-control diagnostics of a dosage regimen. In 
particular, the example in section 6.3.1 was based on event rates being stratified by 
dose, is a simple application of event data that does not require any data not 
routinely recorded in clinical practice. However, the approach does not contribute 
to individualising a dosage regimen as it is population based and a single dose can 
cause different effects between patients. 
Due to these considerations, a drug dose algorithm that uses discrete event 
probabilities within the control is more appropriate. To enable the drug dose 
algorithm to derive dosage regimens with discrete event probabilities within the 
control an adjustment of the system is required. The current system diagram of the 
drug dose algorithm is shown in Figure 4-10. The next step is to incorporate discrete 
event probabilities into the controller, shown in the ‘Dose Estimation’ section; this 
step is shown in Figure 6-2.  
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Figure 6-2: System Diagram of the Stochastic Controller. 
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6.4 Intra-Control Determination of Discrete Event Probability 
A clinical decision about dosing involves many considerations regarding the 
different factors that will affect the drug therapy for the individual patient. Often 
many of these factors are weighted by a clinician’s experience, for instance, with a 
drug that is treating a very serious disease the importance of ensuring the 
concentration of the drug in the body is high enough to obtain a therapeutic effect 
may be paramount compared to the risk of an adverse events occurring. In some 
drug therapy situations the importance is vice versa, such as when the treatment is 
long term. 
This process of weighting multiple outcomes of therapy is important in this 
application of stochastic control. Due to the mechanistic nature of the controller 
the weightings must be interpreted numerically. This numericalisation is 
complicated by subjectivity, as often weightings are established from a clinician’s 
experience, which can be highly variable. The issue of weightings is discussed by Ji 
et al. (2007) [150] where the authors suggest the ranking of different 
concentrations and their respective effectiveness and toxicity responses in patients. 
The most desirable outcome, the combination of a highest possible effectiveness 
with a lowest possible toxicity is given an indifference probability of 1 and then the 
remaining outcomes, in order of depreciating desirability, are ranked in proportion 
to the most desirable outcome until the least desirable outcome, which has an 
indifference probability of 0.  
For example, the most desirable outcome is assigned an indifference probability of 
1, if there is another outcome that is only slightly less desirable then an indifference 
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probability of 0.95, or similar high indifference probability, might be assigned to 
that outcome. The example in Ji et al. (2007) has 5 possible outcomes with 
indifference probabilities of 1, 0.9, 0.6, 0.2 and 0 respectively. Unfortunately, 
subjectivity is still introduced by the process of choosing indifference probabilities. 
When expert clinical opinion is utilised this may not be a major issue, however if 
subjectivity can be compounded and reinforced with statistical methodology then 
this is the optimal solution. 
6.4.1 Development of Discrete Event Control 
To generate probabilities of discrete events occurring dependent on therapy a 
Markov model is a recommended. A standard decision tree model could be used to 
describe the probabilities [151] where probabilities are derived by considering the 
frequency of different outcomes after a certain therapy. In contrast to standard 
decision tree models, Markov models allow probabilities to be time-dependent 
[152] as well as the ability to consider the patient returning to a previous discrete 
event [37]. Both of these aspects of Markov modelling are required to perform the 
novel methodology step of this section; the integration of Markov model 
probabilities within the stochastic control cost function. 
Currently Markov models are used in the cost-effectiveness evaluation of drugs. By 
considering probabilities of future events alongside the cost of future events, a 
predicted cost of a therapy can be calculated. As Markov models describe how a 
random process can evolve over time, this means that different outcomes of 
therapy, and their cost-effectiveness implications, can be considered by repeated 
simulation.  
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For instance, one simulation may consider a situation where the patient will 
respond very well to therapy, experiencing no adverse events, and therefore the 
costs of treating the adverse events are not incurred. However, another simulation 
can consider a situation where the patient experiences multiple adverse events that 
incur costs to treat. The overall distribution of these simulations presents the 
possibilities of cost incurred by a therapy and decisions about the therapy can be 
made based on this distribution. 
In a publication by Zingmark et al. (2005) [37] Markov mixed-effect modelling was 
used to generate time-dependent probabilities. The focus of the publication was to 
derive probabilities of experiencing different levels of side-effects rather than the 
cost-effectiveness of the therapy. Accordingly, changes in a side effect response to 
a drug were recorded for twelve patients every three minutes. Infusion rates of the 
drug were individualised to achieve the same concentration of the drug in each 
patient. The model constructed included three states 0, 1 and 2 for when the 
patient experienced no side effects, mild side effects and moderate to high side 
effects respectively. The Markovian approach to the problem of predicting discrete 
events is effective but requires extra data to derive parameter estimates. 
The model for the drug used to demonstrate the methodology in the publication 
was a two-compartment model with constant intravenous administration. The 
model needed to be linked with the discrete side effect data (0, 1 or 2) collected. In 
this application the risk of transitioning to a different state of side effect is 
interpreted from the PK model. The model presented in the appendix code of the 
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publication formulates the effect compartment amount as shown in equation 2.8 
with        . 
To begin the estimation of probabilities of side effect state the logistic transform is 
used, 
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where       are baseline fixed-effect parameters,    is the future state and    is 
the current state of the patient’s adverse events. Based on the logistic transform 
and respective logits the probability tree shown in Figure 6-3 can be constructed. As 
the dose effect changes over time this means that the probabilities of    |     will 
change over time. Despite these changing probabilities of the future adverse event 
state, the summation of the probabilities given any current state,  (        |  ), 
will always be equal to one. This is an essential characteristic of probability in the 
Markovian model as          represent the entirety of future outcomes 
regardless of the current state occupied. 
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Figure 6-3: Probability Tree of Adverse Event States. 
The diagram of the different states and the probabilities are shown in Figure 6-4 to 
provide a visual representation of the three state Markov model. Each arrow 
represents a probability and each direction the transition occurring, for example, an 
arrow going from 1 to 2 represents the probability  (    |    ). 
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Figure 6-4: Three state Markov model. 
The probabilities generated can be implemented in a control function, which can be 
generalised as, 
 
 ( )  ∑ (     (    |  )       (    |  )
 
     
      (    |  )) 
6.3 
 where           are the weightings given to their respective multipliers. 
Depending on whether the multiplier is perceived as beneficial or harmful to the 
patient’s condition the weightings will be negative or positive respectively. For 
example, the probability of the future adverse event state of the patient being “no 
adverse events occurring”,  (    |  ), is beneficial to the patient therefore will 
be assigned a negative weighting to subtract from the cost function. The values of 
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the weights are subject to clinical opinion however as discussed earlier in this 
chapter there exists methodology to translate the clinical opinion into weighting 
values. Other terms such as those included in previous cost functions used in this 
thesis (equations 5.4, 5.11 and 5.14) would be used alongside these probabilities if 
they are appropriate to control the drug that required estimation of dosage 
regimens. 
6.5 An Example of Discrete Patient Response Control in Imatinib 
Dosing 
6.5.1 Introduction 
The drug dose algorithm was applied to imatinib dosage regimen estimation earlier 
in this thesis (section 5.3) where the required therapeutic target was a trough 
plasma concentration of 1000ng/ml. This target is PK with the intention that it will 
induce a desired PD effect. In this example, the dosage regimen estimation will be 
based on actual targets of those desired PD response thus enhancing the control of 
imatinib. The DPR effects of imatinib used in this example are the PD responses, 
cytogenetic [153] and molecular [154]. 
Cytogenetic response is determined by the amount of Ph+ metaphase cells [155]. In 
this example, the patient is considered to have a cytogenetic response when there 
are no longer any Ph+ metaphase cells; this is the definition of a complete 
cytogenetic response in Bacarrani et al. (2009) [155]. The Ph+ metaphase cell count 
is an indicator for the diagnosis of chronic myeloid leukaemia as the presence of 
Ph+ chromosomes is highly correlated to the onset of the disease [156]. Major 
molecular response is defined as, a ratio of BCR-ABL (a particular gene sequence 
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associated with leukaemia) less than 0.1% [155]. The DPRs from the patient in this 
study, ascending in therapeutic effect, are no response, then cytogenetic response 
and then the combined cytogenetic and molecular response. The highest DPR is a 
dual effect as molecular response only occurs when the effects of the cytogenetic 
response have begun [157].    
As the methodology explained in the previous section is applicable to all discrete 
data the PD effects in this example can be modelled as such. The aim of the 
example will be to use the developed model of discrete treatment data inside the 
cost function of the drug dose algorithm to derive new dosage regimens for 
imatinib patients, which consider both PK and discrete PD effect.  
6.5.2 Method 
The dataset consisted of plasma concentration measurements from the twelve 
patients from the earlier example and an additional seventy-seven sparsely 
sampled chronic myeloid leukaemia patients receiving imatinib therapy. The patient 
samples were all collected at routine clinic visits to The Royal Liverpool University 
Hospital between April 2006 and August 2011. The further blood samples were 
collected and processed in the same manner as described in section 5.3.2. 
The dataset extract for this study includes patient ID number, time interval since 
last dose taken (hours), last dose taken (mg) and plasma concentration 
measurements (ng/ml). Additionally, the dataset for this example included whether 
patients were experiencing molecular and/or cytogenetic response when sampled. 
PD treatment responses were coded as 0: no PD response, 1: cytogenetic response, 
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and 2: cytogenetic and molecular response. In the data there were entries for every 
different transition (0 to 1, 0 to 2, 1 to 0, 1 to 2, 2 to 0, 2 to 1) as well as entries for 
the patient exhibiting the same PD response as before (0 to 0, 1 to 1, 2 to 2). 
The PK model for imatinib, a one compartment oral dose model, was given 
previously in equations 5.12 and 5.13. To translate concentration in the plasma 
compartment into the PD effect of imatinib the following relationship was used.  
 
     
         
       
 6.4 
For each          there is a separate value of      calculated by NONMEM, 
these are shown in equation 6.5  
 
       {
             
             
             
 6.5 
The EC50 value was set as 1000ng/ml as, in lieu of prior information on the 
parameter, the value is linked to inducing cytogenetic and molecular responses in 
the patient [39]. Peng et al. (2004) [138] parameterised a PK/PD model for imatinib 
therapy and EC50 was derived as a trough plasma concentration of 281ng/ml, 
however the clinical outcome of the model, the patient’s reduction in white blood 
cell count, differs to the clinical outcome of this example, the molecular and/or 
cytogenetic response of the patient.  
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Equation 6.1 is the logit transform that uses the amount of the effect 
compartment,     , alongside the logit parameters        . To calculate the logit 
parameters NONMEM1 (Version 7.2) was adjusted to analyse the ordered discrete 
data. The mean parameters values          and their standard errors calculated by 
NONMEM are shown in equation 6.6    
 
   
{
 
 
 
 
             
             
             
              
          
     
 6.6 
The    parameter was fixed based on information in Picard et al. (2007) to allow 
parameter values         to be calculated from the sparsely sampled data.  
The control function for the first imatinib example is given in Equation 5.14. With 
the probabilities of PD effect now being included, in this study the cost function was 
expressed as: 
                                                          
1
 The NONMEM control file for the logit parameter calculation is presented in Appendix II. 
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 6.7 
where                  and     are weightings for each state, which allow the 
control to focus on the PK target, the PD target or penalise for distance from 
current dose. The values of the weightings were different for each current state the 
patient was in and were derived using the weighting methodology explained in 
section 6.3.3 [150].  
For example, if the patient is currently in a state of no response (    ), the cost 
function will need to be more weighted towards the PK target and the PDR 
probabilities as the current dose is not generating a response. However, if the 
patient is in a state of full cytogenetic and molecular response the PK target 
becomes less important as the desired output is already in progress; therefore the 
weightings are orientated to maintaining a high probability that the patient remains 
in full response but also taking into account the current dose is inducing the full 
response.   
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The plasma concentration measurements used in the example of section 5.3 will 
provide feedback to the drug dose algorithm ran in MATLAB2. In addition to the PK 
measurements the PD response of the patient at the time of measurement will also 
be included the drug dose algorithm. This allows the appropriate probabilities of 
future PD response to be used in the estimation of an optimal dosage regimen for 
the patient. The required dosage metrics remained as a seven day dosage regimen 
with daily oral doses. 
6.5.3 Results  
The dosage regimes estimated for the set of twelve patients included in the study 
are shown in Table 6-2. New dosage regimens are now estimated for all but two 
patients. Of interest is that the dosage regimens estimated are different to those 
estimated by the example in Section 5.3, which suggests that the new terms in the 
cost function have caused adjustment of the dosages due to the new therapeutic 
considerations. Overall, these results imply that no patient is to be given the 
standard daily 400mg dose of imatinib to reach the PK and PD targets.  
                                                          
2
 The MATLAB for the drug dose algorithm is presented in Appendix II 
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Table 6-2: Dosage Regimens for each Patient. 
Patient ID Current Daily 
Dose (mg) 
Revised Seven Day Dosage 
Regimen (mg) 
Mean Dosage 
Difference (mg) 
28 400 700, 600, 600, 600, 600, 600, 600. 214 
54 400 600, 600, 600, 600, 600, 600, 600. 200 
56 400 600, 700, 600, 600, 700, 700, 600. 243 
78 400 600, 600, 600, 700, 600, 600, 600. 214 
91 400 500, 500, 600, 500, 400, 500, 500. 100 
101 400 700, 600, 700, 600, 700, 700, 600. 257 
118 400 700, 600, 600, 600, 600, 600, 700. 229 
119 800 No revision needed.  
122 800 No revision needed.  
124 400 800, 800, 700, 700, 700, 700, 700. 329 
244 400 700, 600, 600, 600, 600, 600, 600. 214 
328 400 800, 600, 500, 600, 600, 500, 600. 200 
 
Table 6-3 shows the DPR the patients were in at time of blood sampling and the 
probabilities of transitioning to a different DPR simulated for the dosage they were 
receiving at the time and the estimated dosage regimen. Overall, the probabilities 
of transitioning to or remaining at the highest level of response were improved 
upon by the estimated dosage regimen compared to the dosage the patient was 
currently prescribed.  
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Table 6-3: Comparison of the Percentages of Patient Response After Receiving Current and Revised Dosage 
Regimens. 
P
a
ti
en
t 
ID
 Current Dosage Regimen Revised Dosage Regimen  
State     |    
% 
    |   
% 
    |   
% 
    |   
% 
    |   
% 
    |   
% 
28 2 1.1±0.3 6.4±1.6 92.6±1.5 0.8±0.3 5.0±1.6 94.2±1.9 
54 2 1.1±0.3 6.4±1.6 92.5±1.6 0.9±0.3 5.2±1.6 93.9±1.9 
56 2 1.2±0.3 7.0±1.8 91.8±1.6 0.9±0.3 5.4±1.8 93.7±2.1 
78 2 1.2±0.3 7.1±1.8 91.7±1.7 1.0±0.3 5.7±1.8 93.4±2.1 
91 2 0.7±0.2 4.3±1.1 95.0±1.2 0.6±0.2 3.9±1.1 95.5±1.3 
101 2 1.3±0.4 7.4±1.8 91.3±1.7 1.0±0.4 5.7±1.8 93.4±2.2 
118 2 1.2±0.3 7.2±1.8 91.6±1.7 1.0±0.3 5.7±1.8 93.4±2.1 
119 1 0.4±0.1 4.8±2.3 94.8±2.4 No revision needed 
122 2 0.7±0.2 4.1±1.1 95.2±1.3 No revision needed 
124 0 18.0±3.2 48.9±11.1 33.1±11.9 11.6±2.3 43.5±12.2 44.9±12.9 
244 0 16.5±3.0 48.8±11.5 34.7±12.3 12.0±2.4 44.8±12.3 43.2±13.0 
328 0 18.9±3.4 50.1±10.9 31.0±11.8 13.9±2.7 47.0±12.1 39.1±12.9 
The probabilities over the time course of the dosage regimen are shown in Figure 
6-6 and every other figure until Figure 6-24. The following legend is applicable to all 
even numbered graphs between Figure 6-6 to Figure 6-24: 
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Figure 6-5: Plasma Concentration time profile of Patient 28 receiving imatinib. 
 
Figure 6-6: Markov Model Probabilities of Patient 28 receiving imatinib. 
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Figure 6-7: Plasma Concentration time profile of Patient 54 receiving imatinib. 
 
Figure 6-8: Markov Model Probabilities of Patient 54 receiving imatinib. 
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Figure 6-9: Plasma Concentration time profile of Patient 56 receiving imatinib. 
 
Figure 6-10: Markov Model Probabilities of Patient 56 receiving imatinib. 
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Figure 6-11: Plasma Concentration time profile of Patient 78 receiving imatinib. 
 
Figure 6-12: Markov Model Probabilities of Patient 78 receiving imatinib. 
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Figure 6-13: Plasma Concentration time profile of Patient 91 receiving imatinib (Desired Trough Plasma 
Concentration = x-axis). 
 
Figure 6-14: Markov Model Probabilities of Patient 91 receiving imatinib. 
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Figure 6-15: Plasma Concentration time profile of Patient 101 receiving imatinib. 
 
Figure 6-16: Markov Model Probabilities of Patient 101 receiving imatinib. 
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Figure 6-17: Plasma Concentration time profile of Patient 118 receiving imatinib. 
 
Figure 6-18: Markov Model Probabilities of Patient 118 receiving imatinib. 
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Figure 6-19: Plasma Concentration time profile of Patient 124 receiving imatinib. 
 
Figure 6-20: Markov Model Probabilities of Patient 124 receiving imatinib. 
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Figure 6-21: Plasma Concentration time profile of Patient 244 receiving imatinib. 
 
Figure 6-22: Markov Model Probabilities of Patient 244 receiving imatinib. 
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Figure 6-23: Plasma Concentration time profile of Patient 328 receiving imatinib. 
 
Figure 6-24: Markov Model Probabilities of Patient 328 receiving imatinib. 
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From Table 6-3 and the figures, the results suggest that patients who are already 
experiencing some form of response (in state 1 or 2) are highly probable to either 
improve this response to state 2 or continue in state 2. The dosage adjustments 
made by the drug dose algorithm do cause slight improvements in probabilities 
however the dosage adjustments are large compared to the return in improved 
clinical response probability.  
The dosage regimens estimated will cause higher than target trough plasma 
concentrations in some patients, this can be seen in Figure 6-11 and Figure 6-15. 
This demonstrates that dosage regimens for patients in a state of response do not 
require, based on probabilities of transitioning to a lower or no response, to be 
solely targeted to a trough plasma concentration. 
The three patients (124, 244 and 328) in the dataset who were in a state of no 
response at the time of blood sampling had differing sets of probabilities. All three 
patients require higher dosing to increase the probabilities of transitioning to a 
cytogenetic or/and a molecular response. In the imatinib example of section 5.3  
patient 244 and patient 328 did not require dosage adjustment (see Table 5-5). 
However, both patients require dosage adjustment to improve their probabilities of 
response. Figure 6-21 and Figure 6-23 show that the dosage adjustments take the 
patient’s trough plasma concentrations to above 1000ng/ml. This result will be 
discussed further in the conclusion as the PK response target does not seem to 
coincide with a high probability of response in some patients. 
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6.5.4 Conclusion 
Overall with the addition of imatinib PDR probabilities control theory can be 
formulated more towards clinical decision making. The current methodology of 
individualised dosage regimen control considers cost functions with singular PK/PD 
outcomes. An extension on the current methodology is applied in this study of 
individualised imatinib therapy. In comparison, imatinib therapy was optimised 
previously by estimating a dosage regimen that bought the patient’s plasma 
concentration of the drug to 1000ng/ml [18, 19].  
Novel work in this study included the derivation of a Markov model for imatinib 
molecular and cytogenetic response; previously a linked PK/PD model has been 
derived by Peng et al. (2004) [138] however this considered the white blood cell 
count as the patient response. Further, the cost function of this study, given in 
equation 6.7, was able to discern between doses based on multiple clinical 
outcomes, using the derived Markov model, leading to dosage regimen that was 
more informed and as a consequence improved the patient response to imatinib.  
In all patients the desired outcome of dosage adjustment was to reduce the 
probability of the dosage regimen not causing a PD effect thus increasing the 
chances of cytogenetic and molecular response, the highest PDR response. 
Consequently, the combination of cytogenetic and molecular response was given 
the highest negative coefficient in the cost function. This was done to greatly 
minimise the cost of dosage regimens that induced a high probability of the highest 
level of response ensuring the most efficacious dosage regimens were estimated.  
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This extra adaptability of the algorithm to appropriately dose patients at different 
PD response levels was reflected in revised dose recommendation for the same 
twelve patients from the previous example in section 5.3. Only two patients, 119 
and 122, were not recommended new dosage regimens, shown in Table 6-3. 
Patients who were already at a state of full response are likely to gain only small 
increases to an already high probability of staying at that level of response per each 
100mg dose increase. For these patients, if the cost function was based solely on 
the probabilities of response the drug dose algorithm will always minimise the cost 
function by giving the highest dose possible as this coincides with the highest 
probability possible. This situation of diminishing but unlimited returns is an issue 
with imatinib as it can cause toxic effects at high doses [158]. A possible solution 
might have been possible if toxicity data was available in this set of patients; this 
could be incorporated into the model to provide a ‘cost’ in the cost function for 
doses that were too high.  
Without toxicity data, the final term in the cost function of equation 6.7 was 
formulated to penalise the distance away from a fully responsive patient’s current 
dosage regimen. This meant that the dosage regimens estimated would learn from 
previous dose information that the patient is responding however would still make 
sure the probability of continued response was of an acceptable level.   
The cost function used in this example estimated, for patients who were in 
molecular and/or cytogenetic response, slightly higher doses than their current 
regimen. In the example of section 5.3, the dosage regimens contained doses that 
were far higher than the current dosage regimen. Based on these results, the 
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enhanced cost function of this example is more appropriate for patients responding 
to imatinib therapy with a PD response compared to the technique of dosing 
according to the singular PK target, seen in current methodology [90, 145].  The 
enhanced cost function of this study is suggested to be more appropriate for these 
patients as it takes into account previous dosages that have caused a PD effect and 
uses probabilities of future PD effect to ensure the effect continues.  
Patients who were not presenting a molecular and/or cytogenetic response at the 
time of blood sampling required dosage recommendations based on different 
multiple targets. To derive the optimal dosage regimen for these patients the cost 
function contained the probabilities of the three levels of response and also the PK 
target from the previous example. In this situation the patient’s current dosing had 
not induced a molecular and/or cytogenetic response therefore the cost function 
was set to not learn from dosing history. Instead, the dosage regimen was to induce 
the patient to the therapeutic trough plasma concentration of 1000ng/ml as well as 
a higher probability of PD response to imatinib.  
The three patients who were not responding at time of dosing produced different 
probabilities of PD effect, shown in Figure 6-20, Figure 6-22 and Figure 6-24 to 
responsive patients.  If these non-responding patients remained on their previous 
dosage regimen, the standard of care, the most probable transition would be to 
cytogenetic response. However, when the patient is on the estimated dosage 
regimen, the most likely transition alternates between cytogenetic and the dual 
response of cytogenetic and molecular response. The effect of considering the 
patient’s trough plasma concentration of imatinib with the corresponding 
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probabilities means that the dosage regimen will guide the patient to the desired 
PD effect more effectively than standard clinical practice. 
Overall, this example demonstrates new approaches in control theory by extending 
current methodology to include Markov model probabilities of discrete event 
within a cost function. This novel methodology can be applied to individualise drug 
therapies where probabilities are an appropriate indicator of clinical targets.  
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7 STOCHASTIC CONTROL WITH PHARMACODYNAMIC TARGETS 
This chapter presents an example of the stochastic control method explained in 
Chapter 4 applied to simvastatin therapy. The pharmacometric model is extended 
to predict both PK and PD responses. As simvastatin is dosed to PD targets the cost 
function is formulated accordingly.  
The drug dose algorithm of this thesis is compared to the current guidelines of 
individualisation in simvastatin therapy. To carry out this comparison a randomised 
control trial (RCT) was simulated. Clinical outcomes are investigated to conclude 
whether the stochastic control of dosage regimens improves simvastatin therapy 
compared to current dosing guidelines. 
7.1 Example of Estimating an Optimal Dosage Regimen to Control 
a Pharmacodynamic Response 
7.1.1 Introduction 
So far in this thesis examples of stochastic control have been applied to PK targets 
and discrete probabilistic events. The discrete event application in imatinib dosage 
regimen estimation (section 6.5) demonstrated how stochastic control is used in 
systems where the link between a drug’s PK and PD is either unsure or too complex. 
In this chapter, an application is considered where the PK/PD link is identified by a 
compartmental model.  
To demonstrate the applicability of the stochastic control algorithm beyond PK 
applications, the methodology will be applied to estimate an optimal dose  for the 
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cholesterol lowering drug simvastatin used to treat hypercholesterolemia [159]. 
Simvastatin is prescribed to outpatients and low-density lipoprotein cholesterol 
(LDL-C) is measured at subsequent clinic visits at least four weeks apart . Therefore, 
in this application there were large periods between dose adjustments; which 
means that convergence to a stable maintenance dose will, potentially, be harder 
to achieve.  
Deviations from standard simvastatin therapy have been researched previously, in 
particular Ara et al. (2009) [161] evaluated the cost-effectiveness of prescribing 
high doses of statins early in therapy to avoid cardiac events. The meta-analysis 
included in that study revealed that the highest dose recommended of simvastatin, 
80 mg, caused a 45% LDL-C reduction compared to standard care dosing, 40 mg, 
that caused a 37% reduction in LDL-C. A clear indication of the duration of early 
high-dose therapy was not reported in the paper. Due to the duration of high-dose 
simvastatin therapy not being clear, the meta-analysis reporting of a consequential 
increase in adverse event rate is difficult to translate into dosage 
recommendations. 
Mostly dosage recommendations are derived from studies where simvastatin is 
compared with other statins at fixed dose levels to identify the superior 
intervention for various indications, for example Pedersen et al. (2005) [162] 
studies the comparison of effects that high-dose atorvastatin with usual-dose 
simvastatin had on reducing myocardial infarction.  
The minimal amount of studies into individualised simvastatin therapy motivated 
this study. Potentially using a stochastic control approach in simvastatin therapy 
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could improve the magnitude of LDL-C reduction across the population. This 
suggests that previous studies into simvastatin therapy comparison at fixed dose 
levels produce a limited view of the efficacy of simvastatin. 
7.1.2 Method 
In the absence of data on patient response in simvastatin therapy, previous results 
presented in a publication were used in this example; ten virtual patients were 
generated from distributions described in previous literature on simvastatin PK/PD 
[40]. From these virtual patients, responses to dosing were be simulated. To 
investigate the performance of the stochastic control algorithm for simvastatin 
dosage regimen estimation against standard care there will be two therapy arms in 
the simulation; the standard care arm and the stochastic control dosing arm, which 
will be explained further in the methods section. Primary endpoints from these 
simulations are percentage reduction in LDL-C levels after 3 months, percentage of 
patients achieving the LDL-C target after 3 months and also average time to stable 
maintenance dose. In this example stochastic control methods are applied with the 
simvastatin PK/PD model from Kim et al. (2011) [40] described below: 
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where the first two equations, 7.1 and 7.2, describe the PK of simvastatin 
administered as an oral dose, which is identical to the PKs model used in the 
imatinib example (section 5.3.2, equations 5.12 and 5.13). The concentration of the 
metabolite of simvastatin, simvastatin acid (   ), is described by equation 7.3. The 
simvastatin in the plasma is converted into simvastatin acid producing an active 
metabolite, β-hydroxyacid [40]. The PD of simvastatin is described by equation 7.4 
where the amount of simvastatin acid present in the body is related to the 
reduction of LDL-C over time. This indirect response model was used in the Kim et 
al. (2011) publication to represent the delay between plasma concentrations 
reaching steady state within the patient and the eventual reduction of LDL-C 
concentrations. The graphical representation of this model is shown in Figure 7-1. 
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Figure 7-1: Graphical Representation of the Simvastatin PK/PD Model Derived in Kim et al. (2011) Using 
Notation from Equations 7.1-7.4. 
To reduce the computing time in this study, high throughput computing was 
utilised. The Advanced Research Computing Condor Pool (Condor) is available at 
the University of Liverpool for computer analyses that would incur an impractically 
large computing time performed on a single computer. To reduce computational 
burden, large computer analyses are split into smaller jobs and sent to the Condor 
to be performed by multiple computers. There were three Condor stages in this 
study, the MATLAB initialisation, MATLAB product and MATLAB collection. 
The MATLAB initialisation stage generated the ten patient mean PK/PD parameter 
sets. Shown in Table 7-1, the parameter sets were selected by a discrete uniform 
random number generator3 applied to the Kim et al. (2011) [40] population 
parameter distribution ranges. The initial level of LDL-C for each patient was 
uniform randomly selected from the interval 130-170mg/dl by MATLAB. This initial 
                                                          
3
 MATLAB initialisation code provided in Appendix IV 
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level is chosen to simulate patients who range from borderline high LDL-C levels to 
definite familial hypercholesterolemia [163].  
Table 7-1: Mean PK/PD Parameters for Ten Simulated Simvastatin Patients 
Patient 
No. 
Initial 
LDL-C 
(mg/dl) 
   
(1/h) 
    (l)    
(1/h) 
    
(l) 
   
(1/h) 
    
(1/h) 
          
(mg/l) 
1 167 3.03 9030 0.179 1250 0.318 13.4 0.628 1.86e-04 
2 132 2.42 9157 0.185 1387 0.276 12.3 0.491 1.41e-04 
3 159 3.98 8139 0.203 915 0.355 9.54 0.440 8.23e-05 
4 151 4.52 10169 0.156 1397 0.247 12.0 0.530 1.03e-05 
5 164 2.76 8844 0.228 999 0.370 9.93 0.443 8.78e-05 
6 142 4.42 8548 0.195 1513 0.276 9.09 0.475 2.04e-04 
7 160 3.46 8100 0.235 930 0.471 12.6 0.477 1.12e-04 
8 169 3.04 10138 0.196 1392 0.326 11.5 0.461 3.34e-04 
9 154 4.23 10308 0.146 1505 0.269 11.3 0.625 1.36e-04 
10 132 3.76 8850 0.197 1112 326 10.8 0.530 3.12e-04 
A literature search for simvastatin intra-individual variability did not find any 
advisement on the intra-individual variability of simvastatin PK/PD parameters, the 
closest indication was found reported in Kinlay (2012) [164] that an intra-individual 
variability of 15% had been recorded in the LDL-C level of patients prescribed 
another statin drug, rosuvastatin.  
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Three parameters,   ,    and    , were selected to vary within their distributions 
with respect to time to study intra-individual variability. Due to the relationships 
between all the parameters, varying just these three variables caused the entire 
patient PK/PD to vary with time. In absence of intra-individual variability indication, 
the lognormal distributions of   ,    and     were described by 
   (  (    )      ) where      is the value of the respective parameters in 
Table 7-1.  
In the MATLAB product stage4, the virtual patient parameters were used to inform 
the PK/PD model for simvastatin [40]. The ten virtual patients were simulated 
twenty times through both therapy arms; independently, so treatment in one arm 
does not the affect the treatment in the other and vice versa. This led to four 
hundred computer analysis jobs being submitted to Condor. 
In the standard care arm simulated patients were given an initial starting dose of 
10-20mg of simvastatin and then the dose is increased by 10mg each time the LDL-
C concentration is above the desired target . The second, stochastic control arm of 
simulation involves the same patient treated with dosage regimens estimated from 
the stochastic control algorithm. In both arms the maximum daily dosage of 
simvastatin allowed to be prescribed is 80mg as per medical guidelines . 
In this example, the stochastic differential equations are assumed to be true 
indicators of the PK/PD responses. So as to ensure that the stochastic control 
algorithms are comparable to standard therapy, measurement and prediction 
                                                          
4
 MATLAB product code provided in Appendix IV 
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errors were simulated into the system when needed. Firstly, the system will, as for 
an in vitro trial, receive the feedback in the form of noisy output measurements. 
These are generated by the stochastic differential equation output with a random 
amount of extra noise added. The boundaries of the noise are approximately 7% of 
the true value of LDL-C, in accordance with literature on LDL-C assay error [165, 
166]. These noisy measurements will be used by both the standard arm and the 
stochastic control arm. Secondly, the predictions, used by the Kalman Filter and 
cost function, in the stochastic control arm of the simulation will be subject to a 
random amount of noise within the 10% boundary around the stochastic 
differential equation output.  
The target of the control will be a reduction of LDL-C to 77.3mg/dl, which is 
recommended for individuals who are at a high risk of hypercholesterolemia . 
Therefore the cost function for stochastic control arm of the study is, 
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where  =672 hours (28 days) and      is the noisy prediction of the LDL-C 
concentration in the body.  
The specific endpoints of interest are the difference in time between the standard 
treatment and stochastic control arms to reach the target LDL-C level of 77.3mg/l, 
the average LDL-C levels, the final LDL-C levels and the variability of LDL-C levels 
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over treatment period. These were retrieved from the Condor pool of computers 
using the MATLAB collection stage5. 
7.1.2.1 Methods Summary 
To summarise this example, these steps are taken: 
 MATLAB Initialisation: Random parameters are generated from the PK/PD 
parameter distributions along with a starting LDL-C level to form ten virtual 
patients. 
 MATLAB Product: The set of virtual patients is subject to the standard dosing arm 
for up to ten clinic visits (four weeks apart) or upon reaching the target LDL-C level, 
whichever is soonest. 
o The patient is started on either 10mg or 40mg depending on initial LDL-C 
level, four weeks of treatment is simulated. 
o If target is not reached (according to the noisy measurement value), dose is 
increased by 10mg and another four weeks of treatment is simulated; this 
continues, if target is not met, until ten clinic visits. 
 The same virtual patient (reset to their starting level) is put through the stochastic 
dosing arm for ten clinic visits or upon reaching the target LDL-C. 
o Patient dosing is determined by forecasting, from the initial LDL-C value, 
four weeks ahead to find optimal dose for the patient. Patient is then 
simulated on the optimal dose for four weeks. 
o If target is not reached (according to the noisy measurement value), the 
measurement value is reconciled with noisy prediction value from the 
stochastic differential equations to make an estimate of the LDL-C level. 
Then, from the estimate of LDL-C level, the optimal dose for the next four 
weeks of treatment is estimated. The patient is then simulated for four 
weeks on the optimal dose. This process is repeated until ten clinic visits 
unless the LDL-C target is met. 
 The two arms of simulation were repeated twenty times for each of the ten 
patients leading to four hundred simulations. 
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 MATLAB collection: Results were collected from the Condor pool of computers. 
 
7.1.3 Results  
The results of the simulation indicate a small improvement in treatment when using 
stochastic control methods. A small improvement was to be expected with large 
time intervals between measurements. In eight out of the ten patients the 
stochastic control algorithm estimated doses that led the patient to an average LDL-
C lower than with standard therapy, this is shown in Figure 7-2. 
 
Figure 7-2: The comparison of average LDL-C levels of patients on standard therapy and stochastically 
controlled therapy (bars indicate standard deviation). 
Figure 7-3 shows that only five of the ten patients benefitted from stochastic 
control estimated dosing to reduce their final LDL-C level.  
70
80
90
100
110
120
130
1 2 3 4 5 6 7 8 9 10
LD
L-
C
 L
e
ve
l (
m
g/
d
l)
 
Patient No. 
Standard Therapy
Average LDL-C Level
(mg/dl)
Stochastically Controlled
Therapy Average LDL-C
Level (mg/dl)
193 
 
 
 
 
Figure 7-3: The comparison of end LDL-C levels of patients on standard therapy and stochastically controlled 
therapy (bars indicate standard deviation). 
The variability that is generated by introducing noise to the three parameters and 
incorporating a compliance factor in simulation is evident as some patients have 
end LDL-C levels larger than their respective averages. This suggests that patient’s 
final LDL-C levels are not the lowest measured in the trial.  
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Figure 7-4: The comparison of the variation in LDL-C levels of patients on standard therapy and stochastically 
controlled therapy. 
Figure 7-4 displays the variability of LDL-C levels between measurements. The graph 
shows that the dosage regimens estimated from the stochastic control algorithm 
induce a ‘smoother’ change to LDL-C levels between clinic visits compared to the 
standard dosing arm, causing less severe rises and falls in the LDL-C levels.  
7.1.4 Conclusions 
Overall, the results were encouraging in this application of the stochastic control 
algorithm. Whilst not all endpoints proved significant, this was to be expected due 
to various factors relating to simvastatin therapy. Firstly, LDL-C levels are only 
measured every four weeks (at the most frequent), which means vital feedback is 
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not given to the stochastic control algorithm for lengthened periods. Secondly, 
simvastatin will only then be prescribed at the one daily dosage until the next LDL-C 
level measurement meaning targets are harder to hit precisely. With these 
difficulties it was encouraging to observe large differences in average LDL-C levels 
of patients receiving two different arms of therapy. As evidenced by the final LDL-C 
levels not being too dissimilar between the two arms, the dosage regimens from 
the two arms eventually caused LDL-C levels to converge. 
The stochastic controlled dosing caused reduced variability of LDL-C levels, this was 
encouraging as a steady decline in cholesterol would be more reassuring to patients 
than drastic reductions or gains. Reassurance of the patient is one of the targets 
when utilizing drug dose algorithms and the results here suggest that, even in a 
reduced feedback application, that algorithms could prove beneficial. 
Increasing the number of routine clinic visits would not be feasible for a drug such 
as simvastatin as the drug has an established therapy routine and side effects are 
manageable . However, if information was provided on the LDL-C level of the 
patient in between routine clinic visits this could be fed back into the control. This 
could be used if the patient is experiencing complications or is generally concerned 
with the dosage regimen they have been prescribed.  
Previous studies into simvastatin dosing mainly consist of fixed dose comparisons 
with other statin drugs; in these studies the drugs are compared by their ability to 
reduce cholesterol across the population. Whilst the efficacy of the statin drugs is 
being compared in these previous studies, the individual PK/PD response is rarely 
investigated. This is shown in a study by Tuomilehto et al. (1994) [167] where 
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despite multiple different simvastatin dosages being investigated the clinical 
endpoints are not adjusted for individual PK/PD parameters leading to 
uninformative results.  
Kim et al. (2011) [40] derived the PK/PD model that was used in this study to 
individualise dosage regimens. Similar studies are recommended to investigate 
individual PK/PD response to drugs; with these forms of studies the full potential of 
the drug can be analysed as dosages can be estimated to hit clinical targets 
precisely.  
Using Condor to share computational burden enabled this study to be conducted. 
Whilst simulations have been used previously to determine the benefit of 
individualised therapies [168-170] the use of high throughput computing, such as 
Condor, has not been research. The use of high throughput computing is 
recommended when individualising therapy, especially when considering multiple 
dosage regimens, often computational burden is large when the control is 
performed on a single computer. 
In conclusion, whilst the stochastic control methods in this example caused 
significant improvements in clinical endpoints, there are considerations based on 
the nature of the drug therapy. Firstly, drug therapies with more frequent 
measurements are more likely to show the full adaptability of the stochastic control 
approach. More measurements will reduce discrepancies between what is 
predicted and the actual PK/PD response of the patient, leading to estimated 
dosage regimens causing PK/PD responses within a desired range.  
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Secondly, drug therapies where dosage regimens are allowed to be changed more 
regularly depending on feedback also ensure the drug dose algorithm is fully 
adaptable to the patient. Over four months, a constant daily dose is the best option 
to ensure that compliance is not hindered with patients becoming unsure of their 
drug therapy. However, to induce clinical targets more frequent dosage regimen 
modification may be required.  
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8 CONCLUSIONS AND FURTHER WORK 
This thesis details research into constructing a drug dose algorithm that uses 
stochastic control methodology to estimate an individualised dosage regimen for 
the patient.  
The previous chapters have explained different aspects of this research. In this 
conclusion chapter, particular and novel sections are evaluated. Where applicable, 
recommendations for replication of research and potential future work are 
provided to allow the research of this thesis to be extended. 
8.1 Overview 
The transition from the ‘one size fits all’ paradigm of drug dosing to individualised 
drug dosing is appealing to both patient and clinician as it could lead to safer and 
more effective dosing with reduced costs potentially due to lower adverse drug 
reaction rates and reduced drug burden [14]. The transition is ideally timed with 
the advancement of areas such as pharmacogenetics [63] providing deeper insight 
into patient drug responses.  
Various methodologies are available to enable individualised dosing; these 
methodologies investigate the variability between patients and potential clinical 
factors that cause the variability. This explained variability can then be used to 
estimate individualised dosage regimens for new drug therapy patients. 
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A large amount of research has been conducted in the area of a priori dose 
prediction algorithms that are derived using linear regression methods. The appeal 
of these algorithms potentially lies in the ease of analysis afforded to linear 
regression methods. If linear regression methods of individualising therapy for the 
patient were of an acceptable standard then invasive PK/PD data would not be 
required to be routinely collected. However, as shown in the example of section 
3.1, sources of individual variability are not fully utilised in linear regression 
algorithms meaning the full possibility of patient outcomes are not considered in 
dose estimation.  
Based on the review of linear regression methods, in Chapter 4 stochastic control 
methodology was laid out and then new research was conducted on certain 
components of the approach.  
Intra-individual variability, the variability over time of an individual patient’s PK/PD 
parameters, appears to be rarely considered in control theory. In current 
methodology, patient parameters were derived by either calculating a point 
estimate with no variability attached (MAP Bayesian control) [145] or by 
reweighting a population distribution of PK/PD parameters and assuming inter-
individual variability indicated intra-individual variability (MM stochastic control) 
[90]. This motivated research in this thesis into whether individualised dosing can 
become more accurate when the patient’s PK/PD is fully considered. In an imatinib 
dosing example, section 5.3, PK/PD parameters were represented as distributions 
that consider intra-individual variability. 
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In many drug therapy situations an absence of PK/PD response data for the patient 
complicates the estimation of individualised dosing. In these situations, patient 
PK/PD parameters can be calculated from covariate information. However, some 
covariates are difficult to measure or require a long period to identify.  
In the example of section 5.2, an altered MM approach was utilised, in contrast to 
the standard MM approach that does not consider covariate information [136], a 
patient with an unknown covariate had multiple possible PK parameter sets that 
were weighted by the prevalence of the covariate in the population. This led to an 
estimated dosage regimen that considered possible outcomes for different 
covariate values. Using the altered MM approach means patients can be 
individually dosed according to various predicted PK/PD responses.  
Cost functions are used to determine the optimal dosage regimen that causes a 
therapeutic effect in the patient. Both single PK and PD targets [88, 94] have been 
included in cost functions to perform estimations of individualised dosage 
regimens. However, work in this thesis extended cost functions to include more 
than just one PK or PD target. 
As a novel step, the integration of a Markov model and the cost function was 
investigated in section 6.4 to provide dosage regimen estimation that considered 
probabilities of future patient response. The future patient response could be 
negative such as an adverse event or positive, a therapeutic effect of a drug on the 
body.  
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An example of imatinib dosing in section 6.5 showed an enhanced level of 
adaptability to the patient due to this research. The extra adaptability was 
confirmed as more informed estimates were made for an individual patient dosage 
regimen. This meant that if the condition of the patient being prescribed imatinib 
changed then their dosage regimen could be changed as well, subject to the 
probabilities derived from patient response data. The potential benefits of this 
adaptability include better treatment of the patient and the potential to reduce 
adverse event rates that are dose dependent.   
Individualised dosage regimen estimation can incur a large amount of computing 
time; for the simvastatin dosing example, section 7.1, high throughput computing 
was utilised to reduce computational burden. The simvastatin example was 
fragmented into four hundred simulations that were performed at the same time 
on a cluster of parallel computers.  
In summary, this thesis focused on identifying the appropriate methodology to 
perform individual dosage regimen estimation. Stochastic control was selected to 
be researched further due to the entire distribution of PK/PD response being 
considered and the adaptive properties included in the approach. Research was 
conducted to improve PK/PD parameter representation currently seen in stochastic 
control, by considering intra-individual variability appropriately. The MM stochastic 
control approach was altered to individualise dosage regimens for patient with 
missing covariates. The cost function in control theory was adapted to provide 
estimates of dosage regimen in drug therapies that are consequential on multiple 
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clinical targets. Finally, high throughput computing was investigated in simvastatin 
therapy to reduce computation time. 
8.2 Limitations 
In absence of in vivo PK/PD data, such as in the lidocaine, warfarin and simvastatin 
control examples presented in this thesis, alternative methods were used to inform 
the drug dose algorithm. These examples demonstrate the estimation of 
individualised dosage regimens however the adaptive elements of control theory 
are not utilised. This is seen as a limitation of such examples, as measurements of 
PK/PD response are not fed back to the drug dose algorithm meaning the error 
between prediction and actual measurement is not analysed.   
The intra-individual distributions within this thesis were constructed around point 
estimates calculated in NONMEM®. Information on the distribution of intra-
individual variability was not found in literature for the drug therapies studied in 
examples. Due to this estimated dosage regimens are estimated with the 
assumption that the hypothesised intra-individual distributions appropriately 
described PK/PD parameter behaviour. 
In the example of individualised simvastatin therapy, the limited feedback from 
clinic visits every four weeks appeared to hinder the adaptability of control. The 
adaptability was hindered by reliance on the prediction of LDL-C in the patient for 
an extended period of time that can lead to large divergence from the actual LDL-C 
levels in the patient.  
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With new methodology being introduced in this thesis, validation on an external 
dataset/population is required to determine the ability of the algorithm to 
individualise patient drug dosing outside a derivation dataset. This validation 
process allows methodology to be generalised to patients not used in derivation 
dataset ensuring that widespread use is feasible and effective.  
8.3 Integration with Current Research 
Research in this thesis has studied the individualisation of dosage regimens. This 
section explains suggestions for investigating intra-individual variability in current 
control theory applications. 
In MAP Bayesian control theory, point estimates of the individual PK/PD parameters 
are derived by the product of the prior distribution of the PK/PD parameters and 
the likelihood of PK/PD response measurements [145]. To appropriately predict 
future PK/PD response, a distribution of intra-individual variability can be 
constructed around MAP Bayesian point estimates.  
In absence of intra-individual distribution research, as was encountered in this 
thesis, distributions can be provisionally set as    (  (    )      ) where      is 
the value of the MAP Bayesian point estimate.  
The MM approach produces estimates of PK/PD response based on the posterior 
distribution of individual patient PK/PD parameters [90]. However, as indicated in 
this thesis, the posterior is derived by recalculating the probability of discrete 
parameter points contained in the population PK/PD [43]. In this approach intra-
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individual variability is assumed to be described by inter-individual variability 
present in the population PK/PD distribution.  
To obtain a posterior PK/PD parameter distribution the Kalman filter is used, 
reconciling the probabilities of each discrete population PK/PD parameter point 
with the likelihood of PK/PD response measurements [109]. After Kalman filtering, 
the likelihood does not remain in the posterior distribution [109]. The likelihood is 
the most accurate indication of a patient’s PK/PD parameters at the measurement 
time therefore to understand further about intra-individual response this 
information should remain in the posterior distribution. If the likelihoods of each 
measurement remain in the distribution then further measurement likelihoods can 
be compared to investigate intra-individual variability. 
8.4 Recommendations for Researchers 
The probabilities generated from a Markov model provide an alternative 
individualised drug therapy target when a PD model has not been established. The 
requirements for the Markov model are a hypothesised site of action and an 
associated level of this site. This alternative form of analysis is an extra option when 
analysing drug response and as shown in this thesis leads to more informed dosage 
regimen estimation. 
An advisement for any researcher in the area would be careful consideration of the 
weighting of probabilities in the cost function. When several clinical outcomes are 
being considered in the cost function their respective importance must be correctly 
interpreted by weightings. However, in the process of weighting determination, 
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bias should be minimised. Potential actions to minimise bias would be to consider 
clinical expertise from multiple sources and ranking of outcomes, discussed in 
section 6.4.1.  
The simvastatin study in this thesis alludes to a general consideration for 
application of stochastic control methods to estimate dosage regimens. Whilst the 
application in this study was entirely feasible, reduced feedback (as clinic visits 
where dosage regimens could be altered were a large amount of time apart) meant 
dosage regimens were based largely on predicted levels of LDL-C. These 
recommendations should be considered before future research into the dosage 
regimen estimation for simvastatin or a drug that has similarly reduced feedback 
and dosage regimen change points.  
Notably, including noise within the model for patient response invokes a larger 
computational need. This causes dose estimation for a singular patient to become 
longer than would be required for bedside drug therapy decisions. Advancements 
in research to reduce the time required would be recommended before application 
in ‘real-time’ healthcare. 
One potential solution may be through high throughput computing, which was 
utilised in the simvastatin study. High throughput computing works by splitting a 
large computer analysis into a series of smaller analyses performed on a group of 
networked computers. As ‘cloud’ computing, where information is transferred away 
from a user’s computer, laptop or tablet to be analysed elsewhere, becomes more 
widely used there is potential for high throughput computing to be utilised to great 
effect in individualised drug therapy. For example, a clinician could send a plasma 
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concentration sample through cloud computing to be analysed with indications of 
dosing metrics required; in reply an individualised dosage regimen is sent back 
alongside results of analysis.  
8.5 Further Work 
Stochastic control methods have already included the process of parameter 
estimation in response to measurements taken from a patient [90, 145]. However, 
parameters will be best estimated in recognition of the intra-individual variability in 
PK/PD response to a drug. In section 8.3, suggestions were given as to how intra-
individual variability could be considered with current control theory approaches in 
drug therapy. However, even with these suggestions, parameters are assumed to 
change value only when measurements taken from the patient (time invariant 
parameters).  
To understand intra-individual variability further PK/PD parameters should be time 
variant, represented by distributions that indicate the value the PK/PD parameters 
could be at any given time. Potentially Markov chain Monte Carlo (MCMC) and 
random walk methods could provide a means to calculate time variant parameters. 
Lunn and Aarons (1997) [171] investigated using MCMC methods to estimate 
interoccasion variability however the main focus was looking at variability across 
the patient population.  
As this thesis presents is the first application of Markov models to the cost function 
in a stochastic control method, suggested future work would be application in a 
different drug. Further application will test the approach and develop the 
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methodology for a wider audience. Two examples of data which would be 
interesting to apply, through a Markov model, to control theory would be 
toxicological and health economics data. Both of these forms of data would provide 
additional terms in the cost function to estimate a dose based on multiple 
outcomes. For example, whilst a dosage regimen may be estimated that hits a PK 
target exactly the patient may also be at a high risk of adverse drug effect or the 
cost of therapy could be greatly increased. 
Within imatinib dosing there is further work required to identify the potential for 
dose reduction after cytogenetic and molecular effect has been achieved. Jabbour 
et al. (2008) [172] presented evidence that dose reduction after a target effect had 
been achieved did not affect event-free survival. This leads to a hypothesis that two 
distinct dosing stages could be needed in imatinib therapy, the first stage, which 
involves bringing the patient to cytogenetic and molecular effect, and the second, a 
dose adjustment phase where the patient dosage regimen is reduced carefully 
avoiding any relapse in patient response. If this is achieved the drug burden on the 
patient can be relieved leading to reduced costs of healthcare.  
Different PK responses could be linked to the PD response to improve the 
predictive capabilities of the drug dose algorithm. The effects of imatinib therapy 
are often expected to occur up to a year or more after dose commencement [39]. 
Therefore, the PK profile of imatinib that involves daily cycles of probabilities may 
be too frequent to directly link to effects happening over a time course of several 
months. Counts of cells in the blood may be better indicator of drug response, the 
research by Peng et al. (2004) linking the plasma concentration of imatinib to the 
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white blood cell count of the patient [138] suggests one option, however, other 
blood cell counts may be more indicative of drug response. 
Possible extensions on the simvastatin model presented in section 7.1.2 (see in 
Figure 7-1 and equations 7.1-7.4) would be to improve the predictive capabilities of 
the PD model compartment. The model could benefit from further data analysed to 
confirm whether it is appropriate enough for prediction purposes. For example, 
pharmacogenetic information suggests that genetic variation accounts contributes 
to the variable response to statin therapy [173]. This information could be 
incorporated to construct a superior model for predicting the LDL-C levels of a 
patient between clinic visits. 
To encourage further use of high throughput computing in the area of drug 
therapy, individualisation guidelines on how to conduct the task could be 
established. Two aspects to consider in these guidelines would be computational 
needs and application requirements. Computational needs would include how best 
to run the simulation including, which programme to use to run the code and if the 
simulation is large enough to require multiple computers, just as the example in 
this thesis required. Application requirements would include steps to parallel the 
simulation with healthcare in general. Issues to consider, naming two, are patient 
compliance and number of patient replications required. 
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I APPENDIX: MATLAB CODE FOR SECTION 5.3 
 
%% Drug Dose Algorithm for Imatinib Dosing in MATLAB(R) 
% This drug dose algorithm is based on Pharmacokinetic  
% Targets  
  
%%  Read Data and Use Kalman Filter to Loop In Measurements 
% Data Read 
  
dosres=xlsread('Imat.xlsx'); 
patlist=unique(dosres(:,1)); 
doselist=[]; 
allP=[]; 
  
% Start of Patient Loop 
  
for q=1:1:1%length(patlist) 
   clearvars -except dosres patlist doselist q b con2list doselist 
allP 
   target=patlist(q); 
   vi=find(dosres(:,1)==target); 
   patres=dosres(vi,:); 
   patres(1,1); 
    
% Patient Parameters 
  
    p= [patres(1,6),patres(1,7)*1000,patres(1,8)*1000]; 
    kag=p(1); cl=p(2); vol=p(3); keg=(p(2)/p(3)); 
    peak=round(60*(1/(kag-keg))*log(kag/keg)); 
     
% Target Metrics 
  
    dorange=[patres(1,9) patres(1,10)]; dodays=7; tar=1000; 
     
% Kalman filter 
  
    dosam=size(patres); pos=patres(1,4); 
    con1=[]; 
    kaplot=[]; 
    keplot=[]; 
    xpred=[kag keg patres(1,3)*1000000 pos]; 
     
for l=2:1:dosam(1) 
        pre=[]; 
        mp= [patres(l-1,2), patres(l-1,3), patres(l-1,4), patres(l-
1,5)]; 
        m= [patres(l,2), patres(l,3), patres(l,4), patres(l,5)]; 
        qk=500+20*m(1); 
        for kalp=1:1:5 
            [t,xpred] = ode45(@imat,[mp(1):1/60:(m(1)-1/60)],[kag 
keg xpred(end,3) pos],[],p); 
            pre=[pre xpred(:,4)]; 
        end 
        pred=mean(pre(end,:)); 
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        pk_1k_1=std(pre(end,:)); 
        covkk_1=(pk_1k_1)+qk; 
        diff=m(3)-(pred); 
        rk=m(3)*m(4); 
        sk=covkk_1+rk; 
        kalk=covkk_1/(sk); 
        time=m(1); 
        pos=pred+(kalk*diff); 
        pk_1k_1=(1-kalk)*covkk_1; 
        con1=vertcat(con1,pre); 
end 
% Kalman filter up to 24 Hours 
    xpred=[kag keg xpred(end,3) pos]; 
    if m(1)<24 
        pre=[]; 
        for kle=1:1:5 
            [t,xpred] = ode45(@imat,[m(1):1/60:24],[kag keg pos 
mean(con1(end))],[],p); 
            pre=[pre xpred(:,4)]; 
        end 
        con1=vertcat(con1,pre); 
    end 
     
    con2=con1; 
    tim=[0:1/60:24]'; 
    bestd=[]; 
    s=patres(l,11)+1; 
     
%% Dosage Regimen Estimation 
% Dose For Loop 
    for i=1:1:dodays 
        concrep=[]; 
        pen=[]; 
        if i==1 
            xst=[kag keg xpred(end,3) mean(con1(end))]; 
            xsst=[xpred(end,3) mean(con1(end))]; 
        else 
            xst=[kag keg xdo(end,3) mean(con1(end))]; 
            xsst=[xdo(end,3) mean(con1(end))]; 
        end 
% ode select three top dosages 
        for d=1:1:8                     
            [t,xode] = ode45(@imatode,[0:1/60:(24-
(1/60))],[d*100000000+xsst(end,1) xsst(end,2)],[],p); 
            endconc(d)=xode(end,2); 
            level(d)=((xode(end,2)/tar-1)^2);% 
% add a row of indices 
            bose = [1:length(level); level];   
%sort by value of vector (in row 2) 
            [Y,I] = sort(bose(2,:));   
        end 
% Narrowed to best three dosage regimens  
        bounds=I(1:3); 
        for j=1:1:length(bounds) 
            d = (100000000*bounds(j));  
            % SDE repeat 5 times 
            concsto=[]; 
            for rep=1:1:5 
                [t,xdo] = ode45(@imat,[0:1/60:(24-(1/60))],[kag keg 
d xst(end,4)],[],p); 
                concrep=[concrep xdo(:,4)]; 
211 
 
 
 
                concsto=[concsto xdo(:,4)]; 
            end 
            endstoconc(j)=mean(concsto(end,:)); 
            endstostd(j)=std(concsto(end,:),0,2); 
            pen(j)=((endstoconc(j)/tar-1).^2); 
        end 
        [r,c]=find(pen==min(min(pen))); 
        bd(i)=bounds(c);       
        con1=vertcat(con1,concrep(:,(((c-1)*5)+1):(c*5))); 
        error=std(con1,0,2);   
    end 
    bestd=bd*100000000; 
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II APPENDIX: NONMEM CODE FOR SECTION 6.5 
$PROBLEM IMATINHIB AErun 
$DATA imatAEdatafile.CSV IGNORE=# 
$INPUT ID TIME DV MDV PRES IKA ICL IV CMT AMT ADDL II SS EVID 
$SUBROUTINE ADVAN6 TRANS1 TOL=5 
$MODEL  
 COMP=(GUT) 
 COMP=(CEN) 
 COMP=(EFF) 
$PK 
 KA=IKA 
 CL=ICL 
 V=IV 
 S2 = V/1000 
$DES 
 RATEIN=KA*A(1) 
 DADT(1)=-RATEIN 
 DADT(2)=RATEIN-CL*A(2)      
$ERROR    
; ---------------------PD----------------------- 
; Baseline values 
B1 =THETA(1) 
B2 =B1+THETA(2) 
BSVEM=ETA(1) 
EMAX =THETA(3)*ETA(1) 
IF(PRES.EQ.1) THEN 
B1 =THETA(4) 
B2 =B1+THETA(5) 
213 
 
 
 
EMAX =THETA(6)     
ENDIF 
IF(PRES.EQ.2) THEN 
B1 =THETA(7) 
B2 =B1+THETA(8) 
EMAX =THETA(9)     
ENDIF 
;Conc-Effect 
EC50 =THETA(10) 
CE =F+0.001 
EFF=EMAX*(CE/(CE+EC50)) 
;Logits 
A1 =B1+EFF 
A2 =B2+EFF 
C1 =EXP(A1) 
C2 =EXP(A2) 
;Probabilities 
P1 =C1/(1+C1) 
P2 =C2/(1+C2) 
PA=1-P1 
PB=P1-P2 
PC=P2 
IF(DV.EQ.0) Y=PA 
IF(DV.EQ.1) Y=PB 
IF(DV.EQ.2) Y=PC 
$THETA 
(-60, -1.60, 60) ;B1 
(-60, -2.33, 60) ;B2 
4.80 FIX ;eMAX1 
(-60, -0.001, 60) ;B3 
214 
 
 
(-60, -1.18,60) ;B4 
5.21 FIX  ;eMAX2 
(-60,-20, 60) ;B5 
-2.00 FIX ;B6 
3.00 FIX  ;eMAX3 
1000 FIX  ;EC50 
$OMEGA 
0.05 ;EC50 
$ESTIMATION NUMERICAL MAX=9999 PRINT=1 POSTHOC METHOD=COND LAPLACE LIKE 
$COVARIANCE 
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III APPENDIX: MATLAB CODE FOR SECTION 6.5 
 
%% Drug Dose Algorithm for Imatinib Dosing in MATLAB(R) 
% This drug dose algorithm is based on Pharmacokinetic  
% and Probabilistic Pharmacodynamic Targets derived  
% from a Markov Model. 
  
%%  Read Data and Use Kalman Filter to Loop In Measurements 
% Data Read 
  
dosres=xlsread('Imat.xlsx'); 
patlist=unique(dosres(:,1)); 
doselist=[]; 
allP=[]; 
  
% Start of Patient Loop 
  
for q=1:1:1%length(patlist) 
   clearvars -except dosres patlist doselist q b con2list doselist 
allP 
   target=patlist(q); 
   vi=find(dosres(:,1)==target); 
   patres=dosres(vi,:); 
   patres(1,1); 
    
% Patient Parameters 
  
    p= [patres(1,6),patres(1,7)*1000,patres(1,8)*1000]; 
    kag=p(1); cl=p(2); vol=p(3); keg=(p(2)/p(3)); 
    peak=round(60*(1/(kag-keg))*log(kag/keg)); 
     
% Target Metrics 
  
    dorange=[patres(1,9) patres(1,10)]; dodays=7; tar=1000; 
     
% Kalman filter 
  
    dosam=size(patres); pos=patres(1,4); 
    con1=[]; 
    kaplot=[]; 
    keplot=[]; 
    xpred=[kag keg patres(1,3)*1000000 pos]; 
     
for l=2:1:dosam(1) 
        pre=[]; 
        mp= [patres(l-1,2), patres(l-1,3), patres(l-1,4), patres(l-
1,5)]; 
        m= [patres(l,2), patres(l,3), patres(l,4), patres(l,5)]; 
        qk=500+20*m(1); 
        for kalp=1:1:5 
            [t,xpred] = ode45(@imat,[mp(1):1/60:(m(1)-1/60)],[kag 
keg xpred(end,3) pos],[],p); 
            pre=[pre xpred(:,4)]; 
        end 
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        pred=mean(pre(end,:)); 
        pk_1k_1=std(pre(end,:)); 
        covkk_1=(pk_1k_1)+qk; 
        diff=m(3)-(pred); 
        rk=m(3)*m(4); 
        sk=covkk_1+rk; 
        kalk=covkk_1/(sk); 
        time=m(1); 
        pos=pred+(kalk*diff); 
        pk_1k_1=(1-kalk)*covkk_1; 
        con1=vertcat(con1,pre); 
end 
% Kalman filter up to 24 Hours 
    xpred=[kag keg xpred(end,3) pos]; 
    if m(1)<24 
        pre=[]; 
        for kle=1:1:5 
            [t,xpred] = ode45(@imat,[m(1):1/60:24],[kag keg pos 
mean(con1(end))],[],p); 
            pre=[pre xpred(:,4)]; 
        end 
        con1=vertcat(con1,pre); 
    end 
     
    con2=con1; 
    tim=[0:1/60:24]'; 
    bestd=[]; 
    s=patres(l,11)+1; 
     
%% Dosage Regimen Estimation 
% Dose For Loop 
    for i=1:1:dodays 
        concrep=[]; 
        pen=[]; 
        if i==1 
            xst=[kag keg xpred(end,3) mean(con1(end))]; 
            xsst=[xpred(end,3) mean(con1(end))]; 
        else 
            xst=[kag keg xdo(end,3) mean(con1(end))]; 
            xsst=[xdo(end,3) mean(con1(end))]; 
        end 
%ode select three top dosages 
        for d=1:1:8                     
            [t,xode] = ode45(@imatode,[0:1/60:(24-
(1/60))],[d*100000000+xsst(end,1) xsst(end,2)],[],p); 
%state dependent probability 
            fC1=[]; 
            fC2=[]; 
            for jp=1:1000 
                b=[-1.21+0.224*randn(1) -2.35+0.536*randn(1) 4.8; 
2.33+0.339*randn(1) -2.6+0.343*randn(1) 5.21; 3+0.274*randn(1) -2 
3]; 
                DEFF=((xode(:,2)./(xode(:,2)+500))).*b(s,3); 
                C1=exp(b(s,1)+DEFF); 
                C2=exp(b(s,1)+b(s,2)+DEFF); 
                fC1=vertcat(fC1,mean(C1)); 
                fC2=vertcat(fC2,mean(C2)); 
            end 
            P1=fC1./(1+fC1); 
            P2=fC2./(1+fC2); 
            endconc(d)=xode(end,2); 
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            level(d)=(0.3*((xode(end,2)/tar-1)^2)+0*(1-mean(P1))-
0*(mean(P1)-mean(P2))-0*(mean(P2))+0*(d-(patres(1,3)/100))^2);% 
% add a row of indices 
            bose = [1:length(level); level];   
%sort by value of vector (in row 2) 
            [Y,I] = sort(bose(2,:));   
        end 
% Narrowed to best three dosage regimens  
        bounds=I(1:3); 
        for j=1:1:length(bounds) 
            d = (100000000*bounds(j));  
            % SDE repeat 5 times 
            concsto=[]; 
            for rep=1:1:5 
                [t,xdo] = ode45(@imat,[0:1/60:(24-(1/60))],[kag keg 
d xst(end,4)],[],p); 
                concrep=[concrep xdo(:,4)]; 
                concsto=[concsto xdo(:,4)]; 
            end 
            MMOL=concsto; 
            fC1=[]; 
            fC2=[]; 
            for g=1:1000 
                b=[-1.21+0.224*randn(1) -2.35+0.536*randn(1) 4.8; 
2.33+0.339*randn(1) -2.6+0.343*randn(1) 5.21; 3+0.274*randn(1) -2 
3]; 
                DEFF=((MMOL./(MMOL+500))).*b(s,3); 
                C1=exp(b(s,1)+DEFF); 
                C2=exp(b(s,1)+b(s,2)+DEFF); 
                fC1=vertcat(fC1,mean(C1)); 
                fC2=vertcat(fC2,mean(C2)); 
            end 
            P1=mean(fC1)./(1+mean(fC1)); 
            P2=mean(fC2)./(1+mean(fC2)); 
            endstoconc(j)=mean(concsto(end,:)); 
            endstostd(j)=std(concsto(end,:),0,2); 
            pen(j)=(0.3*(((endstoconc(j)/tar-
1)).^2)*endstostd(j)+0*(1-mean(mean(P1)))-0*(mean(mean(P1))-
mean(mean(P2)))-0*(mean(mean(P2)))+0*(bounds(j)-
(patres(1,3)/100))^2); 
        end 
        [r,c]=find(pen==min(min(pen))); 
        bd(i)=bounds(c);       
        con1=vertcat(con1,concrep(:,(((c-1)*5)+1):(c*5))); 
        error=std(con1,0,2);   
    end 
    bestd=bd*100000000; 
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IV APPENDIX: MATLAB/CONDOR CODE FOR SECTION 7.1 
 
%% Drug Dose Algorithm for Simvastatin Dosing in MATLAB(R) parallel 
%% computed using Condor  
% This drug dose algorithm is based on Pharmacodynamic  
% Targets 
 
%%%%Condor index file 
job=-1; 
excel=[]; 
for is=0:9 
    p= [randi([198,453])/100, randi([1500,2030]), 
randi([1300,1700]), randi([7445,10800]), randi([873,1520]), 
randi([325,464]), randi([868,1440])/100, 1, randi([429,637])/1000 , 
randi([15,3960])/10000000]; 
     
    for k=0:1 
        for jh=0:19 
        job=job+1; 
        filename=strcat('input',int2str(job)); 
        save(filename,'is','jh','k','p')     
        end 
    end 
end 
 
%%%%Condor product file 
 
function product 
  load input.mat; 
  pat=is; num=jh; arm=k; 
  seed=40*pat+1+num+(20*arm) 
  rng(seed) 
    if arm==0 
    base=p(3); 
    kag=p(1); keg=p(2)/p(4); k1=p(2)/p(4); volP=p(4); volA=p(5);  
    k2=p(6)/p(5); k3g=p(7); k4=p(7)/p(3); Emax=p(9); ec=p(10); 
    %stanstartdosing 
    high=1546; 
        if (base+normrnd(0,0.5*(0.07*base)))>high 
            stdoses=40; 
        else 
            stdoses=10; 
        end 
  
    %%%standardSIMULATION loop 
        %firstdose 
         
        dose=[]; time=[]; conmeas=[]; acidmeas=[]; 
        LDLmeas=[]; con=[]; acid=[]; LDLcon=[]; 
        [t,xpred] = ode23(@simv,[0:1:23],[p(1) p(2) p(7) stdoses 0 0 
base],[],p); 
        con=vertcat(con, xpred(:,5)); 
        acid=vertcat(acid, xpred(:,6)); 
        LDLcon=vertcat(LDLcon, xpred(:,7)); 
        %repeateddosing 
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        for ih=1:1:27 
            if rand(1)<0.1 
                doses=0; 
            else 
                doses=stdoses; 
            end 
            [t,xpred] = ode23(@simv,[0:1:23],[p(1) p(2) p(7) doses 
xpred(end,5) xpred(end,6) xpred(end,7)],[],p); 
            con=vertcat(con, xpred(:,5)); 
            acid=vertcat(acid, xpred(:,6)); 
            LDLcon=vertcat(LDLcon, xpred(:,7)); 
        end 
        time=vertcat(time, 24); 
        conmeas=vertcat(conmeas, 
xpred(end,5)+normrnd(0,0.5*(0.1*xpred(end,5)))); 
        acidmeas=vertcat(acidmeas, 
xpred(end,6)+normrnd(0,0.5*(0.1*xpred(end,6)))); 
        LDLmeas=vertcat(LDLmeas, 
xpred(end,7)+normrnd(0,0.5*(0.07*xpred(end,7)))); 
        dose=vertcat(dose, stdoses); 
        doses=stdoses; 
        LDLmeas(end); 
        %dosing until target        
        reps=1; 
        while (LDLmeas(end))>773 && reps<10%(10/0.0259) 
            reps=reps+1; 
            newdose=doses+10; 
                if newdose>80 
                    newdose=80; 
                end 
            for ih=1:1:28 
                    if rand(1)<0.1 
                        doses=0; 
                    else 
                        doses=newdose;  
                    end 
                [t,xpred] = ode23(@simv,[0:1:23],[p(1) p(2) p(7) 
doses xpred(end,5) xpred(end,6) xpred(end,7)],[],p); 
                con=vertcat(con, xpred(:,5)); 
                acid=vertcat(acid, xpred(:,6)); 
                LDLcon=vertcat(LDLcon, xpred(:,7)); 
            end 
            dose=vertcat(dose, newdose); 
            time=vertcat(time, time(end)+24); 
            conmeas=vertcat(conmeas, 
xpred(end,5)+normrnd(0,0.5*(0.1*xpred(end,5)))); 
            acidmeas=vertcat(acidmeas, 
xpred(end,6)+normrnd(0,0.5*(0.1*xpred(end,6)))); 
            LDLmeas=vertcat(LDLmeas, 
xpred(end,7)+normrnd(0,0.4*(0.07*xpred(end,7)))); 
            doses=newdose; 
            LDLmeas(end); 
        end 
        %randomtimes 
         
        simmeas=[pat*ones(length(time),1) num*ones(length(time),1) 
arm*ones(length(time),1) time dose conmeas acidmeas LDLmeas]; 
        end 
    %%%%sto SIMULATION 
    if arm==1 
    base=p(3); 
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    kag=p(1); keg=p(2)/p(4); k1=p(2)/p(4); volP=p(4); volA=p(5);  
    k2=p(6)/p(5); k3g=p(7); k4=p(7)/p(3); Emax=p(9); ec=p(10); 
        %forcast forwards 
        con=[]; 
        acid=[]; 
        LDLcon=[];     
        %dose loop 
        measgiven=base+normrnd(0,0.5*(0.07*base)); 
        for kh=1:1:8 
            controlLDL=[]; 
            %multiple dose chains     
            for r=1:1:5 
                [t,xmu] = ode23(@simv,[0:1:23],[p(1) p(2) p(7) kh*10 
0 0 measgiven],[],p); 
                controlLDL=vertcat(controlLDL, xmu(:,7)); 
                for ih=1:1:27 
                    [t,xmu] = ode23(@simv,[0:1:23],[p(1) p(2) p(7) 
kh*10 xmu(end,5) xmu(end,6) xmu(end,7)],[],p); 
                    controlLDL=vertcat(controlLDL, xmu(:,7)); 
                end 
            end 
            J(kh)=sum((controlLDL-773).^2); 
        end 
        min(J); 
        [r,c]=find(J==min(min(J))); 
        %firstdose with control dose 
        dose=[]; time=[];  conmeas=[]; acidmeas=[]; 
        LDLmeas=[]; con=[]; acid=[]; LDLcon=[]; 
        [t,xpred] = ode23(@simv,[0:1:23],[p(1) p(2) p(7) c*10 0 0 
base],[],p); 
        con=vertcat(con, xpred(:,5)); 
        acid=vertcat(acid, xpred(:,6)); 
        LDLcon=vertcat(LDLcon, xpred(:,7)); 
        %repeated dosing with control dose 
        for ih=1:1:27 
            if rand(1)<0.1 
                doses=0; 
            else 
                doses=c*10; 
            end 
            [t,xpred] = ode23(@simv,[0:1:23],[p(1) p(2) p(7) doses 
xpred(end,5) xpred(end,6) xpred(end,7)],[],p); 
            con=vertcat(con, xpred(:,5)); 
            acid=vertcat(acid, xpred(:,6)); 
            LDLcon=vertcat(LDLcon, xpred(:,7)); 
        end 
        time=vertcat(time, 24); 
        conmeas=vertcat(conmeas, 
xpred(end,5)+normrnd(0,0.5*(0.1*xpred(end,5)))); 
        acidmeas=vertcat(acidmeas, 
xpred(end,6)+normrnd(0,0.5*(0.1*xpred(end,6)))); 
        LDLmeas=vertcat(LDLmeas, 
xpred(end,7)+normrnd(0,0.5*(0.07*xpred(end,7)))); 
        dose=vertcat(dose, c*10); 
         
        %update measurement 
        reps=1; 
        while (LDLmeas(end))>773 && reps<10; 
            reps=reps+1; 
            pred=xpred(end,7)+normrnd(0,0.5*(0.1*xpred(end,7))); 
            pk_1k_1=0.1*xpred(end,7); 
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            covkk_1=pk_1k_1; 
            diff=LDLmeas(end)-pred; 
            rk=0.07*xpred(end,7); 
            sk=covkk_1+rk; 
            kalk=covkk_1/(sk); 
            pos=pred+(kalk*diff); 
            pk_1k_1=(1-kalk)*covkk_1; 
  
            %forcastforwards 
            %dose range loop 
            for kh=1:1:8 
                controlLDL=[]; 
                %multiple dose chains     
                for r=1:1:5 
                    [t,xmu] = ode23(@simv,[0:1:23],[p(1) p(2) p(7) 
kh*10 conmeas(end) acidmeas(end) pos],[],p); 
                    controlLDL=vertcat(controlLDL, xpred(:,7)); 
                    for ih=1:1:27 
                        [t,xmu] = ode23(@simv,[0:1:23],[p(1) p(2) 
p(7) kh*10 xmu(end,5) xmu(end,6) xmu(end,7)],[],p); 
                        controlLDL=vertcat(controlLDL, xmu(:,7)); 
                    end 
                end 
                J(kh)=sum((controlLDL-773).^2); 
            end 
            min(J); 
            [r,c]=find(J==min(min(J))); 
            %dosing with update dose           
            newdose=c*10; 
            for ih=1:1:28 
                if rand(1)<0.1 
                    doses=0; 
                else 
                    doses=newdose;  
                end 
                [t,xpred] = ode23(@simv,[0:1:23],[p(1) p(2) p(7) 
doses xpred(end,5) xpred(end,6) pos],[],p); 
                con=vertcat(con, xpred(:,5)); 
                acid=vertcat(acid, xpred(:,6)); 
                LDLcon=vertcat(LDLcon, xpred(:,7)); 
            end 
            dose=vertcat(dose, newdose); 
            time=vertcat(time, time(end)+24); 
            conmeas=vertcat(conmeas, 
xpred(end,5)+normrnd(0,0.5*(0.1*xpred(end,5)))); 
            acidmeas=vertcat(acidmeas, 
xpred(end,6)+normrnd(0,0.5*(0.1*xpred(end,6)))); 
            LDLmeas=vertcat(LDLmeas, 
xpred(end,7)+normrnd(0,0.5*(0.07*xpred(end,7)))); 
            doses=newdose; 
        end  
         
        simmeas=[pat*ones(length(time),1) num*ones(length(time),1) 
arm*ones(length(time),1) time dose conmeas acidmeas LDLmeas]; 
     
         
    end 
    save('output.mat', 'simmeas','reps','p'); 
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%%%%Condor collection file 
function collsimv 
allsimmeas=[]; 
allreps=[]; 
allp=[]; 
  for index=[0:399] 
    stanres = strcat( 'output', int2str( index ) ); 
    load( stanres ); 
    allsimmeas=vertcat(allsimmeas, simmeas); 
    allreps=vertcat(allreps, reps); 
    allp=vertcat(allp, p); 
  end 
   
save('fulloutput.mat', 'allsimmeas','allreps','allp'); 
 
223 
 
 
 
V GLOSSARY OF TERMS AND ABBREVIATIONS 
Term Meaning Abbreviation 
(if used) 
Adverse Drug Reaction A patient response caused by the administration 
of a drug that is deemed harmful or detrimental 
to the patient. 
ADR 
Area Under the Curve The area under the line on a graph displaying the 
concentration of a drug in the body on the y-axis 
against time on the x-axis    
AUC 
Bayesian Methods A statistical methodology that calculates the 
current probability based in the previously 
calculated probability and the current data. 
 
Bottom-up  An approach to a problem that seeks to analyse 
the expected response from information about 
the parameters of the system.  
 
Controller The designer of a control system. In PK/PD 
application often the controller is likened to the 
clinician to aid comprehension. 
 
Cost Function A function that discerns the optimal estimated 
output of a system subject to different inputs. 
 
Central Plasma 
Compartment 
The compartment of a pharmacokinetic model 
that represents the concentration at the site of 
drug action. 
 
Densely Sampled Data Data that has been sampled from patients with 
high frequency, e.g., four or more samples per 
dose interval. 
 
Discrete Outcome A distinct event that is solely observable and is 
independent of a continuous scale. 
 
Discrete Patient 
Response 
A response from a patient that is considered 
distinct from another response and therefore 
solely observable. 
DPR 
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Term Meaning Abbreviation 
(if used) 
Dosage Regimen A collection of doses subsequent to each other.  
Drug Dose Algorithm A process that is designed to estimate the optimal 
dosage regimen to give to patient given based on 
clinical targets. 
 
Finite Horizon Problem A stochastic control where the state is considered 
over a finite amount of time.  
 
Infinite Horizon 
Problem 
A stochastic control where the state is considered 
over an infinite amount of time. 
 
International 
Normalised Ratio 
A measure of coagulation in the blood derived 
using the prothrombin time. 
INR 
Laboratory of Applied 
Pharmacokinetics 
Group based in Los Angeles, California dedicated 
to the research into individualisation of dosage 
regimens.  
LAPK 
Low-density Lipoprotein 
Cholesterol 
A type of cholesterol used to determine the health 
risk associated with hypercholesterolemia 
LDL-C 
Multiple Model The stochastic control of parameter distributions 
that have discrete points that are considered in 
parallel by a cost function to estimate an optimal 
dosage regimen. 
MM 
Peripheral 
Compartment 
A compartment used in a pharmacokinetic model 
in tandem from the central plasma compartment 
to represent different phases of movement of a 
drug through the body. 
 
Personalised Medicine The ideology that healthcare is a process that is 
orientated by the individual needs of the patient. 
 
Pharmacodynamics The study of what the drug does to the body. PD 
Pharmacokinetics The study of what the body does to the drug. PK 
Pharmacokinetics/ 
Pharmacodynamics 
The dual study of what the body does to the drug  
for the drug to then have effect on the body 
PK/PD 
Pharmacometrics The use of models to represent processes in 
pharmacology. 
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Term Meaning Abbreviation 
(if used) 
Plasma Concentration The amount of a drug in the plasma of the 
blood, often the primary output of 
pharmacokinetic models. 
 
Randomised Control 
Trial 
An experiment in biological creatures to 
compare the efficacy of two or more 
interventions. 
RCT 
Simulation The process of emulating a system based on 
information that is suggestive of system 
behaviour. 
 
Sparsely Sampled Data Data that has been sampled from patients 
with low frequency, for example, one or two 
samples per dose interval. 
 
State A broad term for the output of a stochastic 
control system. 
 
Stochastic Control The mathematical management of a system 
that involves parameters that are inherently 
random.  
 
Top-down An approach to a problem that seeks to 
analyse the parameters of the system from 
measurement of the system output. Contrasts 
with the bottom-up approach. 
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VI GLOSSARY OF REOCCURRING MATHEMATICAL 
NOTATION 
Mathematical 
Notation 
Representation Alternative Forms 
PK/PD based 
  The rate at which PK/PD quantities move 
between compartments in a PK/PD model.  
 
   The volume of distribution in a PK/PD model.  
   The clearance in a PK/PD model.   
   ⁄   
(the apparent clearance) 
  The concentration of PK/PD response in a 
compartment of a PK/PD model 
  (central plasma 
concentration) 
   (oral  dose 
compartment 
concentration) 
  (peripheral 
compartment 
concentration)    (steady 
state compartment 
concentration) 
    (LDL-C compartment 
concentration) 
    The theoretical concentration of effect at the 
site of drug action in the body.  
 
      The baseline value of     in absence of a 
drug. 
 
     The highest value of     possible with drug 
intervention. 
 
     The concentration of the drug at the site of 
action that causes 50% of the drug effects. 
 
  A set of one or more PK/PD parameter(s)  
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Mathematical 
Notation 
Representation Alternative Forms 
Stochastic Control based 
  The action of control in stochastic control 
methodology. For PK/PD this is the dosage 
regimen.  represents the set of all possible   
   (intravenous dose) 
  (IV bolus dose) 
   (maximal dosage 
regimen) 
  The state of the system in stochastic control 
methodology. For PK/PD application this is a 
PK/PD response.   represent the set of all 
possible   
   (the state induced 
by the maximal 
dosage regimen) 
 ̂ (the predicted state 
value) 
 ̃ (the estimated state 
value after 
adjustment in the 
Kalman Filter) 
Alternative forms also 
include  . 
  The set of discrete time points in a stochastic 
control problem. For PK/PD application this is the 
time course of drug therapy.  
 
  The process noise in the system of the stochastic 
control problem. 
 
  Measurements to be feedback into stochastic 
control methodology. For PK/PD application an 
example is blood samples of drug concentration. 
 
  The variance of  . For PK/PD application an 
example is the assay error of a blood sample. 
 
 ( ) The cost function used to determine    from the 
set . 
 
    Weight and target used within  ( ) to 
determine   . 
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Mathematical 
Notation 
Representation Alternative Forms 
Kalman Filter based 
  The variance of  .  ̂ (the predicted 
state variance in the 
Kalman Filter) 
 ̃ (the estimated 
state variance after 
adjustment in the 
Kalman Filter) 
  The state transition model.   
  The variance of .  
  The measurement relationship model of   to  .  
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